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Abstract 
 
This thesis describes research undertaken on the synthesis of conformationally 
constrained analogues of phenylalanine.  
The work is introduced by an overview of the significance of conformationally 
constrained amino acids in chemical biology. An example of how a potent and selective 
conformationally constrained tryptophan was designed and synthesized is provided. 
This section also reviews constrained phenylalanine analogues, detailing the influence 
of their constraints on their stereochemistry. The introductory Chapter ends with the 
description of an investigation into the use of a conformationally constrained 
phenylalanine analogue, Tic, in the development of potent bioactive peptides, and a 
discussion of the potential applications of higher homologues of Tic. 
The second Chapter commences with a short discussion about asymmetric synthesis 
and chiral resolution, followed by an example which illustrates these concepts. This is 
followed by a discussion on the work done in the modification and optimization of the 
Gibson synthesis of the amino acid Sic, which gave multigram quantities of this amino 
acid. Attempts to resolve racemic Sic were unsuccessful. 
The next Chapter begins with an introduction to aromatic C-H bond activation and a 
discussion of conventional Heck and oxidative Heck methodologies used in C-C bond 
formation.  The syntheses of three novel cyclization substrates with varying degrees of 
electron densities in their aromatic rings are documented. Attempts to achieve 
intramolecular cyclization of these molecules via the Fujiwara addition method, the 
Gaunt oxidative Heck method and the Glorius oxidative Heck method, are described. 
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The fourth Chapter introduces the concept of aromatic C-H bond activation via 
chelation assistance. A concise survey of different functional groups that are commonly 
used as ortho-directing groups via chelation with organometallic catalysts is presented 
along with an example that illustrates how this methodology has been used to 
synthesize potentially bioactive compounds. This is followed by a description of the 
synthesis of a new potential cyclization substrate with a ketone as a directing group. 
Attempts to achieve an intramolecular cyclization of this substrate using different [Ru] 
and [Rh] catalysts were unsuccessful.  
Chapter five begins with a brief summary of the use of gold catalysts for C-C bond 
formation via aromatic C-H activation. Four new substrates with potential for 
cyclization with varying degrees of electron densities in their aromatic rings were 
synthesized. Intramolecular cyclization of these substrates using Au(III) and Au(I) 
catalysts proved to be unsuccessful.  
Finally, Chapter six contains the experimental details that support the results described 
and discussed in Chapters 2-5. 
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1.0 Introduction 
1.1 Amino Acids, Peptides and Proteins 
Amino acids are a class of chemical compounds which contain both amine and 
carboxylic acid functional groups. Molecules having the amino and the carboxylic acid 
group attached to the same carbon are called α-amino acids and these are the basic 
building blocks of all proteins (Figure 1).  
 
Figure 1. Some examples of α-amino acids 
Amino acids, exemplified here by 1-5 are non-volatile, white, crystalline compounds 
with no defined melting points. They are relatively stable on heating, but decompose in 
the temperature range 250-300 °C.[1] In their solid state, amino acids assume the low 
energy dipolar structure of zwitterions (chemical compounds which carry a total charge 
of zero, but carry formal negative and positive charges on different atoms) (Figure 2). 
This zwitterionic characteristic of amino acids impedes their solubility in most organic 
solvents.[1] In contrast they are very soluble in water but their solubilities are pH 
dependent and are least at their isoelectric point (the pH at which a molecule carries no 
net charge).  
 
Figure 2. Amino acids in unionised form and zwitterionic form 
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Most amino acids exist as either of two optical isomers. L-Amino acids form the vast 
majority of amino acids found in proteins while D-amino acids are found only in some 
proteins produced by sea-dwelling organisms such as cone snails. D-Amino acids are 
also abundant components of the peptidoglycan cell walls of bacteria.[2] 
Amino acids are found in all living organisms in both their free forms and in peptides 
and proteins. The amide linkage found in peptides is formed by a condensation reaction 
that releases a molecule of water (Figure 3). Multiple amide linkages lead to the 
formation of short polymer chains called peptides or long polymer chains called either 
polypeptides or proteins. Protein biosynthesis may be viewed as an amino acid 
polymerization process based on an mRNA template.[2] 
 
Figure 3. Condensation of two amino acids to form a dipeptide 
There are twenty natural α-amino acids found in nature that form mammalian proteins. 
Several of these amino acids also serve functions distinct from their role in peptides and 
proteins, e.g. tyrosine is involved in the formation of thyroid hormones, while glutamic 
acid acts as a neurotransmitter. Peptides with up to ten amino acids are generally termed 
oligopeptides. Their synthesis can be achieved by both chemical and biotechnological 
methods. Formation of the peptide bond requires activation of one of the two functional 
groups, generally the carboxylic acid group. Activation is usually accomplished by 
formation of a reactive carbonyl species such as acid chloride or a mixed anhydride 
which is susceptible to nucleophilic attack by the amino group of the second amino acid 
residue.[2] These peptides play an important role in the regulation and maintenance of 
H2O
Dipeptide
H2N OH
O
R1 H
H2N OH
O
R2 H
H2N N
H
O
R1 H
OH
O
H R2
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biological processes, and thus have wide applications particularly in diagnostic and 
therapeutic areas. 
 
1.2 Peptides and Proteins in Medicine 
A number of chronic and infectious disorders are caused by a failure of protein or 
peptide function in living organisms. Prion (proteinaceous infection) diseases in 
mammals (which are currently untreatable and universally fatal) are a result of 
conformational changes of a protein.[3] Other diseases such as Alzheimer’s and 
amyloidoses are associated with deposition of insoluble β-amyloid plaques in the brain 
and other extracellular tissue (amyloids are insoluble protein aggregates having specific 
structural traits).[4] Certain types of cancers are caused by the malfunction of the p53 
protein which has a natural tumour suppression function. The p53 protein, also 
described as the guardian of the genome, is responsible for the production of other 
proteins which stop uncontrolled cell division or trigger the programmed death of a cell. 
If the p53 protein is folded incorrectly, then abnormal cell growth due to various 
factors, continues in an uncontrolled manner.[5]  Therefore regulation of p53 is 
necessary from a medicinal point of view. 
Insight into the structure and function of natural peptides and proteins is recognized to 
be important in understanding and exploiting their influence on biological receptors.[6] 
The development of potential therapeutic agents based on peptides has stimulated a 
great deal of interest in the synthesis of unusual and unnatural amino acids.[7] Linear 
peptides however, have found limited use as therapeutic agents since they are highly 
flexible molecules and frequently show poor selectivity towards biological receptors.[8] 
Linear peptides are also more susceptible to enzyme degradation, and their polar 
Chapter 1 
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characteristics limit their ability to pass through membranes which separate them from 
their targets in the cells, leading to poor bioavailability.[9] Chemists have addressed 
these problems by developing new molecules with conformational restrictions.[10] By 
removing some of the conformational freedom of a linear peptide, significant changes 
in the molecule’s potency and selectivity towards biological receptors can be expected. 
Conformational constrains can also increase stability towards enzyme degradation.[11,12] 
Conformationally constrained amino acids that closely imitate the receptor bound 
conformation of endogenous ligands are now being widely used to develop highly 
selective and bioactive compounds.[11-15] 
 
1.3 Conformationally Constrained Amino Acids 
Natural amino acids and peptides have an innate conformational bias, beginning at the 
backbone. Figure 4 shows a part of a tripeptide with the bold bonds defining the 
backbone (central) amino acid. The torsional angles associated with the peptide are a 
result of the amide bonds formed and are denoted as φ, ψ, ω, χ1 and χ2.[16]  
 
Figure 4. Backbone of an amino acid with its torsional angles 
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 Figure 5. Definition of the
The primary angle within the peptide is 
Cα-C where the two Cs are carbonyl carbons (Figure 5). When the C
carbon are central, the backbone nitrogens define the torsional angle 
torsional angle is denoted as 
moieties is characterized by the torsional angles 
so forth, depending on the structure of the side chain group.
Most amino acids in peptides exhibit preferred torsional angles. This is due to steric 
hindrance which prevents access to much of conformational space at typical biological 
receptors. For example, for the 
is an energy barrier between the discrete angles, with the angles at +60°, 180°
having the most favourable energies (Figures 6 and 7). The clockwise direction angle of 
+60° on the Newman projection is denoted as
direction angle of  –60°
to the R group, the angle is 180° and is referred to as 
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 φ, ψ, ω, χ
1
 and χ2 torsional angles in a peptide[16]
φ which is the torsional angle defined by C
ω. The three dimensional structure of the side chain 
χ
1 (N-Cα-Cβ-Cγ), χ2
[16]  
χ
1 torsional angle of a typical amino acid residue, there 
 gauche-(+) while the counterclockwi
 is denoted as gauche-(–). When the NH is diagonally opposite 
trans.[16,17]  
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-N-
α and the carbonyl 
ψ. The Cα-C-N-Cα 
 (Cα-Cβ-Cγ-Cδ) and 
 and –60° 
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Figure 6. The staggered conformations of (R)-amino acids and the values of χ1 angles [17] 
 
Figure 7. The staggered conformation of (S)-amino acids and the values of χ1 angles[17] 
Other angles in the Newman projection are less favorable as they require higher energy 
to overcome steric hindrance.  
 
1.4 Designing Bioactive Peptides and Proteins 
Much work has been done in recent years towards understanding the structure-activity 
relationship of bioactive peptides and proteins.[18,19] Peptides and proteins modulate and 
control most aspects of multicellular life. Novel bioactive peptides can be synthesized 
by exploiting the structural bias present in natural compounds in two dimensional and 
three dimensional spaces. In terms of peptide hormones and neurotransmitters, the basic 
principle in biology is that structural changes are necessary to change a biological 
response, and vice versa, a change in biological activity requires a change in structure. 
Dynamic conformational changes are of critical importance to most biologically active 
peptide hormones and neurotransmitters in the course of their biological lifetime, i.e. a 
typical hormone or neurotransmitter will need to exhibit different conformations during 
its biologically relevant existence and this is an important consideration in drug 
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design.[20] Ramachandran and co-workers were the first to show that low energy 
conformations of peptides and proteins were α-helices,   β-turns and extended 
structures, all of which are interchangeable.[21,22]  
Biologically active peptides are products of genes and they generally target integral 
membrane proteins. Using the biologically active pharmacophore conformation of a 
known peptide to design peptide-mimetic agonists and antagonists that are non-peptides 
is a widely followed strategy in medicinal chemistry. Both agonist and antagonist 
ligands which are potent, receptor selective and stable to proteolytic degradation need 
to be developed as drug candidates to clearly ascertain the structure-activity relationship 
between the ligand and the receptor. Most ligands cannot be directly used as drugs, but 
can be used as agonist or antagonist analogues of known bioactive peptides. In the case 
of peptide hormones and neurotransmitters, the design of an antagonist from an agonist 
often involves specific changes in the peptide structure so that the ligand interacts in a 
fundamentally different way with its receptor to exhibit antagonist activity. This will 
require changes in the three dimensional structure of the ligand, leading to different 
ligand-receptor interactions, producing a different conformation in the antagonist 
ligand-receptor complex from that of the agonist ligand-receptor complex. It is 
important to note that most peptide hormones and neurotransmitters target more than 
one subtype of receptors, but with modest selectivity. For example, there are three types 
of opioid receptor subtypes, (µ), (δ) and (κ), each with different bioactivity profiles. 
Hence there is scope for developing selective agonists and antagonists with positive and 
negative control of their receptor function.[20]  
Incorporation of conformational constraints into ligands helps to determine the ideal 
structure required for agonist or antagonist activity.[23] Without constraints, the 
Chapter 1 
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conformationally flexible hormones and neurotransmitters bind to their receptors and 
become an integral part of the protein, shedding little light on the structure-activity 
relationship. A conformational constraint can be installed into peptides in many ways 
such as the use of D-amino acids, α-substituted amino acids and cyclic peptides 
obtained by cyclization of linear peptides.[17] One of the key approaches towards 
imposing conformational constraint is to introduce a covalent modification designed to 
induce torsional barriers into natural α-amino acids in such a way that the side chain 
group is conformationally biased to just one of the three conformers and that the 
torsional barriers are sufficiently enhanced so that any conformational          
interconversion in χ space would have a significantly higher energy barrier.[20] Figure 8 
illustrates examples of structural templates used to induce constraints in χ-space for 
amino acids. 
 
Figure 8. General structures of some χ-constrained aromatic amino acids[20] 
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In general structure 6, steric effects or torsional strain effects restrict access to certain 
conformations. The free amine is cyclised into a six-membered non-aromatic ring in 
structure 7 which further restricts the conformations available to the structure. Steric 
considerations also dictate the preferred conformations available to structure 8, a 
general structure that can be regarded as a chimeric amino acid (unnatural amino acids 
having structural features of two or more different natural amino acids). Such attributes 
are useful in incorporating two or more pharmacophore elements in the same peptide to 
form bivalent or multivalent ligands. Type 9 structures are inherently chimeric as they 
are based on the pyrrolidine ring of proline and the R groups may represent specific 
functionalities present in other amino acids. Compounds of type 10 are masked 
multivalent structures where the terminal olefin facilitates the introduction of different 
functionalities such as aldehydes or ketones.[20]  
 
1.5 Application of a Conformationally Constrained 
Tryptophan  
Tryptophan is one of the ten essential amino acids which are not produced in the human 
body and have to be taken in through diet. Its structure consists of an indole functional 
group attached to the α-amino acid side chain. The (L)-stereoisomer is prominent in 
structural and enzyme proteins while the (D)-stereoisomer is occasionally found in 
natural peptides in marine organisms.[24] Biologically, tryptophan is responsible for the 
production of serotonin and niacin. Serotonin helps in producing a healthy sleep and 
maintaining a stable mood while niacin is involved in the functioning of the digestive 
system, skin and nerves.[24] The various bioactivities of tryptophan have led scientists 
toward developing constrained analogues of this amino acid which could potentially 
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have higher selectivities toward specific biological receptors. Recently a constrained 
analogue of tryptophan was successfully developed and incorporated into a peptide to 
achieve a new sst4/5-selective somatostatin peptidomimic.
[25] Somatostatin is a peptide 
hormone that regulates the endocrine system and affects neurotransmission and cell 
proliferation (via interaction with G-protein coupled somatostatin receptors) and 
inhibition of the release of certain secondary hormones such as insulin, glucagon, 
gastric acid secretion etc. Somatostatin is also known as Growth Hormone Inhibiting 
Hormone (GHIH) or Stomatotropin Release Inhibitory Factor (SRIF). Somatostatin 
occurs naturally in two major forms: a tetradecapeptide (SRIF-14) and a 28-amino acid 
form (SRIF-28). Figure 9 shows the peptide structure of somatostatin (SRIF-14 and 
SRIF-28). Structure-activity studies have shown that the Phe7-Trp8-Lys9 sequence is of 
key importance for biological recognition.[25] 
 
Figure 9. Structures of somatostatin[25] 
Several cyclic hexa- and octapeptide analogues containing this key sequence have been 
developed, such as octreotide 11 which contains the sequence [–Phe3-(D)-Tyr4-Lys5-] 
(Figure 10). Octreotide residue has found therapeutic applications in the treatment of 
endocrine tumours and acromegaly.[26]  
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Figure 10. Structure of octreotide H-(D)-Phe-Cys-Phe-(D)-Tyr-Lys-Thr-Cys-Thr(ol)[25] 
Ten years ago rapid identification of somotostatin receptor ligands through 
combinatorial chemistry was investigated.[27] Important components in the 
combinatorial library proved to be (2R, 3S)-β-Me-Trp, (L)-Lys-OMe and N-(4-
piperidinyl)benzimidazol-2-one, and researchers were able to combine these 
components to give a highly potent and selective sst2 ligand 12, which was optimized 
by replacing the (L)-Lys-OMe with (L)-Lys-OC(CH3)3  to give 13 (Figure 10).
[28]  
 
Figure 11. A highly potent and selective sst2 receptor ligand
[28] 
The (3S) β-methyl group in the potent ligands 12 and 13 favoured the trans 
conformation of χ1 of the Trp side-chain.[28] This characteristic was explored further by 
the synthesis of new conformationally constrained Trp analogues.[29] These compounds 
were rigidified by a seven membered ring structure wherein the χ1 angle was 
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constrained to trans and gauche-(+) while χ2 was limited to ±5º and ±70° (Figure 
12).[29]  
 
Figure 12. Constraining a tryptophan residue by cyclization[29,30] 
The synthesis of the constrained analogue of tryptophan proceeded via the SeO2 
oxidation of the commercially available substrate 14 to give 15 without the need for 
protection of the carboxylic acid (Scheme 1). Reductive amination with careful control 
of pH gave crude substrate 16 which was then subjected to cyclization with 
EDC/pyridine without any further purification.[29,30] 
 
Scheme 1. Synthesis of constrained tryptophan analogues (oxidation & reductive 
amination)[29,30] 
The cyclization was achieved under basic conditions and product 17 was purified by 
column chromatography (Scheme 2). This was followed by the deprotection of the Boc 
group with TFA and amidification with benzoic acid and diphenylethanoic acid to give 
the two compounds 18a and 18b respectively. [29,30] 
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Scheme 2. Synthesis of constrained tryptophan analogues (cyclization and amidification)[29,30] 
Finally the Cbz protecting group was cleaved-off by a conventional hydrogenation 
method using gaseous hydrogen and Pd/C catalyst to give the corresponding analogues 
19a and 19b (Scheme 3).[29,30] 
 
Scheme 3. Synthesis of constrained tryptophan analogues (deprotection of Cbz)[29,30] 
Following a similar synthetic route, two other substrates 20a and 20b with an additional 
–CH2– in the side chain but without the CONHBzl functionality were also synthesized 
(Figure 13).  
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Figure 13. Substrates without the Lysine carboxyamide sidechain[29,30] 
The four compounds 19a,b and 20a,b were tested for their ability to bind to the five 
human sst receptor subtypes in complete displacement experiments using the [125I] 
labeled universal SRIF radioligand [125I]-[Leu8, D-Trp22, Tyr25]-SRIF-28 (Figure 14).[29]  
 
Figure 14. Structure of [125I]-[Leu8, D-Trp22, Tyr25]-SRIF-28 radioligand 
CHO-K1 and CCL39 cells which express the human sst1-sst5 receptors were grown and 
cell membrane pellets were prepared, followed by receptor autoradiography using the 
[125I] labeled SRIF-28 as a control.[30] The IC50 values were calculated for the four 
compounds 19a,b and 20a,b after quantification of data using a computer assisted 
image processing system.[28]  Results showed that substrate 19a was the most potent and 
selective sst4 and sst5 agonist while substrate 19b was less potent but had good sst5 
selectivity. It was observed that compounds without the lysine carboxylic amide, 20a,b, 
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(Figure 13), were less potent and showed reduced selectivity towards sst4.
[30] Compound 
19a was sufficiently potent to be considered for potential  therapeutic applications as a 
selective agonist for sst4, which is expressed in the lungs and sst5 which is expressed in 
the lymphoid system, in pancreatic beta cells and in corticotroph adenoma cells. 
Researchers are currently pursuing new applications for these constrained analogues.[30] 
This example shows that the incorporation of the conformationally constrained amino 
acid tryptophan, has proven to be a successful approach to obtain highly potent sst4 and 
sst5 selective peptidomimetics.
 
 
1.6 Constrained Phenylalanine (Phe) Analogues 
Phenylalanine is an essential amino acid which is naturally found in the breast milk of 
mammals and is also produced by plants and most microorganisms. It is manufactured 
commercially for use in food and drink and is sold as a nutritional supplement for its 
analgesic and antidepressant effects. Biologically it is responsible for the formation of 
thyroxine (thyroid hormone), adrenaline and noradrenalin which is converted to a 
neurotransmitter. The neurotransmitter is used by the brain to manufacture noradrenalin 
which promotes mental alertness, memory, elevated mood and suppresses appetite. 
Overdoses of phenylalanine can cause anxiety, headaches and hypertension. 
Chemically, phenylalanine is nonpolar due to the presence of the hydrophobic benzyl 
side chain. The various bioactivities of phenylalanine have encouraged researchers to 
develop modified and constrained analogues of phenylalanine which could potentially 
have highly selective biological activities when incorporated in peptides or 
peptidomimetics.[31]  
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Many constrained analogues of phenylalanine have been synthesized. Some of the most 
common structural types of constrained Phe are α-, β- and aryl-substituted analogues, 
and cyclic analogues, and these are described in this section. 
 
1.6.1 α- and β- Substituted Phe 
The introduction of alkyl or phenyl groups at the β-position of an α-amino acid can 
directly enhance the population of one χ1 rotamer in preference to others. Figure 15 
shows how steric interactions between vicinal substituents of compounds 21 and 22 
would favours the trans side chain conformation in preference to the gauche-(–) and 
gauche-(+) conformations (Figure 15).[6,17]   
 
 
Figure 15. The effect of β-substitution on the population of χ1 rotamers of (S)-Phe[17] 
Similarly α- and β- disubstitution of Phe as seen in 23 is also likely to restrict the 
torsional angle χ1.  
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1.6.2 Cα-Cβ Tethered Phe 
Other types of constrained structures are the Cα-Cβ tethered Phe analogues 24-28 
(Figure 16).[17]  
 
Figure 16. The Cα-Cβ tethered analogues of Phe
[17] 
In the above set of structures, 24 is the most rigid structure and it adopts an eclipsed 
conformation. The torsional angle χ1 is fixed to 0°, +120° and –120° depending on the 
stereoisomer whilst χ2 is unrestricted. Structure 25 is also rigid and presumably also 
constrained in an eclipsed conformation similar to 24 with χ1 close to 0° or ±120°. The 
five membered ring structure 26 is expected to have some degree of conformational 
flexibility, but less than 27. It is however, difficult to predict the preferred 
conformation(s).  For structure 27, it is possible to predict that the six membered ring is 
likely to adopt chair conformations. Thus the structural constraints in the amino acid 27 
disfavours the trans conformation but allow access to the gauche-(–) and gauche-(+) 
conformers (Figure 17).[17] 
 
Figure 17. The staggered rotamers of (S)-27[17] 
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The methanocyclohexane derivatives 28a-d have unrestricted χ2 angles, whilst χ1 
angles are fixed at 0°, +120° and –120°, depending upon the stereoisomer under 
consideration (Figure 18).[17]  
 
Figure 18. Different stereoisomers of 28[17] 
 
1.6.3 Ortho-Substituted Aryl Phenylalanine 
The side chain conformation in aromatic amino acids can also be controlled by the 
introduction of a new aryl group onto their aromatic rings. Such modifications would 
not significantly affect the backbone conformation and still allow some degree of 
flexibility to the side chain which is often necessary and sometimes crucial in peptide 
and peptidomimetic activity. Introduction of aryl groups (phenyl or naphthyl) 
particularly at the ortho position of the aromatic ring of Phe as in structures 29 and 30 
(Figure 19), can significantly restrict its conformation in the χ2 space due to the 
interaction between the aryl moiety and the β-hydrogens of the Phe side chain.[32,33]  
 
Figure 19. The χ2 constrained ortho-substituted aryl-phenylalanine structures[32] 
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1.6.4 Aryl Proline Derivatives of Phenylalanine 
The aryl proline derivatives of Phe, 31a,b, are another class of constrained analogues 
which have severely restricted rotational freedom for χ1, but are unrestricted about χ2 
(Figure 20).[34]  
 
Figure 20. Cis- and trans- geometric isomers of aryl-proline derivatives of Phe[17]  
It is observed that in both the cis- and trans- geometric isomers 31a and 31b only the 
gauche-(+) and trans rotamers are physically accessible (Figure 21).[17,34]  
 
Figure 21. The staggered rotamers of (2S,3R)-31b[17] 
 
1.6.5 Pipecolic Acid Derivatives of Phenylalanine 
The pipecolic acid derivatives of Phe are among the most successful and widely used 
Phe analogues in peptides and peptidomimetics. In particular 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic) 32a (Figure 22), which is a 
topographically constrained amino acid, has found applications as a replacement for 
Phe and Tyr in peptides and peptidomimetics.[17,34,35]  
H
N
COOH
H
N
COOH
31a 31b
H
Ph
CO
H
H
N
H
Ph
CO
H
HN
gauche-(+) trans
Chapter 1 
~ 33 ~ 
 
 
Figure 22. Structure of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 32a 
Tic has been used extensively in medicinal chemistry, and is now a commercial 
product.[35] The bicyclic structure of Tic significantly limits the rotational freedom of 
the χ1 and χ2 torsional angles. For (S)-Tic, the gauche-(–) and gauche-(+) 
conformations are both available, whilst the trans rotamer is eliminated (Figure 23).[17]  
 
Figure 23. The staggered rotamers of (S)-Tic 32a[17] 
Conformational analysis of α,β-disubstituted Tic (2R,3S)-33 has revealed that the 
gauche-(+) conformation is preferred over the gauche-(–) (Figure 24).[17,36] 
 
Figure 24. Structure of α,β-dimethy-Tic[17] 
It is postulated that the cyclic tether and substitution in 33 together produce molecules 
which are essentially locked into one conformation.[17] Other α- and β-substituted Tic 
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derivatives have also been synthesized, but conformational analyses of them are 
unavailable.[17]  
 
1.6.6 Higher Homologues of Tic 
Higher homologues of Tic that contain 7-, 8-, 9- and 10-membered rings were first 
synthesized in 1999 via an intramolecular Heck reaction to give the endo-cyclised 
products (Figure 25).[37] Research to identify potential applications of such analogues 
has been undertaken and will be discussed in Section 1.7.2.  
 
Figure 25. Higher homologues of Tic[37] 
 
1.7 Tetrahydroisoquinoline-3-carboxylic acid (Tic) 
Due to its non-natural α-amino acid structure, chemists have found that Tic is an 
interesting residue to incorporate into total or semi-synthetic peptides or peptide 
analogues, such as bradykinin antagonists[38] and ACE inhibitors (hypotensive 
drugs).[39] Tic has also been utilized in farnesyl transferase inhibitors as a replacement 
for Phe.[40] The farnesyl transferase inhibitors (FTIs) are a class of experimental cancer 
drugs that target protein farnesyl transferase with the downstream effect of preventing 
the proper functioning of the Ras protein, which is often abnormally active in cancer. 
Insertion of the Tic analogue into several opioid peptides has also led to dramatic 
changes in their selectivity and affinity for the various opioid receptors, and this will be 
discussed in detail in the following section. 
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1.7.1 A Highly Selective and Potent δ-Opioid Receptor Antagonist 
Incorporating Tic 
The opioid system consists of three main receptor types (µ, δ and κ) and their 
corresponding ligands (enkephalins, endorphins and dynorphins) which govern diverse 
physiological functions in peripheral tissues and the central nervous system (CNS). The 
development of potent opioid agonists and antagonists with high selectivity for each 
receptor type continues to be an important goal in opioid pharmacology. Traditionally, 
the major rationale for the design of ligands for the three major opioid receptor types   
(µ, δ and κ) was the abatement of pain through the use of specific agonists. Research 
has shown that unlike µ-opioid receptors, the δ-opioid receptors do not exhibit a 
dependency profile and hence the δ-opioid receptor antagonists also find applications in 
the treatment of cocaine addiction and alcoholism.  
Research in the early 1980s showed that the various opioid subclasses have different 
preferences in terms of conformational properties of complementary ligands.[41] This 
observation led to the realization that the conformational restriction of peptides either 
locally through incorporation of backbone or side-chain conformational constraints at 
specific amino acid residues or more globally through peptide cyclisations may result in 
improved receptor selectivity. Researchers used this concept to develop a number of 
conformationally restricted opioid peptide analogues with potent µ and/or δ receptor 
agonist/antagonist activity.[42] One such investigation involved the incorporation of the 
conformationally restricted phenylalanine analogues N-Me-Phe and Tic into a known 
potent tetrapeptide amide H-Tyr-(D)-Phe-Phe-Phe-NH2  34  to give the novel peptides 
35 and 36 (Figures 26 and 27).  
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Figure 26. A potent tetrapeptide amide H-Tyr-(D)-Phe-Phe-Phe-NH2
[42] 
 
Figure 27. Incorporation of N-Me-Phe and Tic into a potent tetrapeptide amide[42] 
Astonishing changes in the receptor affinities and intrinsic activities were observed and 
further structure-activity studies led to the discovery of a new class of potent and 
selective δ-opioid antagonists, characterized by the N-terminal sequence H-Tyr-Tic-
Phe-.[42] Consequently more work was done pertaining to this sequence and it was found 
that the Tyr-Tic- peptides represented the minimum requirements of volume, 
conformation and spatial distribution of electronic features to give (rigid) antagonists 
for δ- and κ- receptors.[42-44]  
Researchers then worked towards incorporating more constraints into the peptide by 
incorporation of methyl groups at positions 2 and 6 of Tyr.[45]  This led to the 
development of the dipeptide DMT-Tic-OH [2,6-dimethyl-(L)-tyrosyl-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid] 37 and the tripeptide DMT-Tic-Ala-OH 38 
both of which featured reduced rotational flexibility arising from the modified Tyr 
residue (Figure 28).[45] 
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Figure 28. Structures of DMT-Tic-OH and DMT-Tic-Ala-OH 
These peptides also proved to be highly selective and potent δ-opioid receptor 
antagonists.[46]  
Later N-terminal methylated derivatives of Dmt-Tic-OH 37 and Dmt-Tic-Ala-OH 38 
were also developed (structures 39 and 40 in Figure 29).[47]  
 
Figure 29. Structures of N-methylated DMT-Tic-OH and DMT-Tic-Ala-OH[47] 
Researchers hypothesized that N-alkylation would cause alteration in the peptide 
conformation and an increase in hydrophobicity and stability to proteolysis, all of which 
would assist in enhancing biological activity. The peptides 39 and 40, when tested, 
showed extraordinary δ-opioid antagonist activity, up to 20-fold higher than H-Dmt-
Tic-OH 37.[47]  The results implied that the methyl groups enabled the peptide to better 
fit within the ligand binding domain of the δ-receptor site. The peptides 37-40 now 
provided a scaffold upon which novel peptides with enhanced antagonistic activity 
could be developed.  
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Subsequently the Dmt1-Tic2 dipeptide was incorporated into an opioid peptide 
dynorphin-A 41 as a replacement for Tyr1 and Gly2 (Figures 30 and 31).[48]  
 
Figure 30. Structure of dynorphin-A 
 
Figure 31. [Dmt1-Tic2]-substituted dynorphin-A 
The δ-affinity of the modified structure 42 increased by nearly two orders of magnitude 
and this made this new [Dmt1-Tic2]-dynorphin-A analogue comparable in activity and 
selectivity with deltorphins.[48] (Deltorphins are endogenous linear heptapeptides, 
isolated from skin extracts of frogs belonging to the genus Phyllomedusa, that have a 
higher affinity and selectivity for δ-opioid binding sites than any other natural 
compound known.) The studies indicated that incorporation of Tic at position 2 was a 
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key factor in inducing antagonism and that opioid peptides with Tic in position 2 
produced highly potent and selective δ-opioid antagonists.[45-48]  
Further work on the Dmt-Tic scaffold involved testing of a series of analogues with 
substitutions on Tic (general structure 43 in Figure 32).[49] 
 
Figure 32. Structure of Dmt-Tic with different substituents on Tic[49] 
Fluorine was incorporated at position 6 of Tic (44) in an attempt to increase the 
hydrophobicity and H-bonding capacity inside the ligand-binding domain. The 
structure-activity results showed an anomalous binding pattern, with high δ-opioid 
affinity being observed when L-Tic was used and µ-opioid selectivity and binding being 
observed when the D-Tic stereoisomer was incorporated. This led to a new hypothesis 
that while Tyr/Dmt-(L)-Tic represented the δ-opioid message domain, Tyr/Dmt-(D)-Tic 
could define a µ-opioid message domain.[49] The success of Tic has inspired scientists to 
actively pursue the application of Tic in developing bioactive peptides.[50]  
 
1.7.2 Synthesis and Applications of Higher Homologues of Tic 
Tic has been used to considerable effect in medicinal chemistry. Its presence in ligands 
has been shown to influence both affinity and selectivity, and its widespread use has 
made it a commercial product. The continuing level of interest in Tic is reflected by the 
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fact that a large number of analogues of Tic such as α-methyl-Tic 45,[51] α,β-dimethyl-
Tic 33,[52] β-phenyl-Tic 46,[53] benzo[f]Tic 47, benzo[g]Tic 48, benzo[h]Tic 49[54] and 
others have been targets of synthetic studies (Figure 33). 
 
Figure 33. Some modified analogues of Tic[37] 
Our group was the first to work towards the development of higher homologues of Tic 
having seven (Sic), eight (Hic), nine (Nic) and ten (Xic) membered rings.[37] It was 
anticipated that these compounds namely, 2,3,4,5-tetrahydro-1H-3-benzazepine-2-
carboxylic acid (Sic) 32b, 1,2,3,4,5,6-hexahydro-3-benzazepine-2-carboxylic acid (Hic) 
32c, 2,3,4,5,6,7-hexahydro-1H-3-benzazonine-2-carboxylic acid (Nic) 32d, and 
1,2,3,4,5,6,7,8-octahydrobenzo[d]azecine-2-carboxylic acid (Xic) 32e, together with 
Tic would provide a useful series of compounds for probing bioactive conformations of 
peptide ligands.  
The syntheses of these analogues began with the oxidation of the commercially 
available 2-iodobenzylalcohol 50 followed by four further steps leading to the N-Boc 
protected iodo-alkenes 51-54. These substrates were then subjected to an intramolecular 
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the Heck reaction could be used to make larger ring sized Tic homologues 32b-e 
(Scheme 4).[37]  
 
Scheme 4. Synthesis of higher homologues of Tic[37] 
The alkene was reduced by catalytic hydrogenation, the amine deprotected and the ester 
hydrolyzed to give the Sic, Hic, Nic and Xic amino acids 32b-e (Scheme 5). The 
synthesis will be discussed in more detail in Chapter Two. 
 
Scheme 5. Synthesis of Sic, Hic, Nic and Xic[37] 
Later, these higher homologues of Tic 32b-e, which are essentially constrained 
analogues of Phe, were incorporated into a cholecystokinin-B-gastrin receptor 
antagonist as a replacement for Phe.[55] Compound 59 is a known potent and selective 
CCK2 antagonist (Figure 34).  
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Figure 34. A potent and selective CCK2 antagonist containing Phe
[55] 
Compounds 60-64 represent molecules in which the Phe group in 59 is replaced with 
Tic, Sic, Hic, Nic and Xic (Scheme 6). 
 
Scheme 6. Incorporation of 32a-e into a CCK2 receptor antagonist
[55] 
Initially the affinities of compounds 60-63 at CCKB/gastrin receptors were determined 
by conducting a functional bioassay (the isolated immature rat stomach) and a 
radioligand binding assay (the mouse cortical homogenate).[54] It was found that 
compounds 60-63 shared the same selectivity as 59 but showed lower affinities except 
for 63, (Nic) which showed the same selectivity and affinity as 59. [55] It was suggested 
that the Nic analogue 63 may confer a favorable disposition of the aromatic ring 
comparable to that adopted by the aromatic ring of phenylalanine in 59. [55] However, it 
was recognized that the transposition of Tic, Sic, Hic and Nic analogues of 
phenylalanine would affect a number of factors beyond the simple spatial orientation of 
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the aromatic ring, such as the potential for intramolecular hydrogen bonds, which may 
be altered by the replacement of the secondary amide in 59 with a tertiary amide. [55] 
Further work involved incorporation of 32e (Xic) into 59 giving 64 (n = 4) which 
showed significantly higher potency compared to the 7-membered and 8-membered 
ring analogues 62 and 63.[56] While 59 showed 3000-fold selectivity for the CCK2 
receptor (rat stomach) over the CCK1 (guinea pig pancreas), the selectivities for 64 
were in the order of 18000-fold (rat stomach) and 3000-fold (mouse cortex).[56] The 
results provided more evidence to support the hypothesis that biological behaviour was 
affected significantly by introduction of the ring structures 32a-e into 59.[56]  
Recent research has shown that the peptide H-Dmt-Tic-Gly-NH-CH2-Ph 65 (an 
extended version of the Dmt-Tic pharmacophore) was a potent δ-opioid antagonist as 
well as a very active µ-opioid agonist (Figure 35).[57] 
 
Figure 35. A potent δ-opioid antagonist and µ-opioid agonist peptide[57] 
The outcome of incorporating Sic, Hic, Nic and Xic residues into peptide 65 was 
investigated. Preliminary results showed that the Sic derivative 66 (Figure 36) was a 
very active µ-opioid receptor agonist, even more active than endomorphin-2[58] 
(Endomorphin-2 is an endogenous opioid tetrapeptide with the highest known affinity 
and specificity for the µ-opioid receptor.) 
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Figure 36. A very active µ-opioid receptor agonist[58] 
Moreover 67 (Hic) showed high δ-opioid antagonist activity (Figure 37). Other 
analogues however, were inactive towards both receptors.[58] 
 
Figure 37. A very active δ-opioid antagonist[58] 
Earlier studies on the Dmt-Tic pharmacophore sequences had shown that D- and L-Tic 
exhibited different selectivities and affinities for different opioid receptors.[49] It was 
recognized that in order to understand the effect of the analogues Sic 32b and Hic 32c 
on the opioid receptors more thoroughly, they needed to be used in enantiopure form.  
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arises a need for the development of a synthesis of the compounds which would deliver 
them in enantiopure form.  New routes which deliver these constrained analogues more 
effectively would also be desirable. In this thesis we present work done towards the 
development of new synthetic approaches to Sic, Hic, Nic and Xic and related 
compounds. 
The first objective was to optimize the Gibson synthesis of Sic, Hic, Nic and Xic and 
resolve the amino acids using conventional resolution techniques.  The next objective 
was to develop new efficient synthetic routes towards Sic, Hic, Nic and Xic based on  
C-H activation chemistry.  
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2.0 Synthesis of the Sic Amino Acid 
2.1 Asymmetric Synthesis and Chiral Resolution 
The biological activity of peptides arises through the interaction between an enzyme or 
a receptor and the peptide. The sites of action on the enzyme or receptor are constructed 
from chiral building blocks such as amino acids and carbohydrates and therefore these 
sites themselves are chiral. There is therefore a high possibility that the two enantiomers 
of a given bioactive peptide will interact differently with an enzyme or receptor. 
Therefore the stereochemistry of the two chiral systems (the peptide and the receptor or 
enzyme) can have a profound effect on the degree of interaction and consequently the 
biological response. For example, patients suffering from Parkinson’s disease are 
prescribed (S)-Dopa (3,4-dihydroxyphenylalanine) 68 which is a non-proteinogenic 
amino acid, as it is effective in restoring nerve function.[59] (R)-Dopa 69 however, is not 
only ineffective but very toxic; hence the drug has to be marketed as a single 
enantiomer (Figure 38).  
 
Figure 38. Structure of (R) and (S)-Dopa 
Enantiomerically enriched samples of a compound may be obtained either by 
asymmetric synthesis or by chiral resolution of a racemic mixture.  Asymmetric 
synthesis is a technique used to introduce a desired element of chirality into a 
compound during the course of the synthesis. There are several different synthetic 
approaches which can be used in asymmetric synthesis, such as:  
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Chiral pool strategy – this involves selecting a suitable enantiomerically enriched 
natural product which is readily available, and transforming it into the target molecule. 
Chiral auxiliaries – this involves the use of an enantiomerically enriched compound 
from a natural source or derivative thereof (chiral auxiliary) which is attached to the 
starting material. The construct is subjected to a synthetic sequence which proceeds 
diastereoselectively due to the influence of the chiral auxiliary. The chiral auxiliary is 
then removed and the desired enantiomer of the target molecular is obtained.  
Asymmetric catalysis – this involves the use of metal ligand complexes derived from 
chiral ligands, chiral organocatalysts or biocatalysts (enzymes) to achieve a 
stereochemical bias in the outcome of a chemical reaction towards one of the two 
possible enantiomers.  
The industrial asymmetric synthesis of (S)-Dopa involved the use of an asymmetric 
catalytic hydrogenation process based on a rhodium catalyst with a chiral ligand. It is 
commonly known as the Monsanto process and its developer, W. S. Knowles shared the 
chemistry Nobel prize in 2001 for his work in developing the asymmetric catalytic 
hydrogenation technique.[60]  
The industrial synthesis of (S)-Dopa began with the coupling of vanillin 70 with 2-
acetamidoacetic acid 71 in acetic anhydride to give the phenyl azalactone 72 (Scheme 
7).[61] 
 
Scheme 7. Synthesis of azalactone[61] 
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The azalactone was hydrolyzed to give the acetamido cinnamic acid derivative 73 
which was then subjected to asymmetric catalytic hydrogenation using 
[Rh(COD)(DiPAMP)]BF4 catalyst to selectively give the (S)-enantiomer of 74 (95% 
e.e.) (Scheme 8).[61] 
 
Scheme 8. Hydrolysis of azalactone and asymmetric hydrogenation[61]  
Deprotection of 74 by acid hydrolysis finally gave (S)-Dopa 68 (Scheme 9).[61]  
 
Scheme 9. Deprotection of 74[61] 
Chiral resolution is a method which is widely used for the separation of racemic 
compounds into their enantiomers. Although a major disadvantage of chiral resolution 
compared to the asymmetric synthesis of one of the enantiomers is that only 50% of the 
desired enantiomer can be obtained, it does have the attraction that relatively little new 
chemistry has to be developed. Some of the common methods of resolution involve 
resolution by fractional crystallization of diastereomeric salts,[62] resolution by 
diastereomeric esterification[63] followed by chromatography and also enzyme catalyzed 
kinetic resolution.[64]  
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The enzyme catalyzed resolution of (R,S)-Dopa can be achieved by subjecting the 
racemic ethyl ester of (R,S)-Dopa 75a,b to porcine pancreatic lipase (PPL) enzyme 
(Scheme 10).[64] The enzyme selectively hydrolyses the (R)-Dopa ester 75a, giving (R)-
Dopa 69 as product (54% conv., 96% e.e.), which can be separated. The remaining 
unreacted (S)-Dopa ester 75b can then be hydrolyzed by chemical methods to obtain 
enantiopure (S)-Dopa 68.[64] 
 
Scheme 10 Enzyme catalysed kinetic resolution of (R) and (S)-Dopa ester[64] 
The above case of (S)-Dopa shows how both asymmetric synthesis and enzymatic 
resolution can be used effectively to obtain enantiomerically pure compounds.  
 
2.2 Synthesis of Sic (Gibson Synthesis) 
Earlier attempts to access enantiopure samples of Sic, Hic and Nic by asymmetric 
hydrogenation of the Heck product 81 had met with little success,[64] particularly for 
Hic and Nic. It was therefore proposed that racemic samples of the amino acids should 
be synthesized and chiral resolution procedures investigated. Although several 
syntheses of Tic have been reported,[35] the Gibson synthesis[37] was the only route to 
the higher homologues of Tic up until recently. (In 2008, an alternative synthesis of Sic 
was reported which involved a strategic combination of ring-closing metathesis and 
Diels-Alder reactions.[65]) Guided by the studies on the opioid system described in 
Chapter 1, it was decided to initially target the Sic amino acid. 
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Experimental work began with the oxidation of commercially available alcohol 50 
using MnO2 to give the aldehyde 76. Homologation of 76 was embarked upon using a 
Wittig reaction based on (methoxymethyl)triphenylphosphonium chloride and 
potassium tert-butoxide and this cleanly gave the vinyl ether 77 (Scheme 11). The two 
steps gave excellent yields. 
 
Scheme 11. Oxidation of 2-iodobenzyl alcohol and subsequent Wittig reaction 
The vinyl ether was then hydrolyzed with formic acid and water to give the 
homologated aldehyde 78 (Scheme 12).  
 
Scheme 12.  Enol-ether hydrolysis and reductive amination 
Reductive amination of 78 with (±)-serine methyl ester.HCl gave the amino alcohol 
ester 79. Literature procedure for the synthesis of 79 yielded the product in moderate to 
low yields.[37] Since the Gibson route involved nine reaction steps, it was undesirable to 
have such a low yielding reaction at an early stage in the synthesis. Hence several 
attempts were made to optimize the conditions and maximize the yield (Table 1).   
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Table 1. Optimization of the reductive amination reaction 
 
Entry 
Reaction Characteristics 
 
Yields 
(%) 
78 
(equiv.) 
(±)-
SME.HCl 
(equiv.)
a
 
KOAc 
(equiv.) 
NaBH3CN 
(equiv.) 
Mol. 
Sieves 
(g) 
Filtration 
Extraction 
(1/2) 
1 1 1 1 2 4 (3Å) Yes EtOAc 55 
2 1 1 1 2 8 (3Å) Yes DCM impure 
3 1 2 2 2 5 (3Å) Yes EtOAc 56 
4 1 2 2 2 5 (3Å) No EtOAc/Et2O 69 
5 1 2 2 2 5 (3Å) No Et2O/Et2O 71 
6 1 2 2 2 10 (3Å) No Et2O/Et2O 96 
7 1 2 2 2 10 (4Å) No Et2O/Et2O 100 
a  (±)SME.HCl = (±)-Serine methyl ester hydrochloride 
The first reaction was carried out following the literature procedure.[37] The outcome 
was a disappointingly low yield of 55% (Entry 1). In the next attempt, the amount of 3Å 
molecular sieves was increased 2-fold and DCM was used in the extraction step. It was 
observed that this solvent extracted higher amounts of undesirable inorganic impurities 
from the NaBH3CN quench and gave a very impure product (Entry 2). It was also 
observed that the product amine 79 had a low Rf value, and was unattractive for column 
chromatography with standard solvents. It was thus highly desirable to achieve a clean 
reaction with complete conversion. TLC studies on Entries 1 and 2 showed that some of 
the aldehyde 78 remained unreacted, and so the amount of (±)-serine methyl ester.HCl 
was increased to two equivalents (Entry 3) to drive the reaction to completion. The 
quantities of other reagents were also increased to the same order and a marginally 
better yield was obtained. A major reason for the moderate yields was a tedious workup 
procedure which required the filtration of the aqueous reaction slurry (MeOH + H2O) 
over Celite® through a sintered funnel. The fine inorganic precipitate of the NaBH3CN 
byproducts together with the molecular sieves clogged the sintered funnel leading to a 
very inefficient filtration and a loss in yield. This problem was rectified by eliminating 
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the filtration step and instead conducting a direct extraction of the product from the 
aqueous slurry by using excess organic solvent (EtOAc or Et2O) (Extraction 1; Entries 
4 and 5). The organic extracts could not be dried over MgSO4 at this stage due to the 
presence of MeOH; therefore the extracts were evaporated and the slurry obtained was 
diluted with H2O and then extracted with Et2O (Extraction 2; Entries 4 and 5). Et2O was 
eventually selected as the preferred solvent for both extractions as it gave a slightly 
better yield (Entry 5). It was also observed that increasing the amount of 4 Å molecular 
sieves to 10 g not only assisted in maintaining dry conditions in the reaction but also 
played a role in improving the workup process (Entry 6). It is believed that the choice 
of 3Å or 4Å molecular sieves does not influence the outcome of the reaction 
significantly. 4Å molecular sieves were used in Entry 7 as they were conveniently 
available at the time and are cheaper compared to 3Å molecular sieves. So, after 
carefully streamlining the tedious extraction process, it was possible to optimize this 
crucial reaction to give up to 100% yield.  
The next reaction involved the Boc protection of the secondary amine 79 using Boc-
anhydride followed by treatment with TsCl and Et3N which tosylated the hydroxyl 
group. The tosyl group was eliminated in situ with excess Et3N to give the N-Boc 
alkene ester 80 in satisfactory yield (Scheme 13).   
 
Scheme 13. Boc-protection and in situ elimination of TsOH 
The next step was the key intramolecular Heck reaction of the iodo-alkene 80 using 
Pd(OAc)2 catalyst which gave the bicyclic alkene ester 81 in good yield (Scheme 14). 
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Scheme 14. Intramolecular Heck reaction 
According to the original Gibson synthesis, the bicyclic alkene 81 should next have 
been hydrogenated using hydrogen gas and a Pd/C catalyst. The literature conditions 
however, did not yield the product as anticipated. It was thus decided to exploit 
alternative hydrogenation techniques, in particular catalytic transfer hydrogenation 
(CTH) to achieve the reduction of the alkene.  
Ammonium formate has been widely used as a hydrogen donor in catalytic transfer 
hydrogenation. For example, in 2003, a convenient CTH method for the reduction of 
olefins and the carbon-carbon double bonds in α,β-unsaturated carbonyl compounds 
using the commercially available and inexpensive ammonium formate as hydrogen 
donor under mild conditions was reported (Scheme 15).[66]  
 
Scheme 15. Catalytic transfer hydrogenation[66] 
This methodology was investigated for the desired reduction of the bicyclic alkene 81. 
Following the new literature procedure[66] only partial conversion was obtained (Entry 1 
in Table 2). Hence there was scope for optimization. 
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Table 2. Catalytic transfer hydrogenation of 81 
Entry Conditions for hydrogenation of 81 Results 
1 10% Pd/C (dry), HCOONH4, MeOH, reflux, 12 h 20% conv.
a 
2 10% Pd/C (dry), HCOONH4, MeOH, heat, 50 °C, 24 h 55% conv.
 a 
3 10% Pd/C (dry), HCOONH4, MeOH, heat, 40 °C, 24 h 78% conv.
 a 
4 10% Pd/C (dry), HCOONH4, EtOH, heat, 40 °C, 24 h 90% conv.
 a 
5 10% Pd/C (dry), HCOONH4, H2 gas, EtOH, sonication, 48 h 100% conv.
 a 
a = conversions determined by NMR 
Since the bicyclic alkene 81 and the saturated product 84, both had similar Rf values, it 
was difficult to separate the two compounds by chromatography. The crude mixture 
was repeatedly subjected to the CTH conditions (4 further times) until complete 
conversion was obtained. It was noticed that reflux temperatures caused sublimation of 
the HCOONH4 in the condenser. In order to overcome this issue, the experiments were 
conducted at lower temperatures, (50°C and then 40 °C) but for a longer time. This 
gave higher conversions (Entry 2-3). The solvent MeOH was replaced with EtOH as the 
latter had a higher boiling point compared to MeOH and was safer to use. EtOH also 
appeared to assist in reducing the rate of sublimation of HCOONH4 (Entry 4). Finally 
an attempt was made to use sonication instead of heating along with H2 gas and this 
completed the reduction of the bicyclic alkene 81 to the saturated product 84 over a 48h 
period (Entry 5). This was a clean reaction and the pure product 84, separated by 
filtration through Celite®, did not require any further purification (Scheme 16).  
 
Scheme 16. Catalytic transfer hydrogenation of bicyclic alkene 81 
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The saturated N-Boc ester 84 was then subjected to acid hydrolysis with HCl to 
deprotect the amine and hydrolyze the ester. The resulting HCl salt of the amino acid 
Sic.HCl 85 was obtained in excellent yield (Scheme 17).  
 
Scheme 17. Boc-deprotection and ester hydrolysis in one pot 
The Sic.HCl 86 was then treated with propene oxide to finally yield the racemic Sic 
amino acid 32b (Scheme 14). 
 
Scheme 18. Propene oxide treatment to give Sic amino acid 32b 
About 0.5 g of the racemic amino acid was obtained in the first synthesis. Later the 
entire synthesis was repeated using the optimized conditions and 4.03 g of 84 was 
obtained. 
 
2.3 Resolution of the Sic Amino Acid 
The classical resolution of the Sic amino acid 32b has never been performed. It was 
decided to pursue resolution techniques which were effective for the Tic amino acid 
32b. Kammermeier and co-workers had reported an efficient technique for the 
resolution of Tic via diastereomeric esterification using (–)-menthol 87 followed by 
conventional chromatography (Scheme 19).[63] 
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Scheme 19. Resolution of Tic 32a via diastereomeric esterification with (–)-menthol 87[63] 
The process involved esterification of the racemic Tic 32a with enantiopure (–)-menthol 
87 in the presence of tosic acid. Heating for 30 hours under reflux and work-up gave a 
mixture of diastereomeric esters 88a and 88b. The two menthyl esters were separated 
chromatographically on silica gel using cyclohexane/ethyl acetate (7:3) to give 88a 
(76%) and 88b (83%). The esters were then individually hydrolyzed using sodium 
hydroxide to give the corresponding amino acids (R)-32a (90%) and (S)-32a (94%). 
This method seemed promising for the resolution of the Sic amino acid, and so 32b was 
subjected to diastereomeric esterification using (–)-menthol and tosic acid (Scheme 20). 
 
Scheme 20. Attempted resolution of Sic 32b via diastereomeric esterification 
Hydrated tosic acid was weighed in a flask and suspended in toluene. The flask was 
connected to a Dean-Stark condenser and the reaction mixture was heated to reflux. The 
suspended tosic acid slowly dissolved in the toluene and a stoichiometric quantity of 
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water was collected in the Dean-Stark trap. The flask was then cooled to room 
temperature and the amino acid Sic 32b along with (–)-menthol was added and the 
reaction was allowed to reflux for 30 hours. The Sic amino acid was insoluble in 
toluene. It was anticipated that once the menthyl ester was formed, the product would 
dissolve in the solvent and give a clear solution. However, even after a 30 hour reflux, a 
significant amount of suspended amino acid still remained in the reaction mixture. The 
unreacted amino acid was removed by filtration through Celite® and the solution was 
washed with saturated solutions of NaHCO3 and brine. The organic layer was dried and 
the solvent was evaporated to give a mixture of 89a and 89b in 11% yield after 
preparative TLC [hexane/diethyl ether (1:1) and 1% ethanol]. The 1H NMR spectrum 
confirmed the presence of a mixture of diastereomeric esters, but the separation of these 
diastereomeric esters proved to be very challenging. The literature conditions for Tic 
[cyclohexane/ethyl acetate (7:3)][63] failed to deliver a good separation of the two 
diastereomers. Further, several solvent combinations were examined in several attempts 
to separate the diastereomeric mixture but unfortunately separation could not be 
achieved. The low yielding reaction coupled with the difficulty in chromatographic 
separation did not inspire the desired scale-up of this reaction. Therefore, alternative 
resolution techniques were investigated.  
 
2.4 Enzyme Catalyzed Resolution 
Paal and co-workers had reported an efficient lipase catalyzed dynamic kinetic 
resolution of Tic using CAL-B (Candida antarctica lipase-B) enzyme (Scheme 21).[67] 
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Scheme 21. CAL-B catalyzed dynamic kinetic resolution of Tic[67] 
The CAL-B enzyme hydrolyzed the (R,S)-Tic ester 89 to give (R)-32a in good yield and 
excellent ee. It was decided to investigate whether or not this technique could be used to 
resolve Sic 32b. Before attempting the enzymatic hydrolysis, the Sic amino acid was 
esterified by following a modified procedure reported for the Tic amino acid.[68] Sic 32b 
was esterified using thionyl chloride  and ethanol to give the corresponding ethyl ester 
as its HCl salt 91 in excellent yield (Scheme 22). 
 
Scheme 22. Esterification of Sic 32b using thionyl chloride 
The salt was not purified any further, but directly treated with propene oxide in order to 
release the amino ester following a procedure used earlier for the Sic.HCl salt (see 
Scheme 18). On this occasion, however, the desired compound was not formed and 
instead it was noticed that the amine reacted with the epoxide to give a different 
compound. This new compound was fully characterized as the amino alcohol 93 
(Scheme 23). 
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Scheme 23. Propene oxide treatment of 91 resulted in formation of 93 
It was hypothesized that this reactivity was observed as the amino ester HCl salt 91 as 
well as the amine 92 were soluble in ethanol. In contrast, Sic 32b was insoluble in 
ethanol. This supports the idea that the amine 92 attacked the epoxide and formed 
compound 93. The other regioisomer 94 was not detected in the analysis. This issue was 
resolved by repeating the esterification reaction and subjecting the product to a basic 
work-up using 2 M KOH solution (Scheme 24). 
 
Scheme 24. Esterification of Sic 32b using SOCl2 and EtOH followed by basic work-up 
The amino ester 92 was then subjected to the enzymatic dynamic kinetic resolution 
conditions based on CAL-B (Scheme 25). 
 
Scheme 25. Attempted resolution of Sic-ethyl ester 92 based on CAL-B 
The amino ester 92 was first dissolved in toluene/acetonitrile (4:1) in a test-tube. H2O 
(1 eq.) and dipropylamine (0.25 eq) were then added followed by the CAL-B enzyme. 
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The test-tube was sealed with a rubber septum and placed in a shaker and shaken at    
25 °C for 2 days. The TLC analysis showed the presence of the starting material. More 
of the CAL-B enzyme was added and the tube was shaken for another 6 days.  The 
reaction contents were then filtered through Celite® and washed with dipropylamine 
and water (40 oC). The aqueous layer was separated and the water was evaporated. No 
product residue was obtained. The organic layer was then dried and the solvent 
evaporated and this gave back the starting material 92 in 71% yield. This result, coupled 
with the cost of CAL-B enzyme (£ 250 per 200mg) led to the decision to move on from 
enzyme resolutions and investigate another resolution technique that involved 
diastereomeric salt formation, and a separation by fractional crystallization.  
 
2.5 Resolution by Diastereomeric Salt Formation 
Chiral resolution by the use of a resolving agent that forms a mixture of diastereomeric 
salts which can be separated by fractional crystallization is a widely used technique 
employed to obtain enantiopure molecules. It was decided to investigate this technique 
in order to achieve the resolution of the Sic amino acid 32b.  
Although several resolving agents were available, it was decided to investigate the use 
of (–)-camphor-10-sulfonic acid. Jacewicz and co-workers used the (–)-3-bromo-
camphor-9-sulfonate salt of potassium to resolve the amino acid tyrosine 95 (Scheme 
26 and 27).[68]  
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Scheme 26. Resolution of D,L-tyrosine via diastereomeric salt formation[68] 
The enantiopure D-(–)-tyrosine was obtained over a three-step process which first 
involved the release of the free camphorsulfonic acid. This was followed by the 
diastereomeric salt formation (Scheme 26) and finally the hydrolysis of the salt to give 
the pure enantiomer (R)-95 in 93% ee (Scheme 27).  
 
Scheme 27. Hydrolysis of 98 to give enantiopure (R)-95 
This was very encouraging since the use of methyl isobutyl ketone 97 as solvent 
resulted in a dynamic kinetic resolution of the racemic tyrosine, thereby giving an 
excess of D-(–)-tyrosine in 93% ee.  Unfortunately the 3-bromo-camphor-9-sulfonate 
salt was not commercially available and a similar brominated camphor salt, 3-bromo-
camphor-9-sulfonic acid hydrate was very expensive (£ 122 for 1 g). A subsequent 
literature survey of the use of chiral camphorsulfonic acids revealed that (–)-camphor-
10-sulfonic acid was another widely used chiral resolving agent.[69,70]  Taking 
inspiration from these new findings and following a procedure modified from the one 
described in Scheme 26, the Sic amino acid was subjected to diastereomeric salt 
formation using (–)-camphor-10-sulfonic acid (Scheme 28). 
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Scheme 28. Synthesis of Sic.camphor-10-sulfonate salt 100 
The Sic amino acid was first dissolved in AcOH/methyl isobutyl ketone (2:1) followed 
by the addition of (–)-camphor-10-sulfonic acid. The reaction mixture was then stirred 
and heated to 80 °C for 15 hours. The camphorsulfonate salt of Sic 100 precipitated out 
as an amorphous solid. The reaction was then cooled to room temperature and the 
precipitate was filtered and washed with methyl isobutyl ketone to give the 
diastereomeric salt in 90% yield. The [α] 
 was found to be –10.19 (c 0.864, 1M dm-3 
HCl). In order to ascertain whether a dynamic kinetic resolution had occurred, the 
Sic.CSA salt 100 was subjected to hydrolysis with a base to release the amino acid 
(Scheme 29). The observation that [α] 
 = 0 (c 0.864, 1M dm-3 HCl) for the product 
indicated that the Sic amino acid obtained was racemic and that dynamic kinetic 
resolution had not occurred during salt formation. 
 
Scheme 29. Hydrolysis of the Sic.camphor-10-sulfonic acid salt 100 to give Sic 32b 
It was decided to try and separate the two diastereomeric salts 100 via fractional 
crystallization. After investigating a variety of solvents, it was found that the best 
crystals were obtained in H2O/MeCN (1:1).  The crystallization process and the [α]D 
values of the different components are illustrated in the flowchart below (Figure 39). 
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Figure 39. Flowchart illustrating the sequence of fractional crystallization 
The Sic.CSA salt 100 was crystallized in H2O/MeCN (1:1) and the first batch of 
crystals were separated, dried and the [α]D value was determined to be –11.57. These 
salt crystals were then hydrolyzed with base to give Sic amino acid. Unfortunately the 
[α]D value for this Sic was zero which indicated that it was still racemic. The mother 
liquor separated from batch-1 was allowed to crystallize for another two days, and new 
crystals were obtained. The [α]D of batch-2 crystals was determined to be –7.81. 
However, the Sic amino acid obtained from these batch-2 crystals also gave an [α]D 
value of zero. The results indicated that the two diastereomeric salts were crystallizing 
simultaneously using H2O/MeCN and therefore they could not be separated 
fractionally.  
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2.6 Conclusion 
The Gibson route to the synthesis of the Sic amino acid 32b was optimized to give an 
overall yield of 15% (9 steps). One of the key steps involving the reductive amination 
with D,L-serine methyl ester using sodium cyanoborohydride was modified and the 
yield was optimized to 96% (lit. 53-61%). A new and safer method for the 
hydrogenation of the bicyclic alkene 81 was developed based on catalytic transfer 
hydrogenation. Three different resolution techniques were investigated in order to try to 
achieve the resolution of Sic. The diastereomeric esterification reaction with (–)-
menthol was a poor yielding reaction and the two diastereomeric esters could not be 
separated via chromatography. An enzymatic resolution of Sic-ethyl ester also did not 
yield the desired results. Chiral resolution via diastereomeric salt formation was 
attempted but this is a trial and error method and a lot of factors can affect the rate of 
crystallization. As a result, the resolution of the Sic amino acid continues to remain a 
challenge and more work needs to be done to identify an efficient and effective 
resolution technique in order to obtain enantiopure Sic.  
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3.0 Aromatic C-H Activation Based Coupling 
3.1 Aromatic C-H Activation 
The development of more economical ways to form C-C bonds has always been an area 
of great interest in organic chemistry. Over the last decade substrates containing a 
reactive C-H bond rather than a C-X bond have received much attention as they are 
considered to offer cleaner and more economical alternatives.[71,72] The efficient 
exploitation of C-H activation chemistry remains a long term goal for organic chemists. 
In particular, catalytic systems for C-C bond formation via C-H activation are being 
sought.[73,74,75]  
 
3.2 The Mizoroki-Heck Reaction 
The Mizoroki-Heck reaction is one of the most fundamental and versatile metal-
catalyzed processes for C-C bond formation in organic synthesis (Scheme 30).[76,77,78]  
 
Scheme 30. Reaction conditions reported by Mizoroki and Heck[76,77] 
The original reaction reported by Mizoroki[76] in 1971 involved the coupling of 
iodobenzene 101 with styrene 102 in MeOH at 120 °C using PdCl2 as catalyst and 
potassium acetate as base, to form stilbene 103. In 1972, Heck[77] acknowledged the 
Mizoroki publication and reported his independent work done on the same reaction but 
Mizoroki/Heck conditions
Conditions: 
Mizoroki (1971): 101 (1 eq.), 102 (2 eq.), PdCl2 (0.1 eq.), CH3COOK (1.2 eq.), MeOH, 120 
oC, 2 h, (90%)
Heck (1972)     : 101 (1 eq.), 102 (1.2 eq.), Pd(OAc)2 (0.1 eq.), nBu3N (1 eq.), 100 
oC, 2 h (75%)
101 102 103
I
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with different reaction conditions, i.e. using Pd(OAc)2 as the catalyst, a hindered amine 
as base and no solvent. Over the years, this reaction has had a transformational effect on 
organic synthesis. R. F. Heck was jointly awarded the Nobel prize in 2010 for his 
pioneering work on palladium catalyzed cross coupling in organic synthesis.[79]  
The Mizoroki-Heck reaction primarily requires an aryl or vinyl halide and an alkene as 
starting materials. The mechanism involves the oxidative addition of the halide 
followed by the co-ordination and carbometallation of the olefin and finally the 
formation of the product by a β-hydride elimination process. A base then regenerates 
the Pd(0) catalyst (Figure 40). 
 
Figure 40. Mechanism of the Mizoroki-Heck reaction[80] 
The halide is extruded as hydrohalic acid in the C-C bond forming process. A major 
drawback of the Mizoroki-Heck reaction is that this process is not atom efficient. A lot 
of work has been done, particularly in recent years, to try to develop efficient processes 
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for the oxidative coupling of an unfunctionalised arene directly with an alkene, thereby 
obviating the need for a prehalogenated substrate. The C-H bond strengths in arenes are 
relatively high (for example, benzene: 110 kcal mol-1) and this significantly reduces 
their reactivity towards functionalization. Early work in this area included the 
development of a Pd(II) catalyzed direct oxidative coupling of arenes with alkenes (the 
Fujiwara-Moritani or oxidative Heck reaction).[81,82]  
 
3.3 The Fujiwara-Moritani (Oxidative Heck) Reaction 
Fujiwara and Moritani reported the first example of direct oxidative coupling of arenes 
with alkenes wherein a styrene-palladium chloride complex 104a was heated in 
benzene 105 in the presence of acetic acid to give trans-stilbene 106, albeit in low yield 
(Scheme 31).[81,82] 
 
Scheme 31. The Fujiwara-Moritani (oxidative Heck) reaction[81,82] 
Although this novel reaction was stoichiometric in palladium, it opened a new area of 
research into Pd(II) catalyzed reactions between aromatic compounds and alkenes. 
Subsequent work on the Fujiwara-Moritani reaction led to the development of a 
catalytic system facilitated by Cu(OAc)2 and using O2 gas as oxidant (Scheme 32).
[83] 
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AcOH
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Scheme 32. The catalytic Fujiwara-Moritani (oxidative Heck) reaction[83] 
It has been proposed that the reaction proceeds via a solvated aryl-palladium species 
107 formed from the homogeneous solution of an arene and a Pd(II) salt in a polar 
solvent via an electrophilic aromatic substitution reaction (Figure 2).[80,83] The alkene 
then coordinates to the unstable aryl-palladium species and inserts into the aryl-
palladium bond to give 108. The intermediate formed rapidly undergoes β-hydride 
elimination to give the desired alkenated arene and a palladium-hydride species which 
then presumably decomposes into an acid and palladium metal.  An oxidant present in 
the reaction then oxidizes Pd(0) to Pd(II) in situ to facilitate the continuation of the 
catalytic cycle (Figure 41).[80,83] 
 
Figure 41. Proposed mechanism for the Fujiwara-Moritani (oxidative-Heck) reaction[80] 
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3.4 The Fujiwara-Addition Reaction 
The next objective of our work was to develop new and more efficient synthetic routes 
to the constrained amino acids Sic, Hic, Nic and Xic by exploiting catalytic coupling 
reactions based on C-H bond activation chemistry. Recent research on Fujiwara-
Moritani type reactions has produced several new catalytic systems and one such 
development is a Pd(OAc)2/TFA system used by Fujiwara to achieve C-C bond 
formation via electrophilic aromatic C-H bond cleavage and alkene addition (Scheme 
33).[14,15] Note that the alkene addition observed in this reaction is in contrast to the 
alkene substitution observed in the Heck and oxidative Heck reactions. 
 
Scheme 33. Pd(II) catalysed C-C bond formation involving electrophilic aromatic C-H bond 
cleavage[84] 
Fujiwara hypothesized that Pd(II) in TFA generates the mono-cationic species 
[PdO2CCF3]
+ which activates the arene to give intermediate 111 (Scheme 5). The 
reaction proceeds via the insertion of the alkene into the Pd-C bond followed by 
protonation by the TFA media and reductive elimination to give the coupled product 
and regenerate [PdO2CCF3]
+ (Figure 41).[84]  
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Figure 42. Proposed mechanism for the addition of arenes to alkenes in the Pd(II)/TFA 
system[84,85] 
A significantly more direct synthesis of Sic was thus proposed based on the non-
halogenated starting material 112. It was anticipated that an intramolecular cross 
coupling, inspired by the Fujiwara addition reaction, would generate the cyclized 
product 84 (Scheme 34).  
 
Scheme 34. Proposed precursor to Sic 
Although most examples of the Fujiwara addition that have been reported are 
intermolecular systems, one reaction did involve an intramolecular C-C bond formation 
via aromatic C-H activation (Scheme 5).[84] The substituted acrylic ester 113 was 
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subjected to Pd(OAc)2/TFA conditions with benzoquinone to give the cyclized product 
114 in modest yield (Scheme 35).[84]  
 
Scheme 35. Example of intramolecular C-C bond formation using the Pd(OAc)2/TFA system
[84] 
In substrate 112 the alkyl group on the benzene ring is weakly electron donating due to 
inductive effects. An electrophilic attack by Pd at the ortho position would generate an 
intermediate carbocation, and the positive charge would be stabilized by the alkyl chain 
(Figure 43).  
 
Figure 43. Proposed mechanism for ortho-selective coupling 
It was hypothesized that this electron donating effect together with conformational 
constraints in the substrate, would favour the coupling of the alkene at the ortho 
position of the arene.  In order to test the hypothesis, the synthesis of a new non-
halogenated Heck substrate was undertaken.  
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3.4.1 The Fujiwara Addition Approach to Sic 
The new proposed approach to the amino acid Sic began with similar chemistry to the 
Gibson synthesis but the initial substrate was the relatively inexpensive non-
halogenated benzyl alcohol 115. The alcohol was oxidized with MnO2 to give 
benzaldehyde 116 in excellent yield. Although benzaldehyde was commercially 
available, the oxidation step was preferred as it provided a fresh product for the next 
step (benzaldehyde is known to be unstable and even the commercially available 
compound needs to be distilled before use). Benzaldehyde 116 was then subjected to a 
Wittig reaction based on (methoxymethyl)triphenylphosphonium chloride and 
potassium tert-butoxide to give the enol ether 117 (Scheme 36). 
 
Scheme 36. Oxidation of benzyl alcohol and subsequent Wittig reaction 
The enol ether 117 was then hydrolyzed in formic acid to give the homologated 
aldehyde 118 (Scheme 36). It has been reported in the literature that this aldehyde is an 
unstable compound and is susceptible to polymerization,[86] but it proved possible to 
isolate the compound in good yield and it remained unaffected by decomposition when 
stored in a refrigerator. The homologated aldehyde was then subjected to reductive 
amination using (±)-serine methyl ester and NaBH3CN to give the amine 119 (Scheme 
36).  
 
Scheme 37. Enol-ether hydrolysis and reductive amination 
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This key reaction however gave a very poor yield, a result attributed to the unstable 
nature of the aldehyde 118. The crude 1H NMR spectrum of the product obtained after 
work-up revealed the presence of several benzylic impurities which were attributed to 
polymerization by-products of the aldehyde. The amine product 119 was eventually 
separated via careful column chromatography using hexane/Et2O [1:1 and then 0:1]. It 
was recognized at this point that this pathway was not feasible for scale-up, and hence 
further synthesis towards the Fujiwara addition Sic precursor 112 was discontinued.  
 
3.4.2 Fujiwara Addition Approach to Nic  
The medicinal chemists in Italy had reported that incorporation of conformationally 
constrained Phe analogues containing larger rings into opioid receptors led to 
interesting agonist and antagonist activities (see Section 1.7.2). Since the synthesis of 
the non-halogenated Fujiwara addition Sic precursor was not feasible, it was decided to 
focus on the larger rings. Previous studies on the Heck reaction for the synthesis of the 
higher homologues of Tic (Gibson synthesis) had shown that the cyclization of the Nic 
analogue gave the highest yield.[87] It was hypothesized that the longer alkyl chain 
reduced the stereoelectronic constraints and hence facilitated an efficient Heck 
coupling. Therefore it was decided to attempt to access the amino acid Nic via Fujiwara 
addition chemistry.  
A synthetic route to the Nic Fujiwara addition precursor was developed starting from 
the commercially available 4-phenylbutanoic acid 120. Reduction of the carboxylic acid 
was achieved using BF3.OEt2/NaBH4,
[88] a combination of reagents that generates BH3 
in situ which reduces the carboxylic acid to the alcohol 121 (Scheme 38).  
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Scheme 38. Reduction of 4-phenylbutanoic acid 120 
The alcohol 121 was then oxidized to the aldehyde 122. Several methods were 
investigated to identify the best conditions for the oxidation, including systems based 
on MnO2, Swern oxidation and PCC (pyridinium chlorochromate) (Table 1, Entries     
1-4). It was found that PCC with MgSO4 gave the best yield (Table 3, Entry 5) and 
hence these conditions were used in scale-up (Scheme 39).[89] Typically 5 g of the 
alcohol 121 gave 4.1 g of the aldehyde 122 after filtration through SiO2 and the product 
did not require any further purification. 
Table 3. Oxidation of 4-phenylbutanol 122 
Entry Oxidation reagent(s) 
Reagent quantity 
(equiv.) 
Results 
1 MnO2 25 No reaction 
2 Oxalyl chloride/DMSO 1.5:2.5 15% conv.a 
3 PCC 1.5 25% yield 
4 PCC 3 68% 
5 PCC/MgSO4 3:2.5(wt. equiv) 86% 
a = determined by NMR 
 
Scheme 39. Oxidation of 4-phenylbutanol 121 using PCC/MgSO4 in DCM 
Although MgSO4 is not a requirement in the oxidation reaction, it was found to assist in 
both the reaction and the work-up process. The PCC oxidation generates a viscous 
pyridinium by-product which sticks to the vessel during the work-up process, trapping 
the product and leading to lower yields. MgSO4 adsorbs the by-products onto its surface 
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and remains as a suspended solid in the reaction vessel which is easily filtered using a 
pad of SiO2.  
Aldehyde 122 was then subjected to reductive amination using (±)-serine methyl ester 
hydrochloride and NaBH3CN using the optimized conditions reported in Chapter 2 to 
give the secondary amine 123 in very good yield (Scheme 40). 
 
Scheme 40. Reductive amination of 4-phenylbutanal 122 
The amine 123 was then protected with Boc-anhydride and the hydroxyl group was 
tosylated and the tosyl group was eliminated in situ with excess Et3N to give the N-Boc 
alkene ester 124 in excellent yield (Scheme 41).  
 
Scheme 41. Boc-protection and in situ elimination of tosyl group 
The alkene was then subjected to the Fujiwara addition conditions [Pd(II)/TFA][84] to 
attempt to achieve an intramolecular C-C coupling via C-H activation (Scheme 42). 
 
Scheme 42. Attempted Fujiwara addition using Pd(OAc)2/TFA conditions 
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The reaction was initially carried out according to the procedure reported by Fujiwara 
wherein TFA was placed in a dry tube followed by addition of a catalytic amount of 
Pd(OAc)2, which gave an orange coloured solution on stirring. Substrate 124 was 
weighed in a vial and dissolved in DCM and the solution was added to the reaction 
mixture.  Effervescence was observed after addition and the reaction mixture turned 
dark red. The reaction was allowed to stir for 24 h at room temperature, then diluted 
with DCM and washed with H2O (Table 2, Entry 1). The organic layer was washed 
with a saturated solution of Na2CO3 and dried over MgSO4 and the solvent was 
evaporated to give a crude product. TLC studies showed streaking and many spots 
which suggested that decomposition had occured. The crude 1H NMR spectrum showed 
traces of starting material 124 and a very complex pattern of resonances which was 
consistent with decomposition. The reaction was thus conducted for shorter time 
lengths (Table 4, Entries 2 and 3), but unfortunately the TFA media was found to be too 
harsh for the substrate and decomposition was again observed.  
Table 4. Attempted Fujiwara addition on substrate 124 using Pd(OAc)2/TFA conditions 
Entry Reactants Time Results 
1 Pd(OAc)2 (1 mol%)/TFA 24 h Decomposition 
2 Pd(OAc)2 (1 mol%)/TFA 12 h Decomposition 
3 Pd(OAc)2 (1 mol%)/TFA 6 h Decomposition 
The substrate incompatibility with the reaction conditions was attributed to the 
instability of the Boc group in TFA. It was later decided to introduce a different 
protecting group such as -Cbz (stable to TFA) to achieve the cyclization. In the mean-
time, an alternative coupling method was investigated.  
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3.5 The Gaunt Oxidative Heck Reaction 
Recently Gaunt and coworkers developed a general method for the selective 
intermolecular alkenylation of indoles via a palladium catalysed C-H functionalization 
reaction (Scheme 43).[90] 
 
Scheme 43. C3 selective alkenylation of indoles[90] 
The proposed mechanism for the C-H functionalization proceeds via palladation at C3 
to give 128 followed by rearomatization to intermediate 129 (Figure 44). The alkene 
then inserts into the C-Pd bond to give the intermediate 130 and subsequently β-hydride 
elimination yields the alkenylated indole 131 and Pd(0). The latter is oxidized in situ by 
Cu(OAc)2 to Pd(II) to continue the catalytic cycle.[90]  
 
Figure 44. Proposed mechanism for C3 selective alkenylation of indoles[90] 
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The possibility of achieving a C2 functionalization was also investigated. This was 
found to be possible when the solvent combination was changed to 1,4-dioxane/AcOH 
and a soluble oxidant such as tBuOOBz was used (Scheme 44).[90]  
 
Scheme 44. C2 selective alkenylation of indoles[90] 
It was hypothesized that under acidic conditions the deprotonation in intermediate 128 
would be slowed down, thereby allowing for a migration of the C3-PdX bond in 128 to 
the highly activated C2 position of the iminium intermediate 132. This ultimately gives 
the C2 alkenylated indole 134 (Figure 45).[90] 
 
Figure 45. Proposed mechanism for the C2 selective alkenylation of indoles[90] 
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In preparation for the proposed study on the use of oxidative Heck conditions to achieve 
ring closure en route to conformationally constrained amino acids, a model reaction 
was performed based on the conditions reported by Gaunt for the C3 functionalization 
of indoles. A satisfactory yield was obtained (Scheme 44).  
 
Scheme 45. C3 alkenylation of indoles via Gaunt’s oxidative Heck method 
 
3.5.1 The Gaunt Oxidative Heck Approach to Nic 
Having succeeded in running the model reaction, it was decided to subject substrate 124 
to Gaunt’s oxidative Heck conditions and investigate the possibility of achieving a 
cyclization to give product 57 (see section 1.7.2 and Scheme 46).  
 
Scheme 46. Attempted cyclization of 124 via Gaunt’s oxidative Heck method 
The reaction was first attempted using the conditions reported by Gaunt[90] (Table 3, 
Entry 1). Substrate 124 was placed in a flask and dissolved in 9:1 DMF:DMSO. 
Cu(OAc)2 was added to the reaction vessel followed by catalytic amounts of Pd(OAc)2. 
The reaction was fitted with a condenser and heated to 70 °C and stirred for 18 h. The 
reaction mixture was then filtered through Celite® and the solvent was evaporated and 
the crude product was characterized. The result was disappointing as 90% of the 
starting material was recovered and no cyclization product was observed. It was 
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hypothesized that the system may require more energy and hence the reaction was 
repeated and subjected to higher temperatures of 130 and 160 °C (Table 3, Entries 2 and 
3). In each case there was no evidence for the generation of the desired product and the 
starting material 124 was recovered in 68 and 87% yield respectively. The reaction time 
was extended to 24 h, but still no product was obtained (Table 5, Entry 4). 
Table 5. Attempted oxidative Heck coupling of 124 
Entry 
Reaction characteristics 
Result 
Recovery 
(%) 
Catalyst 
(0.1 equiv.) 
Oxidant  
(2 equiv.) 
Temperature 
°C 
Time 
hrs. 
1 Pd(OAc)2 Cu(OAc)2 70 18 No reaction 90 
2 Pd(OAc)2 Cu(OAc)2 130 6 No reaction 68 
3 Pd(OAc)2 Cu(OAc)2 160 6 No reaction 87 
4 Pd(OAc)2 Cu(OAc)2 130 24 No reaction 70 
It has been established that in general C-H activation in arenes is more facile than in 
alkanes.[91] This is attributed to the electron rich nature of the arene.[21] It was 
hypothesized that incorporation of electron donating groups such as –OMe onto the 
arene would make the arene more electron rich and thereby promote C-H activation. In 
order to test this hypothesis the synthesis of a new 4-methoxy substituted Nic precursor 
was undertaken.  
 
3.5.2 Synthesis of 4-Methoxy Nic 
The synthesis began with the borane reduction of commercially available 4-
methoxyphenylbutanoic acid 136. Since BH3.THF complex was commercially available 
as a 1 molar solution in THF, it proved more convenient to use than the combination of 
BF3.OEt2/NaBH4 previously used en route to the Nic substrate. The 4-
methoxyphenylbutanol 137 was obtained in excellent yield (Scheme 47). 
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Scheme 47. Reduction of 4-methoxy-1-phenylbutanoic acid 136 
Oxidation of 137 was achieved by PCC/MgSO4 to give the aldehyde 138 in good yield 
(Scheme 48). 
 
Scheme 48. Oxidation of 4-methoxy-1-phenylbutanol using PCC/MgSO4 in DCM 
The aldehyde 138 was then subjected to reductive amination using (±)-serine methyl 
ester hydrochloride and NaBH3CN to give the corresponding secondary amine 139 in 
excellent yield (Scheme 49). 
 
Scheme 49. Reductive amination of 4-methoxy-1-phenylbutanal 138 
The amine 139 was then protected with a Boc group using Boc-anhydride and the 
hydroxyl group was tosylated and the tosyl group was eliminated in situ with excess 
Et3N to give the N-Boc alkene 140 in very good yield (Scheme 50). 
 
Scheme 50. Boc-protection and in situ elimination of tosyl group 
Substrate 140 was then subjected to the Gaunt oxidative Heck conditions. 
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3.5.3 The Gaunt Oxidative Heck Approach to 4-Methoxy Nic 
The reaction was first attempted using the conditions reported by Gaunt[90] (Scheme 51, 
Table 3, Entry 1).  
 
Scheme 51. Attempted cyclization of 140 via Gaunt’s oxidative Heck method 
The experiment was conducted following the procedure described in Section 3.5.1. 
Unfortunately once again no cyclised product was obtained and the starting material 
141 was recovered in 84% yield. Subsequently, the reaction was repeated at higher 
temperatures (130 and 160 °C), but in each case there was no evidence for the 
formation of the desired product and the starting material 140 was recovered in 90 and 
84% yields respectively (Table 6, Entries 2 and 3) .  
Table 6. Attempted oxidative Heck coupling of 140 
Entry 
Reaction characteristics 
Result 
Recovery 
(%) 
Catalyst 
(0.1 equiv.) 
Oxidant  
(2 equiv.) 
Temperature 
(°C) 
Time 
 
1 Pd(OAc)2 Cu(OAc)2 70 18 h No reaction 84 
2 Pd(OAc)2 Cu(OAc)2 130 6 h No reaction 90 
3 Pd(OAc)2 Cu(OAc)2 160 6 h No reaction 84 
The outcome of the experiments described in Section 3.5.1 and 3.5.3 showed no 
evidence of aromatic C-H activation. It was therefore clear that the Nic and 4-methoxy-
Nic were stable towards Gaunt oxidative Heck conditions and did not undergo C-H 
activation. Also it became clear that the use of the Boc-protecting group in substrate 
140 rendered it unsuitable for the Fujiwara addition method. It was hence decided to 
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synthesize a new substrate which would incorporate a Cbz-protecting group instead of 
Boc- and two –OMe groups at positions 3 and 4 of the aromatic ring. It was postulated 
that the two methoxy groups would make the arene highly electron rich and enhance the 
chances of C-H activation. The Cbz- group, which is stable to TFA conditions, would 
facilitate further investigation of the Fuijiwara addition method.  
3.5.4 Synthesis of 3,4-Dimethoxy Nic 
The commercially available 3,4-dimethoxyphenylbutanoic acid 142 was reduced with 
BH3.THF to give the corresponding alcohol 143 (Scheme 52).  
 
Scheme 52. Reduction of 3,4-dimethoxy-1-phenylbutanoic acid 
The alcohol 143 was then oxidized using PCC/MgSO4 to obtain the aldehyde 144 in 
good yield (Scheme 53). 
 
Scheme 53. Oxidation of 3,4-dimethoxy-1-phenylbutanol 143 using PCC/MgSO4 in DCM 
Reductive amination of the aldehyde using (±)-serine methyl ester hydrochloride and 
NaBH3CN yielded the corresponding secondary amine 145. On this occasion, the 
product obtained was impure, and hence purification by column chromatography with 
hexane/Et2O [1:1 and then 0:1] was required to give the pure amine in moderate yield 
(Scheme 54).  
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Scheme 54. Reductive amination of 3,4-dimethoxy-1-phenylbutanal 144 
The free amine 145 was converted to 146 in a one pot reaction wherein the amine was 
protected using CbzCl and Et3N followed by tosylation of the hydroxyl group and 
elimination of the tosyl group in situ to give the N-Cbz protected 3,4-dimethoxy alkene 
146 (Scheme 55). 
 
Scheme 55. Boc-protection and in situ elimination of tosyl group 
 
3.5.5 The Gaunt Oxidative Heck Approach to 3,4-Dimethoxy Nic 
The resulting alkene was then subjected to the Gaunt oxidative Heck conditions 
(Scheme 56). 
 
Scheme 56. Attempted cyclization of 146 via Gaunt’s oxidative Heck method 
The experiment was initially performed under Gaunt’s oxidative Heck conditions 
(Entry 1, Table 5). The reaction did not show any formation of the product, and hence 
subsequent reactions were carried out at higher temperatures (Table 7, Entries 2 and 3), 
but no product was observed. 
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Table 7. Attempted oxidative Heck coupling of 146 
Entry 
Reaction characteristics for Gaunt oxidative Heck method 
Result 
Recovery 
(%) 
Catalyst 
(0.1 equiv) 
Oxidant 
(2 equiv.) 
Temperature 
(°C) 
Time 
 
1 Pd(OAc)2 Cu(OAc)2 70 12 h No reaction 68 
2 Pd(OAc)2 Cu(OAc)2 130 6 h No reaction 70 
3 Pd(OAc)2 Cu(OAc)2 160 6 h No reaction 71 
Since substrate 146 had a Cbz group, it was expected to be stable to the TFA conditions 
of the Fujiwara addition reaction (Scheme 57).  
 
Scheme 57. Attempted cyclization of 146 via Fujiwara addition method 
Therefore 146 was subjected to the Pd(OAc)2/TFA conditions and the reaction was 
stirred for 24 hours, but after work-up, 82% of the starting material was recovered 
(Table 8, Entry 1).  
Table 8. Attempted Fujiwara addition on 146 
Entry 
Reaction characteristics for  
Fujiwara addition method Result 
Recovery 
(%) 
Catalyst system Temperature (°C) Time 
1 Pd(OAc)2 (1 mol%)/TFA r.t. 24 h No reaction 82 
2 Pd(OAc)2 (1 mol%)/TFA 80 6 h decomp. -- 
It was decided to modify the Fuijiwara addition reaction conditions and a new reaction 
was conducted at a higher temperature of 80 °C. The reaction mixture gave a black 
residue on work-up which did not show any effective separation by TLC. Its 1H NMR 
spectrum showed very complex resonances which indicated decomposition (Table 6, 
Entry 2). No starting material was recovered. 
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Having made three different substrates 124, 140 and 146 but failed to achieve the 
desired cyclization it was decided to investigate an alternative intramolecular coupling 
method involving C-H activation. 
 
3.6 The Glorius Oxidative Heck Cyclization 
In 2008, Glorius and co-workers reported an efficient synthesis of functionalized 
indoles from commercially available anilines by palladium catalysed intramolecular 
oxidative coupling (Scheme 58).[92]   
 
Scheme 58. The Glorius oxidative cyclization[92] 
It is proposed that the reaction proceeded via an electrophilic palladation of the 
nucleophilic enamine followed by deprotonation to give the Pd-complex 150.[92] 
Previous studies[93,94]  on the base assisted Pd-catalysed intramolecular coupling 
reactions have suggested that the basic conditions render an electrophilic aromatic 
palladation via 151 unlikely. Hence it is postulated that a plausible mechanism would be 
an intramolecular C-H activation either via σ-bond metathesis 152 or base-assisted 
deprotonation 153 (Figure 6). Reductive elimination then finally generates the indole 
product 149 and Pd(0) that is reoxidised by the oxidant Cu(OAc)2 (Figure 46).
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Figure 46. Proposed mechanisms for the Glorius oxidative cyclization[92] 
 
3.6.1 The Glorius Oxidative Cyclization Approach to Nic 
Derivatives 
The three substrates 124, 140 and 146 were individually subjected to the Glorius 
oxidative cyclization conditions (Scheme 59).  
 
Scheme 59. Attempted cyclization of 124, 140 & 146 via Glorius oxidative cyclization method 
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Substrate 125 was added to a dry flask and dissolved in DMF. The oxidant Cu(OAc)2 (3 
equiv.) and K2CO3 (3 equiv.) were added to the solution followed by a catalytic amount 
of Pd(OAc)2 (10 mol%). The flask was fitted with a condenser and the reaction was 
heated to 80 °C for 12 hours. TLC studies showed only a single spot associated with the 
starting material. After work-up, the starting material was recovered in 88% yield 
(Table 9, Entry 1). 
Table 9. Attempted Glorius oxidative coupling 124, 140 and 146 
Entry Substrate 
Temperature 
(°C) 
Time  
 
Result 
Recovery 
(%) 
1 124 80 12 h No reaction 88 
2 124 140 6 h No reaction 84 
3 124 160 6 h No reaction 81 
4 140 80 12 h No reaction 80 
5 140 140 6 h No reaction 87 
6 140 160 6 h No reaction 83 
7 146 80 12 h No reaction 78 
8 146 140 6 h No reaction 80 
9 146 160 6 h No reaction 76 
*Conditions: Substrate (1 eq.), Pd(OAc)2 (10 mol%), Cu(OAc)2 (3 eq.), K2CO3 (3 eq.), DMF, heat. 
The reaction was repeated at higher temperatures but no positive result was obtained. At 
every attempt, the starting material was recovered in 81-84% yield (Entries 2 and 3). 
Substrate 140 was also subjected to the Glorius oxidative cyclization conditions at 
different temperatures and the result was similar to that obtained for 125. The starting 
material 140 was recovered in 80-87% yield (Entries 4-6). Finally the dimethoxy 
substrate 146 was tested under the same conditions at different temperatures but without 
success (Entries 7-9).  
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3.7 Conclusion 
In pursuit of aromatic C-H activation based coupling, three new substrates with 
different degrees of electron density in the aromatic ring (124, 140 and 146) were 
synthesized. The feasibility of achieving an intramolecular coupling via C-H activation 
using the Fujiwara addition method, Gaunt oxidative Heck method and the Glorius 
oxidative Heck method were examined. Having failed to generate any cyclization 
products using these techniques, it was decided to move away from oxidative Heck 
chemistry and investigate significantly different C-H activation approaches to 
constrained Phe analogues. 
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4.0 Chelation Assisted Coupling 
4.1 Chelation Assisted Ortho-Selective Coupling 
Over the last few decades, many attempts have been made to develop C-H activation 
chemistry using transition metal catalysts.[74,95] A significant area of development has 
been catalytic reactions which functionalize aromatic C-H bonds ortho to certain 
coordinating groups such as acyls, imines, hydroxyl, carboxylic acid and carboxylic 
esters (Scheme 60).[96] 
 
Scheme 60. Chelation assisted ortho-alkylation[96] 
 
4.1.1 Ketones as Chelating Agents for Ru-Catalysis  
In 1993, Murai reported his work on an efficient catalytic addition of aromatic carbon-
hydrogen bonds to olefins (Scheme 61).[97] 
 
Scheme 61. [Ru]-catalysed ortho-functionalization of 2-methyl acetophenone[97] 
The reaction between 2-methyl acetophenone 154 and trimethylvinylsilane 155 under 
ruthenium catalysis led to the generation of the ortho-coupled product 156 in excellent 
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yield. Several further examples were reported which suggested that the organometallic 
complex RuH2(CO)(PPh3)3 could cleave C-H bonds in a variety of aromatic systems 
and facilitate addition to a range of alkenes.[97] It is postulated that the coordinating 
groups in the substrates pre-bind to the catalyst (structure 158 in Scheme 3) and 
promote the formation of a stable five-membered metallacyclic intermediate 159. Since 
aromatic C-H bonds are generally weak (bond dissociation energies in the range of 105-
110 kcal mol-1), the amount of energy released as a result of the formation of the five-
membered cyclic system is believed to be sufficient to be responsible for the observed 
high efficiency and selectivity of the C-H bond activation. Chelate formation is 
followed by the insertion of the alkene into the metal-hydrogen bond (or metal-carbon 
bond) followed by reductive elimination to give the ortho-alkylated product 161 
(Scheme 62). 
 
Scheme 62. Proposed mechanism for chelation assisted ortho-coupling[96, 97]
 
 
4.1.2 Esters as Chelating Agents for Ru-Catalysis 
Murai and co-workers also reported that esters could be used as chelating agents for 
ortho-directed addition of aromatic systems to alkenes via C-H activation. One example 
was the reaction of methyl 2-trifluoromethylbenzoate 162 with triethoxyvinylsilane 163 
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which gave the coupling product 164 in 97% yield. Characterization data revealed that 
C-C bond formation occured exclusively at the position ortho to the ester group 
(Scheme 63).[98] 
 
Scheme 63. Esters as chelating agents for [Ru]-catalysed ortho-selective coupling[98] 
 
4.1.3 Imines as Chelating Agents for Ru-Catalysis 
Imines have also been used by Murai as chelating agents for ortho-directed C-H/olefin 
coupling reactions (Scheme 64).[99] 
 
Scheme 64. Imines as chelating agents for [Ru]-catalysed ortho-selective coupling[99] 
The reaction of N-(2-methylbenzylidene)-tert-butylamine 165 with triethoxyvinylsilane 
163 gave the coupling product 166 in excellent yield using 2 mol% Ru3(CO)12 as 
catalyst. Interestingly the RuH2(CO)(PPh3)3 catalyst gave a poor yield of 166 and traces 
of the unsaturated analogue 167. Replacing the electron donating group (methyl) in the 
aromatic system 165 with an electron withdrawing group such as –CF3 or –F also gave 
the corresponding products in very good yields using the Ru3(CO)12 catalyst, implying 
that this is a relatively active and versatile catalyst.   
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4.1.4 Imines as Chelating Agents for Rh-Catalysis  
Turning to catalysts based on metals other than ruthenium, Jun and co-workers have 
reported that Wilkinson’s catalyst, Rh(PPh3)3Cl, also effects an efficient ortho-
alkylation of aromatic imines with various olefins (Scheme 65).[100]  
 
Scheme 65. Imines as chelating agents for [Rh]-catalysed ortho-selective coupling[100] 
The reaction of ketimine 168 with tert-butylethene 169 gave the coupling product 170 
(after an acidic work-up) in excellent yield using Rh(PPh3)3Cl as catalyst. The 
alkylation is aided by chelation of the imine which directs the addition towards the 
ortho position. It has been postulated that the mechanism for this reaction is similar to 
that illustrated for ruthenium catalysis in Scheme 3.[100]  
Subsequently, Bergman and co-workers extended this research and reported the use of 
Wilkinson’s catalyst to achieve a selective intramolecular coupling (Scheme 66).[101] 
 
Scheme 66. [Rh]-catalysed alkene addition on intramolecular systems[101] 
The coupling proceeded selectively at the more hindered site ortho to the directing 
group in 171 to provide a functionalised bicyclic ring system that can be hard to obtain 
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using other methods. The final product was the bicyclic ketone 172, obtained after an 
acidic workup.[101] 
 
4.1.5 Rh-Catalysis in the Synthesis of Mescaline Analogues 
Later Bergman described an ortho directed tandem cyclization reaction using a different 
rhodium catalyst to synthesize a tricyclic mescaline analogue 174 (mescaline 173 is 
known for its hallucinogenic activity) (Figure 46).[102]  In doing so, he demonstrated 
that chelation assisted C-H bond activation of this type can be used to synthesise 
potentially biologically active compounds.  
 
Figure 47. Structure of mescaline 173 and a tricyclic analogue of mescaline 174 
The synthesis began with the treatment of bis-phenol 175 with tetravinyltin 176 and 
copper(II) acetate in the presence of oxygen, which gave the bis-vinyl ether 177 in good 
yield (Scheme 67). 
 
Scheme 67. Cu(II) mediated synthesis of bis-vinyl ether 177[102] 
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The bis-vinyl ester 177 was then reduced using a mild reducing agent, based on a 
pyrrolidine-modified aluminium hydride reagent, to give the aldehyde 178 (Scheme 
68).[102]    
 
Scheme 68. Controlled reduction of ester 177 to aldehyde 178[102] 
Aldehyde 178 was converted to the benzylimine 179 by treatment with benzylamine in 
the presence of 4Å molecular sieves (Scheme 69).[102]   
 
Scheme 69. Formation of imine to give 179[102] 
Subjecting imine 179 to a tandem C-H activation cyclization reaction employing a 
catalytic amount of [RhCl(coe)2]2 and an electron-rich ligand, dicyclohexyl ferrocenyl 
phosphine, gave the tetrahydrobis(benzofuran) 180 (Scheme 70).[102]    
 
Scheme 70. [Rh]-catalysed intramolecular tandem cyclization[102] 
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The tricyclic aldehyde 180 was then converted to the mescaline analogue 181 via a 
Henry reaction followed by reduction of the intermediate nitroalkane to the amine by 
LiAlH4 (Scheme 71).
[102]
    
 
Scheme 71. Final steps of the synthesis of the tricyclic mescaline analogue 181[102] 
 
4.1.6 Chelation Assisted Rh-Catalysed Enantioselective Cyclization 
It is also of note that Bergman has developed an enantioselective version of this 
reaction.  For example, the asymmetric cyclization of ketimine 182 in the presence of a 
chiral monophosphine ligand (S,R,R)-184 [which is a (S)-Binol derived 
phosphoramidite], gave the bicycle 183 in excellent yield and 96% e.e. (Scheme 
72).[103]   
 
Scheme 72. Chelation assisted ortho-directed enantioselective cyclization[103] 
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4.2 Application of Chelation-Assisted C-H Activation in 
the Synthesis of Constrained Amino Acids 
In view of the remarkable catalytic activities of ruthenium and rhodium catalysts in 
various types of C-H activation based ortho-selective couplings, it was hypothesised 
that this type of reaction could be used to achieve an intramolecular cyclization to yield 
the desired conformationally constrained amino acids. In order to test this hypothesis, 
the synthesis of a new substrate bearing a benzylic ketone was initiated.  
 
4.2.1 Synthesis of Keto-Substituted Substrate for Ru/Rh Catalysis  
4-Oxo-4-phenylbutanoic acid 193 was commercially available. Initially it was regarded 
as an ideal starting material as it had a keto group at the benzylic position, and so a new 
synthesis was initiated, directed towards the potential chelation-assisted cyclization 
substrate 194 (Scheme 73). 
 
Scheme 73. Synthesis of [Ru]-catalysed cyclization precursor 186 
In order to introduce the amine into the substrate, it was necessary to convert the 
carboxylic acid to the corresponding aldehyde so that a reductive amination reaction 
could be conducted. The synthesis of 4-oxo-4-phenylbutanal 188 from 4-oxo-4-
phenylbutanoic acid has been reported[104] and is a two step process. Using the reported 
method, the keto-acid 185 was first subjected to acid catalysis to give phenyl lactone 
187 in excellent yield (Scheme 74). 
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Scheme 74. Synthesis of phenyl lactone 187 
The phenyl lactone was then reduced using DIBAL-H. Substrate 187 was dissolved in 
anhydrous toluene and cooled to –78 °C. DIBAL-H (1M soln. in toluene) was carefully 
added dropwise using a syringe. The reaction mixture was stirred for about 4 hours and 
complete conversion was observed by TLC. The excess DIBAL-H was quenched by 
adding AcOH slowly to the cooled reaction mixture (–78 °C). Water was then added 
and the organic layer separated, dried and the solvent evaporated to give the crude keto-
aldehyde 188 which was purified by column chromatography to give the pure product 
in moderate yield (Scheme 75). 
 
Scheme 75. Reduction of phenyl lactone 187 to keto-aldehyde 188 
Having made the keto-aldehyde 188, it was then subjected to the key reductive 
amination reaction using (±)-serine methyl ester hydrochloride and NaBH3CN (Scheme 
76). It was hypothesised that the amine would react with the aldehyde in preference to 
the ketone, but unfortunately this reaction did not stop at the desired secondary amine 
189. 
 
Scheme 76. Attempted reductive amination of 188 using (±)-serine methyl ester hydrochloride 
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The reductive amination of 188 was conducted using the procedure developed earlier 
(see Chapter 2, Section 2.2). The organic extracts were dried and evaporated to give a 
crude product. TLC analysis using hexane/Et2O (1:1) revealed a new spot at Rf  0.32. 
Initially this was thought to be an impurity as all previous reductive amination products 
had shown poor separation on TLC using hexane/Et2O (1:1). The reductive amination 
products usually showed a streak on the TLC and separated only in neat Et2O or 
hexane/Et2O (1:1) with 1% MeOH. On this occasion, however, the material on the 
baseline could not be eluted during column chromatography [hexane/Et2O (1:1) and 1% 
MeOH]. The earlier oversight was corrected and the unknown fraction obtained earlier 
at Rf 0.32 [hexane/Et2O (1:1)] was isolated and characterised. Although the product was 
very impure, preliminary NMR data indicated the formation of a pyrrole ring, 191 
(Figure 47).  
 
Figure 48. Chemical shifts for 190 and the related pyrrole 191 
The 1H NMR spectrum of product 191 was compared with the spectrum of a known 
compound 190.[104] The resonance for H5 in 191 was seen as a triplet at δ 6.33 ppm with 
J = 3 Hz which was similar to H2 in structure 190 (J = 2.9 Hz). The resonance for H1 in 
190 is down-field of H2 and presents as a multiplet in the range δ 6.55-6.57 ppm while 
H4 in structure 191, gives rise to resonance slightly up-field of H5. This is seen as a 
doublet-doublet at δ 6.27 ppm with J = 3, 2 Hz., as this structure has a tertiary nitrogen 
atom.  The resonance associated with H6 in 191 is also seen as a doublet-doublet at δ 
7.02 ppm with J = 3, 2 Hz.  which is close to the multiplet range of δ 6.86-6.88 ppm 
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reported for H3 in 190. A subsequent 1H COSY spectrum of 191 revealed the 
correlation of H4, H5 and H6 confirming their arrangement in the ring. An HMQC 
spectrum for 191 was plotted with 1H spectrum v/s 13C DEPT 90 to assign the carbons 
in the pyrrole ring. Since the substrate was very impure, an attempt was made to purify 
it by column chromatography so that a more thorough investigation could be done. 
Unfortunately, due to the small quantity of crude compound obtained (approx. 13 mg), 
it was lost in the dilute fractions and could not be isolated. Due to the inadequacy of the 
analytical data, it cannot be stated with absolute certainty that compound 191 was 
formed, but the preliminary NMR data is consistent with the formation of 191 (Scheme 
77).  
 
Scheme 77. Proposed Paal-Knorr reaction product 191 
It was hypothesised that compound 191 was the outcome of a Paal-Knorr reaction 
which occured between the keto-aldehyde and the (±)-serine methyl ester. The Paal-
Knorr pyrrole synthesis is the condensation reaction of a 1,4-dicarbonyl compound 192 
with an excess of a primary amine or ammonia to give a pyrrole 193 (Scheme 78). 
 
Scheme 78. The Paal-Knorr pyrrole synthesis 
The reaction can be conducted under neutral or weakly acidic conditions. Addition of a 
weak acid such as acetic acid accelerates the reaction. The reaction conditions in 
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Scheme 77 were suited to a Paal-Knorr condensation and hence the pyrrole 191 may 
well have formed.  
In light of this impediment, it was decided to protect the benzylic keto-group in order to 
prevent the Paal-Knorr reaction. A modified synthetic route to 186 (Scheme 73) was 
thus adopted.  
 
4.2.2 Modified Synthesis of the Keto-Substrate for Ru/Rh Catalysis  
The new synthesis began with the esterification of the carboxylic acid group in 4-oxo-4-
phenylbutanoic acid 185 by refluxing with MeOH in the presence of H2SO4. This gave 
the keto-ester 194 in excellent yield (Scheme 79). 
 
Scheme 79. Esterification of 185 
The esterification of the carboxylic acid was necessary to prevent side reactions 
occurring in the next step which was the protection of the keto group. There are several 
methods available for the protection of ketones, one of the most common being 
condensation with ethylene glycol to form a ketal (Scheme 80). 
 
Scheme 80. Ketone protection by ethylene glycol 
However, a major drawback to this approach was the fact that the resulting ketal would 
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conditions, it was hypothesised that the ketal may be cleaved and the regenerated 
ketone would again give the undesired Paal-Knorr reaction. Hence a more robust 
method of protection was required and it was thus decided to react the ketone 194 with 
ethane dithiol to give a 1,2-dithiolane which should be very stable to acidic conditions. 
A modified procedure based on conditions reported in literature[105] was used to protect 
the ketone to give the dithiolane-ester 195 in good yield (Scheme 81). 
 
Scheme 81. Ketone protection by ethane dithiol 
The protected keto-ester 195 was then reduced using LiAlH4 to give the corresponding 
alcohol in excellent yield (Scheme 82). 
 
Scheme 82. Reduction of ester 195 using LiAlH4 to give the alcohol 196 
Oxidation of the alcohol 196 using PCC/MgSO4 gave the aldehyde 197 in moderate 
yield (Scheme 83). 
 
Scheme 83. Oxidation of alcohol 196 using PCC/MgSO4 to give aldehyde 197 
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The aldehyde was then subjected to reductive amination using (±)-serine methyl ester 
hydrochloride and NaBH3CN to give the secondary amine in excellent yield (Scheme 
84). 
 
Scheme 84. Reductive amination of aldehyde 196 to give amine 197 
The amine was protected using Boc-anhydride and the hydroxyl group was tosylated 
and the tosyl group eliminated with excess base to give the alkene ester 199 in moderate 
yield (Scheme 85). 
 
Scheme 85. Boc-protection and tosyl-elimination to give N-Boc-alkene 199 
The final step required to deliver the target substrate 186, was the deprotection of the 
ketone in 199. Although several methods have been reported in the literature for the 
conversion of a dithiolane to a ketone, it was found that most methods were either 
inefficient or incompatible with the substrate (Table 10). 
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Table 10. Attempted methods for the deprotection of dithiolane 199 
Entry Conditions  Results 
1 Hg(ClO4)2, MeOH, rt Decomposition 
2 DMSO, 150 °C, 6 h No reaction, 199 recovered 68% 
3 (NH4)2Ce(NO3)6, 3:1 (MeCN/H2O) Decomposition 
4 Cu(II)O, Cu(II)Cl2, 9:1 (acetone/DMF) 5% conversion 
a 
5 tBuOOH, acetone, heat 10% conversion a 
6 tBuOOH, EtOH, heat 8% conversion a 
7 MeI (3 eq), Na2CO3 (3 eq),5:1 (acetone/H2O), heat, 6h 12% conversion
 a 
8 MeI (5 eq), Na2CO3 (3 eq),5:1 (acetone/H2O), rt, 24h 30% yield 
b 
9 MeI (10 eq), Na2CO3 (3 eq),5:1 (acetone/H2O), 40 °C, 6h 20% yield 
b 
10 MeI (10 eq), Na2CO3 (3 eq),5:1 (acetone/H2O), rt, 3 days 40% yield 
b 
11 MeI (20 eq), Na2CO3 (3 eq),5:1 (acetone/H2O), rt, 10 days 100% conversion, 68% yield 
 a = conversions determined by NMR; b = yields obtained after column chromatography [hexane/Et2O (1:1)] 
Initially mercury perchlorate[106] was used to try to achieve the deprotection of 199, but 
unfortunately the compound decomposed during the reaction (Entry 1). Another 
literature method which involved heating with DMSO[107] was attempted, but the 
dithiolane group seemed too stable for these conditions and the starting material was 
recovered (Entry 2). Ceric ammonium nitrate[108] was then used to try and deprotect the 
ketone, but unfortunately this reagent also caused the decomposition of the compound 
(Entry 3). Later a Cu(II)O/Cu(II)Cl2 based method
[109] was attempted which finally 
showed some conversion (Entry 4). This method however proved to be very inefficient, 
and hence a different method using tert-butyl hydroperoxide[110] was used (Entry 5). A 
minor improvement in conversion was observed, but the method was inefficient. A 
change of solvent from acetone to EtOH was also tried to see if it would improve the 
yields, but no significant improvement in conversion was seen (Entry 6). Finally a 
methyl iodide based deprotection technique[111] was examined (Entry 7). This method 
showed a promising improvement in the conversion and hence attempts were made to 
optimize this technique. Since MeI has a low boiling point, it was hypothesized that 
reflux conditions would lead to the loss of the reagent even with an efficient condenser, 
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and hence reduce the efficiency of the reaction. Therefore it was decided to repeat the 
reaction at room temperature for 24 h (Entry 8). This reaction showed significantly 
higher conversion compared to all previous trials and the deprotected substrate 186 was 
obtained in 30% yield. An attempt was made to warm the reaction mixture to 40 °C and 
increase the amount of MeI used to 10 equivalents, but it was observed that the reaction 
gave only 20% yield, even lower than the previous trial (Entry 9). It became clear that 
the duration of the reaction was the key to achieving higher conversion, and so in the 
next attempt the reaction was stirred for 3 days (Entry 10). This showed a remarkable 
improvement in the conversion and the product 186 was obtained in 40% yield. So 
finally it was decided to further increase the amount of MeI used to 20 equivalents and 
to stir the reaction for 10 days (Entry 11). This reaction gave 100% conversion, and 
68% of the pure keto alkene ester 199 was isolated after column chromatography 
[hexane/Et2O (1:1)] (Scheme 86). 
 
Scheme 86. MeI based deprotection of ethane dithione to give the 186 
Having finally made the substrate 186, chelation assisted ruthenium and rhodium 
catalysis was investigated. 
 
4.3 Attempted Cyclization of Keto-Substrate using Ru/Rh 
Catalysts  
Initially a model reaction was conducted under the same conditions reported by 
Murai[97] (Scheme 87). 
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Scheme 87. Model reaction based on conditions reported by Murai 
The catalyst RuH2(CO)(PPh3)3 was added to a dry flask, and the flask was evacuated 
and saturated with nitrogen. Anhydrous toluene was then added and stirred to form a 
suspension. 2-Methylacetophenone 154 and 3,3-dimethylbut-1-ene 169 (5 equiv.) were 
then added using a syringe. The reaction flask was connected to a condenser and 
refluxed for 8 h. The reaction mixture was then cooled to room temperature and diluted 
with diethyl ether and filtered through silica. The solvent was evaporated and the 
product was obtained as a red oil in excellent yield. Having validated the reaction, 
substrate 194 was subjected to ruthenium catalysis (Table 11 and Scheme 88). 
Table 11. Attempted Ru and Rh catalysed cyclization of 186 
Entry Reaction Conditions Result 
1 RuH2(CO)(PPh3)3, tol., reflux, 12 h No reaction, starting material recovered 90% 
2 RuH2(CO)(PPh3)3, tol., reflux, 24 h No reaction, starting material recovered 95% 
3 Ru3(CO)12, tol., reflux, 24 h No reaction, starting material recovered 92% 
4 [Rh(Cl)(PPh3)3], tol., reflux, 24 h No reaction, starting material recovered 98% 
 
Scheme 88. Ru and Rh catalysed cyclization of 186 
The reaction was first conducted under the conditions described in Scheme 87 (Entry 
1). At the end of 12 hours, no product was seen to develop and the starting material was 
recovered in 90% yield. The reaction duration was then increased to 24 hours, but even 
O
O
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91%, lit 99%
154 169 170
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then, no product development was seen on TLC or by NMR spectroscopy (Entry 2). 
Later Ru3(CO)12 was used as the catalyst as it had proved to be more effective than 
RuH2(CO)(PPh3)3 for the imine-directed reactions studied by Murai
[99] (see Section 
4.1.3, Scheme 5). Despite this change and the 24 hours reflux, no product was seen 
(Entry 3). Finally the Rh(Cl)(PPh3)3 catalyst used by Jun and Bergman was tried, but no 
cyclization product was obtained (Entry 4). In all cases (Entries 1-4) the starting 
material was recovered in 90-98% yields.  
 
4.4 Conclusion 
The chelation assisted ortho-selective coupling using different ruthenium and rhodium 
catalysts was investigated. The failure of 186 to undergo either ruthenium or rhodium 
catalysed cyclization may be attributed to either the challenges associated with nine-
membered ring formation or the presence of additional functional groups that may 
compete for catalyst binding sites.  Thus, it was decided to move away from the 
chelation assisted coupling approach and explore a significantly different approach to 
C-H activation based on gold catalysis. 
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5.0 Gold Catalysed Coupling 
5.1 Catalysis by Gold 
Over the years, various metal catalysts have been investigated in the pursuit of catalytic 
functionalization of aromatic C-H bonds to form C-C bonds.[112] There has been a 
particular interest in developing reaction systems which would work under mild and 
environmentally benign conditions and in turn provide a more economical way to 
construct molecules containing arene groups. Among the various metal catalysts that 
have been explored, one of the less exploited metals until recent times is gold (Au). 
Although gold had been known since ancient times and recognised for its uniqueness 
among other metals for its resistance to corrosion and oxidation, the applications of 
gold in the past were limited to coinage and jewellery. Over the years, the potential of 
gold metal in other areas has been realised and today gold is widely used in plating, 
electronics, electrochemistry, dentistry, pharmaceuticals, and chemistry, most recently 
in catalysis.[113,114]  
Previously gold was not widely used in catalysis as it was considered to be an 
expensive and rare metal. It was later proved that gold was in fact more abundant than 
many other precious metals such as palladium, platinum or ruthenium.[115] It was in the 
1980s that gold salts were first used in heterogeneous catalysis for the hydrogenation of 
alkenes.[116] Subsequently, gold catalysis has become an area of keen interest and is 
developing rapidly. In general, gold catalysts have proven active for selective oxidation 
reactions, oxidative decomposition of halogen compounds, catalytic combustion of 
hydrocarbons, hydrogenation of carbon oxides, and reduction of nitrogen oxides with 
propane, carbon monoxide or hydrogen.[115,117] A remarkable aspect of gold catalysts is 
that most of them show a high selectivity or activity under mild conditions (lower 
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temperatures and pressures).[118] Gold catalysts complement other transition metal 
catalysts (Pd, Pt, etc.); for example, gold compounds are easily reduced, hard to oxidize 
and they tend not to undergo β-hydride elimination.[119]  
Gold salts are carbophilic Lewis acids and this allows them to activate C-C multiple 
bonds leading to the formation of new C-C, C-N or C-O bonds. Substrates such as 
alkynes, alkenes or arenes, α,β-unsaturated ketones, β-diketones or allenes can be 
activated by Au(I) or Au(III) catalysts.[118,119] Moreover gold catalysts can activate C-H 
bonds, an increasingly important step in the formation of new bonds.  
 
5.2 A Gold(III)-Catalysed Substitution Reaction 
Among the various transformations catalysed by gold, the chemistry reported by He and 
co-workers stimulated the next approach to the synthesis of conformationally 
constrained analogues of phenylalanine via C-H activation chemistry. He and co-
workers explored Au(III) catalysed reactions between arenes and primary alcohol 
triflates such as 202a-c or methanesulfonate esters (Scheme 89).[120] 
 
Scheme 89 Au(III) catalysed functionalization of arenes[120] 
These reactions gave linear products with carbon-carbon bond formation occuring 
between the primary carbon of the sulfonate ester and the arene. For example, 
pentamethylbenzene 201 reacted with the triflate 202a in the presence of a catalytic 
amount of gold(III) chloride and silver triflate to give 203a. Interestingly, when the 
TfO
X
X
reflux, DCE
70-92%
201 202a   X = H
202b   X = Cl
202c   X = Ph
203a  X = H
203b  X = Cl
203c  X = Ph
AuCl3 (5 mol%), AgOTf (15 mol%)
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trimethyl substituted benzene 204 was reacted with the triflate 202a, a mixture of linear 
and branched products 205 and 206 was obtained (Scheme 90).[120]  
 
Scheme 90 Au(III) catalysed functionalization of 204 gave a mixture of linear and branched 
products[120] 
A similar reaction based on the dimethyl benzene 207 gave the branched product 209 in 
higher yield along with relatively small amounts of the linear product 208 (Scheme 
91).[120]  
 
Scheme 91 Au(III) catalysed functionalization of 1,4-dimethylbenzene 207[120]  
In the final reaction in this series, benzene 210 gave predominantly the branched 
product 212 and only traces of the linear product 211 (Scheme 92).[120]  
 
Scheme 92 Au(III) catalysed functionalization of benzene 210[120] 
It was proposed that the reactions proceed via formation of arylgold(III) species  which 
then react with the sulfonate ester to give the coupled products 203, 205, 208 and 211 
(Scheme 93).[120]  
TfO
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Scheme 93 Proposed mechanism for Au(III) catalysed arene functionalization[120] 
It is hypothesised that the reason for the formation of increasingly more branched 
product for increasingly less electron rich arenes 210, 213, 207 and 210 is because the 
reaction of the gold intermediate with triflate 211a passes through a transition state with 
a carbocationic character. The substrates with fewer methyl groups presumably react 
more slowly and hence the carbocationic species rearranges to a more stable form 
leading to the formation of the branched products 215, 209 and 203. 
He and co-workers also described the use of this method to construct cyclic structures 
(Scheme 94).[120]  
 
Scheme 94 Au(III) catalysed intramolecular functionalization of arenes[120] 
For example, 3-phenoxypropyltriflate 213a was cyclised to the corresponding bicyclic 
compound 214a in good yield using gold(III) chloride as the catalyst. It was observed 
that introducing more methoxy groups onto the aromatic ring (substrates 213b and 
213c) gave progressively higher yields for the cyclised products 214b and 214c, 
indicating that gold-catalysed intramolecular coupling was more facile for electron rich 
arenes.  
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The interesting results described above using gold(III) chloride inspired an investigation 
into the possibility of using gold catalysis to synthesize constrained amino acids. It was 
hypothesised that Au(III) should cyclise the moderately electron rich substrate 215 to 
give the desired bicyclic product 216 (Scheme 95). 
 
Scheme 95 Proposed Au(III) catalysed cyclization  
In order to test this hypothesis, a new synthesis was initiated towards the desired 
substrate 215. 
 
5.2.1 Synthesis of a Triflate Substrate for Gold(III) Catalysis 
The commercially available phenoxy ester 217 was reduced using LiAlH4 (2 M soln. in 
Et2O) to give the corresponding alcohol 218 in excellent yield (Scheme 96). 
 
Scheme 96 Reduction of ester 217 to alcohol 218 by LiAlH4 
Alcohol 218 was then subjected to the previously optimised oxidation conditions (see 
Chapter 3, Section 3.4.2) based on PCC/MgSO4. However, in this case, the substrate 
decomposed and failed to yield the desired aldehyde 219 (Scheme 97). 
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Scheme 97 Failed attempt to oxidize alcohol 218 to aldehyde 219 using PCC/MgSO4 
The aldehyde 219 was essential for the subsequent reductive amination reaction. A 
literature survey at this point revealed that the aldehyde could be synthesised via 
hydrolysis of its acyclic acetal 220 which was commercially available.[121] A modified 
synthesis was then initiated beginning with the hydrolysis of 220 which gave aldehyde 
219 in excellent yield (Scheme 98).  
 
Scheme 98 Hydrolysis of acyclic acetal 220 to aldehyde 219 
The aldehyde 219 was then subjected to a reductive amination reaction using (±)-serine 
methyl ester hydrochloride to give the secondary amine 221 in good yield (Scheme 99).  
 
Scheme 99 Reductive amination of 219 using (±)-serine methyl ester.HCl 
The amine 221 was then selectively protected by following a modified literature 
procedure involving Boc-anhydride and NaHCO3 under sonication.
[122] The Boc-
protected phenoxy ester 222 was obtained in excellent yield (Scheme 100). 
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Scheme 100 Selective Boc-protection of amine 221 to give N-Boc substrate 222 
The final step in the approach to the desired substrate for gold catalysis involved the 
conversion of the alcohol group in 222 to its triflate. Several methods were investigated 
to achieve this functionalization (Table 12). 
Table 12 Attempted triflation of 222 
Entry Conditions Results 
1 OTf2, pyridine, 4 Å mol. siev., DCM, 0 
ºC, 2 h 223 obtained, 81% yield 
2 PhNTf2, KO
tBu, DMF, 0 °C, 1 h 223 obtained, 78% yield 
3 PhNTf2, Et3N, DCM, rt.,12 h No reaction, 222 recovered 90% 
4 TsCl/Et3N (1:1), DCM, rt., 12 h 223 obtained, 80% yield 
5 MsCl/Et3N (1:1), DCM, rt.,  12 h 223 obtained, 71% yield 
Initially standard reaction conditions based on triflic anhydride were used, but the 
reaction failed to generate the desired product 215 (Entry 1).[123] Instead it was found 
that the triflic acid had been eliminated in situ to give the alkene 223. Subsequently, a 
milder triflating agent, phenyl triflamide, was used along with a strong base KOtBu, but 
this again led to the formation of the alkene 223 (Entry 2).[124] Later a different base, 
Et3N, was tried instead of KO
tBu, but no reaction was obtained and the starting material 
222 was recovered (Entry 3). Finally attempts were made to incorporate tosyl and mesyl 
groups on 222 using only one equivalent of the base. It was hypothesised that reducing 
the quantity of base would prevent the elimination of the HOTs or HOMs, and give 
products containing tosylates and mesylates (Entries 4 and 5). Unfortunately, it was 
observed that these reactions also directly gave the alkene product 223 (Scheme 101).   
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Scheme 101 In situ elimination of HOTf, HOTs, HOMs to give alkene 223 
TLC analysis did not conclusively confirm the formation of 215 as an intermediate 
prior to the formation of 223. Nevertheless it seems reasonable to hypothesise that 215 
was formed but was very unstable due to the presence of an acidic proton which was 
easily removed under basic conditions resulting in the expulsion of the triflate, tosylate 
or mesylate to give the alkene 223 (Scheme 102).  
 
Scheme 102 Cleavage of acidic proton in 215 by base to give 223 
As it was not possible to obtain substrate 215, a molecule that had been designed to be 
activated for gold-catalysed cyclization by inclusion of a powerful leaving group, it was 
decided to investigate alternative catalytic systems using gold catalysts.  
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5.3 A Gold(III)-Catalysed Addition Reaction 
He and co-workers had also reported an efficient gold-catalysed hydroarylation reaction 
of activated alkenes.[125] The reaction had several attractions: (a) it was atom economic 
as it was run under solvent-free conditions and gave a clean product, (b) the reaction 
proceeded efficiently at ambient temperature under air atmosphere, and (c) it was 
hypothesised that a range of different functional groups could be tolerated.[125] In a 
typical example, 1,3,5-trimethoxybenzene 224 was reacted with methyl vinyl acetate in 
the presence of a catalytic amount of gold(III) chloride and silver triflate under neat 
conditions at room temperature to give the addition product 225 in excellent yield 
(Scheme 103). 
 
Scheme 103 A Au(III) catalysed intermolecular addition reaction[125] 
Mechanistically, the Au(III) catalysed reactions are not well defined. Although Au(III) 
is known to activate alkynes, there are relatively fewer examples of  alkene activation in 
the literature. Two possible mechanisms have been proposed for the alkyne 
reactions.[125] These two mechanisms are modified here for the alkene substrate which 
was used in the reaction depicted in Scheme 103.  In the first, a Friedel-Crafts-like 
mechanism, it is hypothesised that Au(III) acts as a Lewis acid and this may coordinate 
with the carbonyl oxygen of methyl acrylate. Nucleophilic attack by the arene onto the 
Au(III) co-ordinated carbocation gives the unstable species 226. The reaction then 
releases H+ and finally the gold-enolate reverts back to its keto form to give the addition 
product 227 and the Au(III) catalyst is regenerated (Scheme 104). 
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Scheme 104 Proposed Friedel-Crafts-like mechanism for Au(III) catalysed addition reaction 
The second proposed mechanism begins with the auration of the arene to give 228 and a 
simultaneous activation of the alkene by an electrophile (E+) such as Au(III) or Ag(I). 
The activated alkene is then attacked by the aurated arene 228 to give the intermediate 
229 and the electrophile is eliminated in the presence of H+ to give the product 227 
(Scheme 105).  
 
Scheme 105 Proposed auration mechanism for Au(III) catalysed addition reaction 
It has been hypothesized that electron rich arenes are more likely to follow the auration 
pathway.[125] 
Success of the reaction depicted in Scheme 103 suggested that a gold(III) chloride 
catalysed cyclization of alkene 223, which had already been generated in good quantity 
as a result of attempts to synthesise substrate 215, could potentially give the constrained 
protected amino acid 216 (Scheme 106). 
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Scheme 106 Proposed Au(III) catalysed cyclization 
Hence the remainder of substrate 222 was reacted with tosyl chloride and Et3N to 
induce the elimination of tosic acid in situ and provide 223 in good yield (Scheme 107). 
 
Scheme 107 Tosylation and in situ elimination of HOTs to give alkene 223 
Initially a test reaction was conducted under conditions slightly modified from those 
described by He and co-workers by the use of a solvent, dichloroethane (Scheme 
108).[125]  The product 225 was obtained in good yield. 
 
Scheme 108 Test reaction for the Au(III) catalysed addition reaction 
Although the original reaction for these substrates (Scheme 15) had been conducted 
without solvent, there were several reactions reported on other substrates which used 
DCE as a solvent.[125] It was desirable to use a solvent for the proposed reaction with 
substrate 223 as the compound was a very viscous oil.  
Substrate 223 was then subjected to Au(III) catalysis and a range of different reaction 
conditions were examined (Table 13 and Scheme 109). 
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Table 13 Attempted Au(III) catalysis on 223 
Entry Conditions Results 
1 5% AuCl3/15% AgOTf, DCE, rt., 24h No reaction, 223 recovered 91% 
2 5% AuCl3/15% AgOTf, DCE, rt., 5 days No reaction, 223 recovered 88% 
3 5% AuCl3/15% AgOTf, MeCN, rt., 24h No reaction, 223 recovered 79% 
4 5% AuCl3/15% AgOTf, MeCN, rt., 5 days No reaction, 223 recovered 71% 
5 5% AuCl3/15% AgOTf, DCE, reflux, 24h No reaction, 223 recovered 78% 
6 5% AuCl3/15% AgOTf, DCE, reflux, 48h No reaction, 223 recovered 80% 
 
Scheme 109 Attempted Au(III) catalysed cyclization of 223 
The reaction was first attempted following the standard procedure used in the test 
reaction (Table 13, Entry 1).[125] Substrate 223 was dissolved in DCE, and a catalytic 
amount of Au(III) chloride (5 mol%) was added followed by silver triflate (15 mol%). 
The reaction mixture was stirred for 24 h at room temperature. The reaction mixture 
was then passed through a pad of silica and the solvent was evaporated. The starting 
material 223 was recovered in 91% yield (Entry 1). The reaction was then repeated and 
the reaction time was extended to 48 h, but still no product was obtained and the 
starting material was recovered in 88% yield (Entry 2). Next, it was decided to try a 
different solvent, MeCN, as He and co-workers had reported the use of MeCN as an 
effective solvent for the addition of indoles to electron deficient alkenes and alkynes 
catalysed by Au(III).[126] Using MeCN instead of DCE no product was obtained and the 
starting material was recovered in 79% yield (Entry 3). The reaction time was again 
extended to 48 h, but again no product development was seen (Entry 4). It was then 
hypothesized that heating may be required to overcome an activation energy barrier and 
therefore a new reaction was attempted under reflux conditions for 24 h (Entry 5). But 
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in this case, no product was obtained, and the starting material was recovered in 78% 
yield. Finally the reaction time for the reflux reaction was extended to 48 h, but no 
reaction was observed, and the starting material was recovered in 80% yield (Entry 6).   
The readily available substrate 223 had failed to give an eight-membered ring under 
Au(III) catalysis and so it was decided to explore the use of new substrates that would 
lead to six-membered rings using this approach. 
 
5.3.1 New Substrates for the Au(III)-Catalysed Addition Reaction 
Two new substrates 232 and 233 were synthesised from benzaldehyde 230 and 3-
methoxy benzaldehyde 231 respectively. It was hypothesised that these substrates 
would follow the Friedel-Crafts like mechanism (see Scheme 104) in preference to 
auration and generate six membered ring products 234 and 235 (Scheme 110). 
 
Scheme 110 Proposed synthesis of alkenated substrates 232 and 233 for Au(III) catalysis 
The two substrates were taken forward simultaneously, beginning with the reductive 
amination of 230 and 231 using (±)-serine methyl ester hydrochloride and NaBH3CN 
(Scheme 111). 
 
Scheme 111 Reductive amination of 230 and 231 using (±)-serine methyl ester.HCl 
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The corresponding amines 236 and 237 were obtained in good yield. The amines were 
then selectively protected using Boc-anhydride under sonication conditions to give the 
N-Boc amino esters 238 and 239 in excellent yields (Scheme 112).  
 
Scheme 112 Selective Boc-protection of amines 236 and 237 to give N-Boc substrates 238 and 
239 
The N-Boc amino esters 238 and 239 were then reacted with tosyl chloride and Et3N 
and the tosic acid was eliminated in situ to give the corresponding N-Boc alkenes 232 
and 233 (Scheme 113).  
 
Scheme 113 Tosylation of 238 and 239 and in situ elimination of HOTs to give alkene 232 and 
233 
The two new substrates 232 and 233 were then subjected to Au(III) catalysis (Table 3). 
Table 14 Attempted Au(III) catalysed cyclization of 232 and 233 
Entry Substrate Conditions Results 
1 232 5% AuCl3/15% AgOTf, DCE, rt., 24h No reaction, 232 recovered 87% 
2 232 5% AuCl3/15% AgOTf, DCE, rt., 48h No reaction, 232 recovered 91% 
3 233 5% AuCl3/15% AgOTf, DCE, rt., 24h No reaction, 233 recovered 90% 
4 233 5% AuCl3/15% AgOTf, DCE, reflux, 24h No reaction, 233 recovered 91% 
5 233 5% AuCl3/15% AgOTf, DCE, reflux, 48h No reaction, 233 recovered 86% 
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Substrate 232 was first subjected to Au(III) catalysis following the standard procedure 
described earlier, but after 24 hours, no reaction product was obtained, and the starting 
material was recovered in 87% yield (Table 14, Entry 1). The reaction was then 
repeated and continued for a longer time duration of 48 hours, but still no product was 
seen to develop, and the starting material was recovered in 91% yield (Entry 2). The 
methoxy-substituted substrate 233 was then subjected to Au(III) catalysis under 
standard conditions, but no reaction was observed and the starting material was 
recovered in 90% yield. It was then decided to subject 233 to reflux conditions with the 
Au(III) catalyst. On this occasion also, no product development was observed (Entry 4). 
Finally the reaction time was increased to 48 hours under reflux, but in spite of this no 
cyclised product was obtained (Entry 5) (Scheme 114).  
 
Scheme 114 Attempted Au(III)-catalysed cyclization of 232 and 233 
Having failed to achieve a successful cyclization with substrates 232 and 233, it was 
hypothesised that a more electron rich arene than 233 would provide a substrate that 
electronically resembled the successful hydroarylation partner 224 (see Scheme 103) 
and would lead to a six-membered ring as successfully achieved with substrate 213 (see 
Scheme 94). Hence it was decided to synthesise a new substrate, starting with 3,5-
dimethoxybenzaldehyde. It was hypothesised that this electron rich arene would follow 
the auration pathway (see Scheme 105) in preference to the Friedel-Crafts like 
mechanism. 
R
N
Boc
COOMe
AuCl3 (5 mol%), AgOTf (15 mol%)
rt. - reflux, 24 h - 5 days
N
COOMe
Boc
232  R = H
233  R = OMe
234  R = H  
235  R = OMe
R
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3,5-Dimethoxybenzaldehyde 240 was subjected to reductive amination using (±)-serine 
methyl ester hydrochloride and NaBH3CN to give the amine 241 in good yield (Scheme 
115).  
 
Scheme 115 Reductive amination of 240 using (±)-serine methyl ester.HCl 
The amine 241 was then protected using Boc-anhydride and the hydroxyl group was 
tosylated using TsCl and Et3N, followed by in situ elimination of tosic acid to give the 
corresponding N-Boc-alkene 242 in good yield (Scheme 116).  
 
Scheme 116 Boc-protection and in situ elimination of TsOH to give 242 
The new electron rich arene 242 was then subjected to Au(III) catalysis (Table 15 and 
Scheme 117) 
Table 15 Attempted Au(III) catalysed cyclization of 242 
Entry Conditions Results 
1 5% AuCl3/15% AgOTf, DCE, rt., 24h No reaction, starting material recovered 91% 
2 5% AuCl3/15% AgOTf, DCE, reflux, 24h No reaction, starting material recovered 89% 
Substrate 242 was tested first by following the standard procedure using Au(III) 
chloride and AgOTf and stirring in DCE for 24 hours at room temperature.[14] However, 
no product formation was observed, and the starting material was recovered in 91% 
MeO CHO
240
MeO
N
H
COOMe
HO
(±)-serine methyl ester.HCl
KOAc, NaBH3CN
4Å mol. siev.
MeOH
241
OMe
79% OMe
Boc2O, TsCl
Et3N, DCM, 48 h
82%
MeO
OMe
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COOMe
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OMe
N COOMe
Boc
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Chapter 5 
~ 129 ~ 
 
yield (Table 15, Entry 1). The reaction was then repeated under reflux conditions for 24 
hours, but still, there was no cyclization, and the starting material was recovered in 89% 
yield.  
 
Scheme 117 Attempted Au(III) catalysed cyclization of 242 
It was clear from the results described above that the Au(III)Cl/AgOTf system was 
ineffective in achieving the desired cyclization of the substrates 223, 232, 233 and 242. 
Hence, it was decided to investigate a significantly different catalyst, a gold(I) catalyst 
PPh3AuCl, as it had shown promising results for intermolecular hydroarylation of 
alkenes.[15]  
 
5.4 A Gold(I)-Catalysed Addition Reaction 
Che and co-workers have reported an efficient method for the intermolecular 
hydroarylation of aliphatic and aryl alkenes such as 245 with indoles exemplified by 
244 using a combination of PPh3AuCl and AgOTf as catalyst (Scheme 118).
[127] 
 
Scheme 118 Au(I) catalysed intermolecular hydroarylation of alkenes with indoles[127] 
MeO
OMe
N COOMe
Boc
242
AuCl3 (5 mol%), AgOTf (15 mol%)
rt. - reflux, 24 h
N
COOMe
BocMeO
OMe
243
N
Me
N
Me(PR3)AuCl (2 mol%)
AgOTf (2 mol%)
tol., 80 oC, 1.25 h
50-100 %
244 245 246
PR3 = PPh3, P(
tBu)2(o-biphenyl), P(4-C6H5OMe)3, PCy3, P(C6F5)3, PEt3
Chapter 5 
~ 130 ~ 
 
It was proposed that the reaction proceeds via the formation of an alkene-Au(I) 
coordinated species 247 which is then attacked by the nucleophilic indole 244 to give a 
gold complex intermediate 248. This intermediate then undergoes protonolysis to give 
the observed product 246 (Scheme 119).[16] 
 
Scheme 119 Proposed mechanism for Au(I) catalysed hydroarylation of alkenes with 
indoles[127] 
In order to verify the efficacy of the Au(I) catalysis reaction, it was decided to attempt a 
test reaction using N-methyl indole 244 and vinyl anisole 249 (Scheme 120). 
 
Scheme 120 Model reaction for Au(I) catalysis 
The catalysts, (PPh3)AuCl and AgOTf, were weighed and added to a vial containing 
toluene. A mixture of N-methyl indole 244 and vinyl anisole 249 was prepared in 
nucleophilic
attack
protonation
reductive 
elimination
alkene
coordination
[Au(PPh3)]
+
Me
245
Me
247
+[(Ph3P)Au]
N
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H+N
Me
248
(Ph3P)Au
H+
N
Me
246
N
OMe
N
OMe(PPh3)AuCl (2 mol%)
AgOTf (2 mol%)
tol., 80 oC, 1.25 h
78% (lit. 95%)
244 249 250
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toluene and added to the vial and the reaction mixture was stirred at 85 °C for 12 hours. 
The coupled product 250 was obtained in good yield after passing the reaction mixture 
through a pad of silica.  
Having succeeded in conducting the model reaction, the three substrates 223, 233 and 
242 were subjected to Au(I) catalysis (Table 16 and Scheme 121). (Since 232 was the 
least electron rich arene in the series that had been synthesised earlier, it was 
hypothesised that it was least likely to give the cyclised product. Hence substrate 232 
was not tested for Au(I) catalysis.) 
Table 16 Attempted Au(III) catalysed cyclization on 223, 233 and 242 
Entry Substrate Conditions Results 
1 223 
2 mol% (PPh3)AuCl, 2 mol% AgOTf,  
tol., 85 °C, 12 h 
No reaction, 223 recovered 94% 
2 233 
2 mol% (PPh3)AuCl, 2 mol% AgOTf, 
 tol., 85 °C, 12 h 
No reaction, 233 recovered 92% 
3 233 
2 mol% (PPh3)AuCl, 2 mol% AgOTf,  
tol., reflux, 12 h 
No reaction, 233 recovered 71% 
4 242 
2 mol% (PPh3)AuCl, 2 mol% AgOTf,  
tol., 85 °C, 12 h 
No reaction, 242 recovered 80% 
5 242 
2 mol% (PPh3)AuCl, 2 mol% AgOTf, 
 tol., reflux, 12 h 
No reaction, 242 recovered 76% 
Substrate 223 was first subjected to Au(I) catalysis following the standard procedure 
used successfully in the test reaction,[15] but after 12 hours no product development was 
seen. The starting material was recovered in 94% yield (Entry 1). Subsequently, 
substrate 233 was tested, but without any success (Entry 2). The reaction was then 
repeated for 233 under reflux conditions, but there was no product formation, and the 
starting material was recovered in 71% yield (Entry 3). Finally, substrate 242 was tested 
under standard conditions as well as reflux conditions, but no cyclization product could 
be obtained (Entries 4 and 5). 
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Scheme 121 Attempted Au(I) catalysed cyclization of 223, 233 and 242 
 
5.5 Conclusions 
Subjecting a series of alkenated substrates 223, 232, 233 and 242, to Au(III) and Au(I) 
catalysis, revealed that the catalysts were ineffective in achieving the desired 
cyclization which would have produced constrained amino acids. It is hypothesised that 
the different functionalities on the substrates may have interacted with the catalyst and 
rendered it inactive. The synthesis of constrained amino acids via a C-H activation 
pathway continues to remain a challenge for synthetic chemists.  
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6.0 Experimental 
6.1 General Experimental 
All reactions and manipulations involving organometallic compounds were performed 
under an inert atmosphere of dry nitrogen, using standard vacuum line and Schlenk 
techniques. All glassware was oven-dried prior to use. Experiments requiring sonication 
were performed in a Bandelin Sonorex TK52-H sonicator. 
Dichloromethane (DCM) was distilled over calcium hydride before use. 
Tetrahydrofuran (THF) and toluene were distilled over sodium benzophenone ketyl and 
used immediately. Alternatively, solvents were dried over alumina in Innovative 
technology solvent towers (water content measured by Karl Fischer titration). Solvents, 
dichloroethane (DCE), dimethylformamide (DMF), ethanol (EtOH) and methanol 
(MeOH) were purchased from Sigma Aldrich as anhydrous solvents with 99.9% purity. 
Lipase B candida Antarctica (CAL-B), recombinant from Aspergillus oryzae (~9 
units/mg) enzyme was purchased from Sigma Aldrich. 4Å and 3Å molecular sieves 
were dried in an oven for 24 h before use. All other reagents were used as purchased 
from commercial sources. Extra precautions were taken while handling Sodium 
cyanoborohydride. 
Thin layer chromatography (TLC) was performed on Merck silica gel glass plates (60Å, 
F254) and Fluka silica gel aluminium plates (60Å, F254), using UV light (254 nm) 
and/or iodine as visualising agent and/or vanillin or KMnO4 soln. and heat as 
developing agents. Preparative TLC was performed using Merck silica gel glass plates 
(60Å, F254). Flash column chromatography was performed using BDH silica gel 
(particle size 33-70 µm). 
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Melting points were recorded on a Buchi 510 melting point apparatus in open 
capillaries and are uncorrected. 
Infra red spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer. 
The following abbreviations are used to define the intensities: s = strong, m = medium, 
w = weak, br = broad. 
Mass spectra were recorded on Micromass Platform II and Micromass AutoSpec-Q 
spectrometers by the mass spectrometry service at Imperial College London. 
Optical rotations were recorded on a Perkin Elmer 241 polarimeter using a sodium low 
pressure light (sodium D line 589.3 nm) and a 1 dm path length. Concentrations (c) are 
given as g/100mL. 
NMR spectra (1H and 13C) were recorded at room temperature on Bruker AV 400 
instruments in CDCl3 unless otherwise stated. J values are reported in Hertz and 
rounded up to the nearest 0.5 decimals. Chemical shifts in ppm. The following 
abbreviations are used to define the multiplicities: s = singlet, d = doublet, t = triplet, q 
= quartet, quin = quintet, br = broad. The protons and carbons were assigned with the 
aid of  DEPT 90 (distortionless enhancement by polarization transfer) and DEPT 135, 
1H/1H COSY (correlation spectroscopy) and 1H/13C HMQC (heteronuclear multiple 
quantum coherence) correlation experiments wherever necessary.  
Elemental analyses were performed by the London Metropolitan University elemental 
analysis service. 
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6.2 Experimental for Chapter 2 
2-Iodobenzaldehyde (76)
[37]
:   
 
2-Iodobenzyl alcohol 50 (5.00 g, 21.4 mmol) was dissolved in chloroform (100 mL), 
and then MnO2 (50.00 g, 575.2 mmol) was added slowly to the solution. The reaction 
mixture was stirred overnight (12 h) at room temperature and then filtered over Celite®. 
The filtered solution was evaporated under reduced pressure to yield compound 76 
(4.21 g, 85 %) as a white crystalline solid. M.p. 37-38 °C (lit. 38-39 °C)[37]; Rf = 0.42 
(SiO2; hexane/ethyl acetate 19:1); IR υmax(neat)/cm
-1 C=O 1694 (s); 1H NMR (400MHz, 
ppm, CDCl3) δ 7.27 (1 H, td, J 7.5, 1.5 CArH4), 7.45 (1 H, t, J 7.5, CArH5), 7.86 (1 H, 
dd, J 7.5, 1.5 CArH6), 7.93 (1 H, d, J 7.5, CArH3), 10.05 (1 H, s, CHO); 
13C NMR 
(100MHz, ppm) δ 100.8 (ArC2), 128.7, 130.0, 130.3, 135.5 (ArC3,4,5,6), 140.7 (ArC1), 
195.7 (CHO); MS (EI) m/z (%) 232 (M+, 100), 203 (MH+ – CHO, 15), 104 (M+ – I, 48). 
The experimental data was consistent with the values reported in literature.[37] 
 
(E) and (Z)-2-Phenyl-1-methoxyethene (77)
[37]
:   
 
Potassium tert-butoxide (20.10 g, 179.1 mmol) was added portionwise to a stirred 
suspension of (methoxymethyl)triphenylphosphonium chloride (50.01 g, 145.8 mmol) 
I
CHO
1
2
3
4
5
6
I
OMe
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in THF (100 mL) under nitrogen in an ice bath. After stirring the red solution at room 
temperature for 30 min, 2-iodobenzaldehyde 76 (20.80 g, 89.6 mmol) in THF (50 mL) 
was added via a cannula. The reaction mixture was stirred at room temperature for 12 h 
and its colour was seen to change from dark red to an opaque yellow-brown. Saturated 
aq. NH4Cl (100 mL) was added with stirring. The organic layer was decanted and the 
aqueous layer was extracted with diethyl ether (75 mL × 3). The combined organic 
layers were dried over MgSO4 and evaporated under reduced pressure to give a viscous 
brown oil. Vacuum distillation at 170 °C yielded compound 77 as a pale yellow oil 
(19.00 g, 82 %). IR υmax(neat)/cm
-1 C=C 1635 (s), C-O-C 1237 (m); 1H NMR 
(400MHz, ppm, CDCl3) δ = 3.79 (3 H, s, (E)- or (Z)-CH3), 3.81 (3 H, s, (E)- or (Z)-
CH3), 5.57 (1 H, d,  J 7, (Z)-CHOCH3), 6.08 (1 H, d, J 13, (E)-CHOCH3), 6.27 (1 H, d, 
J 7, (Z)- ArCH=CHOCH3), 7.01 (1 H, d, J 13, (E)- ArCH=CHOCH3), 6.87 – 6.92 (2 H, 
m, (E)- and (Z)- CArH5), 7.29 – 7.37 (2 H, m, (E)- and (Z)- CArH4), 7.88 – 7.91 (2 H, m, 
(E)- and (Z)- CArH6), 8.10 (2 H, d, J 6.5, (E)- and (Z)- CArH3); 
13C NMR (100MHz, 
ppm) δ 56.7 [(E)-OCH3], 60.9 [(Z)-OCH3], 99.6 [(Z)-ArC2)], 99.9 [(E)-ArC2], 109.2 
[(Z)-ArCH=CHOCH3], 109.6 [(E)-ArCH=CHOCH3], 125.3, 127.5, 128.0, 128.5, 128.6, 
129.7 [(E)- and (Z)- ArC4,5,6], 138.4, 139.7 [(E)- and (Z)- ArC1], 139.3, 139.5 [(E)- and 
(Z)- ArC3], 149.2 [(Z)-ArCH=CHOCH3], 150.7 [(Z)-ArCH=CHOCH3] ; MS (EI) m/z 
(%) 260 (M+, 100), 118 (M+ – I, – CH3, 68), 217 (MH
+ – CHOCH3, 12), 90 (MH
+ – I, – 
CH=CHOCH3, 48). The experimental data was consistent with the values reported in 
literature.[37] 
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(2-Iodophenyl)ethanal (78)
[37]
:  
 
Formic acid (17.80 g, 386.9 mmol) was added to a solution of (E) and (Z)-1-(2-
iodophenyl)-2-methoxyethene 77 (5.00 g, 19.2 mmol) in DCM (50 mL). The reaction 
was stirred at room temperature in a foil-covered vessel for 64 h. Water (100 mL) was 
then added to the reaction mixture and the organic layer was separated. The aqueous 
layer was extracted with DCM (50 mL × 3). The combined organic layers were washed 
with saturated aq. Na2CO3 (50 mL), brine (50 mL), dried over MgSO4 and evaporated 
under reduced pressure to give the title compound 78 as a brown oil (3.80 g, 80%). IR 
υmax(neat)/cm
-1 C=O 1709 (s); 1H NMR (400 MHz, ppm, CDCl3) δ  3.91 (2 H, d, J 1.5, 
ArCH2), 7.03 (1 H, td, J 7.5, 1.5, CArH4), 7.25 (1 H, dd, J 7.5, 1.5, CArH6), 7.37 (1 H, td, 
J 7.5, 1, CArH5), 7.91 (1 H, dd, J 7.5, 1, CArH3 ), 9.79 (1 H, t, J 1.5, CHO); 
13C NMR 
(100 MHz, ppm) δ 54.7 (ArCH2), 101.1 (ArC2), 128.8, 129.3, 130.9 (ArC4,5,6), 136.2 
(ArC1), 139.7 (ArC3), 198.4 (CHO); MS (EI) m/z (%): 246 (M
+, 31), 217 (M+ – CHO, 
64), 119 (M+ – I, 100), 90 (M+ – I, – CHO, 61). The experimental data was consistent 
with the values reported in literature.[37] 
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N-[2-(Phenyl)ethyl]serine methyl ester (79)
[37]
:  
 
(±)-Serine methyl ester hydrochloride (2.50 g, 16.0 mmol), potassium acetate (1.50 g, 
15.3 mmol) and activated 4 Å molecular sieves (10 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(100 mL) was added via a cannula and the reaction mixture was stirred for 15 min. A 
solution of (2-iodophenyl)ethanal 78 (2.00 g, 8.1 mmol) was prepared in dry methanol 
(10 mL) and transferred to the reaction vessel via a syringe. The mixture was stirred for 
2 h, and then a solution of sodium cyanoborohydride (1.20 g, 19.1 mmol) in MeOH    
(10 mL) was slowly added over 30 min (evolution of gas was observed with mild 
exotherm). The reaction mixture was then stirred at room temperature for 15 h. Excess 
sodium cyanoborohydride was quenched by adding 6M HCl (5 mL). The gas evolved 
was passed through 5M NaOH. When no more gas was seen to evolve, the mixture was 
rendered alkaline by careful addition of saturated Na2CO3 solution (25 mL). The 
mixture was filtered through a sintered funnel and the slurry was thoroughly washed 
with MeOH. The solvent was removed under reduced pressure leaving an aqueous 
slurry which was diluted with H2O (50 mL) and then extracted with Et2O (3 × 75 mL). 
The combined organic layers were dried over MgSO4 and evaporated in vacuo to give 
the title compound 79 as a colourless oil (2.73 g, 96%). IR υmax(neat)/cm
-1 NH, OH 
3312 (br), C=O 1735 (s), C-N 1205 (m); 
1H NMR (400 MHz, ppm, CDCl3) δ 2.18 (2 H, 
s, NH and OH), 2.73 – 2.80 (1 H, m, ArCHHCH2N), 2.87 – 3.03 (3 H, m, 
ArCHHCH2N), 3.46 (1 H, dd, J 6.5, 4.5, CHCOOCH3),  3.60 (1 H, dd, J 10.5, 6.5, 
CHHOH ), 3.77 (3 H, s, COOCH3), 3.79 (1 H, dd, J 10.5, 4.5, CHHOH ), 6.90 – 6.94 (1 
I
H
N COOMe
OH
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H, m, CArH4), 7.24 – 7.32 (2 H, m, CArH5,6), 7.83 (1 H, dd, J 8, 1, CArH3); 
13C NMR 
(100MHz, ppm) δ 41.4 (ArCH2), 48.0 (ArCH2CH2), 52.2 (COOCH3), 62.2 (CH2OH), 
62.5 (CHCOOMe), 139.6 (ArC3), 142.1 (ArC1), 128.2, 128.4, 128.8 (ArC4,5,6), 100.7 
(ArC2), 173.4 (COOMe); MS (CI, NH3) m/z (%) 372 (MNH4
+, 12), 350 (MH+, 100). 
The experimental data was consistent with the values reported in literature.[37] 
 
Methyl 2-{N-[2-(2-iodophenyl)ethyl-N-(tert-butoxycarbonyl)-amino}prop-2enoate 
(80)
[37]
: 
 
 
Di-tert-butyl dicarbonate (2.11 g, 9.7 mmol) was added to a solution of N-[2-(2-
iodophenyl)ethyl]serine methyl ester 79 (2.81 g, 8.1 mmol) in dry DCM (10 mL) under 
N2. The mixture was stirred for 20 h at room temperature. Tosyl chloride (2.30 g,     
12.1 mmol) was dissolved in dry DCM (5 mL) and added to the reaction vessel 
followed by triethylamine (3.40 mL, 24.1 mmol). The mixture was stirred for 12 h and 
then diluted with DCM (25 mL), washed with dil. HCl (25 mL), saturated Na2CO3 
solution (25 mL), brine (25 mL), dried over MgSO4 and the solvent evaporated under 
reduced pressure. Column chromatography (SiO2; hexane/diethyl ether 7:3; Rf = 0.62) 
yielded compound 80 as a colourless oil (2.20 g 63%). IR υmax(neat)/cm
-1 C=O 1735, 
1706 (s), C=C 1632 (m), C-N 1158 (s); 
1H NMR (400 MHz, ppm, CDCl3) δ 1.43 (9 H, 
s, C(CH3)3), 3.05 (2 H, t, J 8, ArCH2), 3.66 (2 H, t, J 8, CH2N), 3.79 (3 H, s, COOCH3), 
5.35 (1 H, s, =CHH), 5.91 (1 H, s, =CHH ), 6.88 – 6.91 (1 H, m, CArH4), 7.25 – 7.32 (2 
H, m, CArH5,6), 7.79 (1 H, d, J 8, CArH3); 
13C NMR (100 MHz, ppm) δ 49.9 
I
N
Boc
COOMe
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(ArCH2CH2), 28.2 (C(CH3)3), 39.5 (ArCH2), 52.3 (COOCH3), 81.2 (C(CH3)3), 100.4 
(ArC2,), 128.3, 128.6, 130.4 (ArC4,5,6), 117.7 (=CH2), 139.5 (ArC3), 140.1, 141.7 (ArC1 
and CCOOMe), 153.9 (C=O, Boc), 165.1 (COOMe); MS (CI, NH3) m/z (%) 449 
(MNH4
+, 80), 432 (MH+, 33), 393 (MNH4
+ – C(CH3)3, 100), 332 (MH
+ – COOC(CH3)3, 
57). The experimental data was consistent with the values reported in literature.[37] 
 
2-Methoxycarbonyl-3-(tert-butoxycarbonyl)-4,5-dihydro-3H-3-benzazepine (81)
[37]
:
 
 
 
Methyl 2-{N-[2-(2-iodophenyl)ethyl-N-(tert-butoxycarbonyl)-amino}prop-2-enoate 80 
(4.64 g, 10.8 mmol) was introduced in a flask containing DMF (50 mL) (saturated with 
nitrogen gas) and stirred at room temperature. 3 Å sieves (2 g) was added followed by 
Pd(OAc)2 (483 mg, 2.1 mmol), tetrabutylammonium chloride (2.99 g, 10.8 mmol) and 
NaHCO3 (2.26 g, 26.9 mmol). The flask was fitted with a condenser, and after 
saturation with nitrogen, was immersed into a preheated oil bath at 110 °C. After a few 
minutes the reaction mixture turned deep brown. The heating was continued for 3-4 h 
until complete conversion was seen on TLC. The reaction mixture was cooled to room 
temperature and filtered through Celite® (DCM) to give a brown oil after evaporation of 
the solvents under reduced pressure. Column chromatography (SiO2; light 
petroleum/diethyl ether, 5:1; Rf = 0.52) afforded the title compound as pale yellow oil 
81 (2.2 g. 67 %) which crystallised on refrigeration. M.p. 70-72 °C (lit. 68-69 °C); IR 
υmax(neat)/cm
-1 C=O 1708 (s), C=C 1637 (m), C-N 1158 (s); 
1H NMR (400 MHz, ppm, 
CDCl3) δ 1.43 (9 H, s, C(CH3)3), 3.14 (2 H, t, J 5, ArCH2), 3.79 (2 H, t, J 5, CH2N), 
3.84 (3 H, s, COOCH3), 6.92 (1 H, s, C=CH), 7.33 – 7.35 (1 H, m, CArH3), 7.22 – 7.25 
N
COOMe
Boc
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(3 H, m, CArH4,5,6); 
13C NMR (100 MHz, ppm) δ 28.1 (C(CH3)3), 36.9 (ArCH2), 52.3 
(COOCH3), 81.5 (C(CH3)3), 126.4, 128.5, 130.6 (ArC4,5,6), 126.1 (C=CH), 131.7, 132.1 
(ArC1,2), 133.7 (ArC3), 139.9 (C=CH), 152.7 (C=O, Boc), 166.6 (COOMe); MS (CI, 
NH3) m/z (%): 321 (MNH4
+, 44), 304 (MH+, 100), 204 (M+ – COOC(CH3)3, 76). The 
experimental data was consistent with the values reported in literature.[37] 
 
3-tert-Butyl 2-methyl 1,2,4,5-tetrahydrobenzo[d]azepine-2,3-dicarboxylate (84)
[37]
: 
 
2-Methoxycarbonyl-3-(tert-butoxycarbonyl)-4,5-dihydro-3H-3-benzazepine 81 (100 
mg, 0.3 mmol) was introduced into a flask containing EtOH (25 mL). The flask was 
saturated with H2 and ammonium formate (416 mg, 6.7 mmol) and the catalyst       
(10% Pd/C) (20 mg, 20%) were carefully added to the reaction mixture. The flask was 
then connected to a condenser and sonicated for 48 h. The reaction mixture was cooled 
to room temperature and filtered through Celite® (EtOH) and the solvent was 
evaporated in vacuo to give a white residue. The residue was extracted into Et2O (25 
mL × 3) and the extracts were dried over MgSO4. The solvents were evaporated to give 
the product 84 as a colorless oil (0.10 g, 100%).  IR υmax(neat)/cm
-1  C=O 1697 (s), 
1746 (s), C–N 1165 (w); 1H NMR (400 MHz, ppm, CDCl3) δ 1.40 and 1.45 [18 H, 2 × 
s, C(CH3)3 rotamers], 2.77 – 3.41 (10 H, m, ArCH2CH2, ArCH2CH, CHHN rotamers), 
3.63 and 3.65 (6 H, 2 × s, COOCH3 rotamers), 4.21 and 4.32 (2 H, 2 × dt, J 15, 5, 
CHHN rotamers),  4.95  and  5.25, (2 H,  2 × dd, J 8, 4, ArCH2CH rotamers), 7.02 – 
7.21 (8 H, m, CArH3,4,5,6 rotamers); 
13C NMR (100 MHz, ppm) δ 28.2 [C(CH3)3], 35.4, 
N
COOMe
Boc
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35.8, 36.9 and 37.2 (ArCH2CH2 and ArCH2CH rotamers), 41.4 and 42.5 (CH2N 
rotamers), 51.9 (COOCH3), 56.1 and 57.9 (CHCOOCH3 rotamers), 80.3 [C(CH3)3], 
126.3, 126.4, 127.0, 127.2, 129.0, 129.3, 130.4 and 130.5 (ArC3,4,5,6 rotamers), 136.0, 
136.3, 140.0 and 140.1 (ArC1,2 rotamers), 155.2 and 155.7 [COOC(CH3)3 rotamers], 
171.4 and 171.6 COOCH3; MS (CI, NH3) m/z (%) 323 (MNH4
+, 32), 306 (MH+, 12), 
250 (MNH4
+ – OC(CH3)3, 18), 146 (MH
+ – COOCH3 – COOC(CH3)3, 100). The 
experimental data was consistent with the values reported in literature.[37] 
 
2,3,4,5-Tetrahydro-1H-benzo[d]azepine-2-carboxylic acid hydrochloride (85)
[37]
: 
 
A suspension of 3-tert-butyl-2-methyl-1,2,4,5-tetrahydrobenzo[d]azepine-2,3-
dicarboxylate 84 (1.20 g, 3.9 mmol) in 3M HCl (40 mL) was stirred at 90 °C for 24 h. 
The reaction mixture was cooled to room temperature and washed with Et2O (20 mL) 
and the aqueous layer was evaporated under reduced pressure to give the product 85 as 
a white solid (0.88 g, 98%). M.p. 240-243 °C, decomp. (lit. 242-245 °C, decomp.)[37]; 
IR υmax(neat)/cm
-1  C=O 1738 (s); 1H NMR (400 MHz, ppm, MeOH) δ 3.09 – 3.28 (3 
H, m, ArCH2CH2 and ArCHHCH), 3.38 – 3.53 (2 H, m, ArCH2CHHN, ArCHHCH), 
3.59 – 3.70 (1 H, m, ArCH2CHHN), 4.18 (1 H, dd, J 8.5. 1.5, ArCH2CHCOOH), 7.20 – 
7.40 (4 H, m, CArH3,4,5,6); 
13C NMR (100 MHz, ppm) δ 31.4 (ArCH2CH2N), 34.8 
(ArCH2CH), 44.8 (ArCH2CH2N), 57.7 (ArCH2CH), 127.3, 127.7, 129.1, 130.0 
(ArC3,4,5,6), 136.2, 139.1 (ArC1,2), 169.2 (COOH); MS (CI, NH3) m/z (%) 192 (MH
+ – 
ClNH2
COOH
Chapter 6 
~ 144 ~ 
 
HCl, 100), 146 (M+ – HCl –COOH, 24). The experimental data was consistent with the 
values reported in literature.[37] 
2,3,4,5-Tetrahydro-1H-benzo[d]azepine-2-carboxylic acid (32b)
[37]
: 
 
A solution of 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylic acid hydrochloride 
85 (0.68 g, 2.9 mmol) was prepared in EtOH (30 mL). Propene oxide (2.50 mL,       
35.7 mmol) was added with a syringe and the flask was stirred at 50 °C for 4 h. The 
product 32b precipitated as a white solid. The reaction mixture was cooled to room 
temperature and the solvents were evaporated under reduced pressure to give the amino 
acid 32b as a white solid (0.46 g, 81%). M.p. 266-268 °C, decomp. (lit. 267-274 °C, 
decomp.); IR υmax(neat)/cm
-1  C=O 1598 (s); MS (CI, NH3) m/z (%) 209 (MNH4
+, 9), 
192 (MH+, 100), 146 (M+ – COOH, 25). The experimental data was consistent with the 
values reported in literature.[37] 
 
 
 
 
 
 
NH
COOH
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(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2,3,4,5-tetrahydro-1H-benzo[d] 
azepine-2-carboxylate (89a,b): 
 
A solution of tosic acid hydrate (0.15 g, 0.8 mmol) in toluene (50 mL) was refluxed 
using a Dean-Stark condenser and water was removed. The flask was then cooled to 
room temperature and (–)-menthol (0.12 g, 0.78 mmol) and 32b (0.10 g,   0.52 mmol) 
were added to the flask. Reflux using Dean-Stark was continued for 30 h. The flask was 
then cooled to room temperature and the contents were filtered over Celite®. The 
organic extract was washed with saturated Na2CO3 (50 mL) and brine (50 mL) and 
dried over MgSO4 and the solvent was evaporated under reduced pressure to give a 
crude oil which was purified via preparative TLC (SiO2; Et2O/hexane 1:1 and 1% 
EtOH; Rf = 0.23) to yield the product as a colorless oil (23 mg, 11%).                           
IR υmax(neat)/cm
-1  C=O 1737 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 0.72 and 0.76 [6 
H, 2 × d, J 7, CH2CH(CH3)CH2 (2 × C-10) diastereomers], 0.82 – 1.10 [12 H, m, 
CH(CH3)2, (2 × C-8,9) diastereomers],  1.23 – 2.07 [18 H, m, 
(CH3)2CHCHCH(O)CH2CH(CH3)CH2CH2, (2 × C-2,3,4,5,6,7) diastereomers], 2.74–
3.46 [14 H, m, 2 × ArCH2CH2NHCH(CO)CH2 diastereomers], 3.55 and 3.62 [2 H, 2 × 
dd, J 9, 2, ArCH2CH × 2 diastereomers], 4.76 [2 H, 2 × td, J 11, 4, CH(O), (2 × C-1) 
diastereomers], 7.14 – 7.22 (8 H, m, 2 × CArH3,4,5,6 diastereomers); 
13C NMR (100 
MHz, ppm) δ 16.2, 16.3 [CH3CH, (2 × C-10)], 20.8, 20.9, 23.2, 23.4 [(CH3)2CH, (2 × 
C-8,9)], 26.2, 26.3 [(CH3)2CH, (2 × C-7)], 31.0, 31.4 [CH(CH3)CH2, (2 × C-5)], 34.2, 
34.3 [2 × CH2CH(CH3)], 38.7, 38.8 (2 × ArCH2CH2N),  41.3, 41.4 (2 × ArCH2CH), 
NH
O
O
8
9
7
21
6
5 4
3
10
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40.8 [CH(O)CH2, (2 × C-6)], 46.3, 46.7, 47.0, 47.1 [2 × ArCH2CH2N and 
(CH3)2CHCH, (2 × C-2)], 59.6, 60.1 (2 × ArCH2CH), 75.1, 75.2 [CH(O)CH2, (2 × C-
1)], 126.3, 126.4, 126.7, 126.8, 129.2, 130.0 (2 × ArC3,4,5,6), 138.7, 138.9, 141.9, 142.0 
(2 × ArC1,2), 172.2, 172.3 (2 × C=O); HRMS (ESI) calcd. for C21H32NO2
 (330.2433), 
found 330.2429; Elemental analysis calcd. (%) for C21H31NO2 (329.23): C 76.55, H 
9.48, N 4.25 found: C 76.6, H 9.2, N 4.1. 
 
Ethyl 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylate hydrochloride (91)
[128]
: 
 
2,3,4,5-Tetrahydro-1H-benzo[d]azepine-2-carboxylic acid 32b (1.00 g, 5.2 mmol) was 
added to a flask containing EtOH (20 mL). The flask was then cooled to –10 °C and 
SOCl2 (0.57 mL, 7.9 mmol) was added slowly using a syringe. The flask was warmed 
to room temperature and stirred for 4 h followed by reflux for 1 h. The reaction mixture 
was then cooled to room temperature and the solvent was evaporated under reduced 
pressure to give the product 91 as a light brown solid (1.36 g, 100%). M.p. 74-76 °C;  
IR υmax(neat)/cm
-1  C=O 1743 (s);  1H NMR (400 MHz, ppm, ethanol d6) δ 1.32 (3 H, t, 
J 7, COOCH2CH3), 3.10 – 3.40 (3 H, m, ArCH2CH2N, ArCHHCH), 3.41 – 3.54 (2 H, 
m, ArCHHCH, ArCH2CHHN), 3.61 – 3.80 (1 H, m, ArCH2CHHN), 4.18 (1 H, dd, J 9, 
2, CHCOOC2H5), 4.26 (2 H, q, J 7, COOCH2CH3), 6.87 – 7.45 (4 H, m, CArH3,4,5,6);
 13C 
NMR (100 MHz, ppm) δ 13.4 (COOCH2CH3), 31.5 (ArCH2CH2N), 33.4 (ArCH2CH), 
44.5 (ArCH2CH2N), 57.4 (ArCH2CH), 62.4 (COOCH2CH3), 127.2, 127.9, 129.2, 130.1 
(ArC3,4,5,6), 136.0, 139.2 (ArC1,2), 168.8 (COOC2H5); MS (ESI) m/z (%) 220 (MH
+ – 
NH2
COOEt
Cl
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HCl, 100), 146 (M+ – HCl – COOC2H5, 12). Elemental analysis calcd. (%) for 
C13H17NO2 (255.74): C 61.05, H 7.09, N 5.48 found: C 61.1, H 6.9, N 5.5. The 
experimental data was consistent with the values reported in literature.[128] 
 
Ethyl 2,3,4,5-tetrahydro-3-(2-hydroxypropyl)-1H-benzo[d]azepine-2-carboxylate 
(93): 
 
Ethyl 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylate hydrochloride 91 (1.36 g, 
5.3 mmol) was dissolved in EtOH (20 mL). Propene oxide (4.5 mL, 63.9 mmol) was 
added using a syringe and the reaction mixture was stirred at 50 °C for 4 h. The flask 
was then cooled to room temperature and reaction mixture was filtered over Celite® and 
the filtrate was evaporated to give a brown oil which was purified by column 
chromatography (SiO2; Et2O/hexane 1:1; Rf = 0.52) to give the product 93 as a white 
solid (0.82 g, 58%). M.p. 79-81 °C; IR υmax(neat)/cm
-1  OH 3408 (br), C=O 1731 (s);  
1H NMR (400 MHz, ppm, CDCl3) δ 1.23 (3 H, J 7, COOCH2CH3), 1.35 (3 H, d, J 6.5, 
NCH2CH(OH)CH3), 2.23 – 2.46 (2 H, m, NCHHCH(OH)CH3 and ArCHHCH2N or 
ArCHHCH), 2.74 – 3.27 (6 H, m, ArCHHCH2N, ArCHHCH and ArCHHCH2N or 
ArCHHCH), 4.03 (2 H, q, J 7, COOCH2CH3), 4.74 (1 H, m, NCH2CH(OH)CH3), 7.05 
– 7.36 (4 H, m, CArH3,4,5,6); 
13C NMR (100 MHz, ppm) δ 14.3 (COOCH2CH3), 19.0 
(NCH2CH(OH)CH3), 36.4 and 39.5 (ArCH2CH2N and ArCH2CH), 57.8 and 59.2 
(ArCH2CH2N and NCH2CH(OH)CH3), 66.7 (ArCH2CH), 75.1 (NCH2CH(OH)CH3), 
126.7, 127.0, 128.7 and 129.8 (ArC3,4,5,6), 139.6 and 141.4 (ArC1,2), 170.2 
N
COOEt
OH
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(COOCH2CH3); MS (ESI) m/z (%) 300 (MNa
+, 8), 278 (MH+, 100), 232 (M+ – 
CH3CHOH, 38); Elemental analysis calcd. (%) for C21H29NO6S (423.17): C 59.55, H 
6.90, N 3.31 found: C 59.6, H 6.7, N 3.2. 
 
Ethyl 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylate (92): 
 
2,3,4,5-Tetrahydro-1H-benzo[d]azepine-2-carboxylic acid 32b (0.64 g, 3.3 mmol) was 
added to a flask containing EtOH (20 mL). The flask was then cooled to –10 °C and 
SOCl2 (0.57 mL, 7.9 mmol) was added slowly using a syringe. The flask was warmed 
to room temperature and stirred for 4 h followed by reflux for 1 h. The reaction mixture 
was then cooled to room temperature and treated with 2M KOH (10 mL). The aqueous 
layer was extracted with Et2O (10 mL × 3). The organic layers were dried over MgSO4 
and the solvent evaporated to give the ester 92 as a colorless oil which was purified by 
column chromatography (SiO2; Et2O/hexane 1:1 and 1% EtOH); Rf = 0.47) (0.32 g, 
44%). IR υmax(neat)/cm
-1  C=O 1729 (s);  1H NMR (400 MHz, ppm, CDCl3) δ 1.30 (3 
H, t, J 7, CH2CH3), 2.69 (1 H, s, br, NH), 2.77 – 3.09 (3 H, m, ArCH2CH2N, 
ArCHHCH), 3.13 – 3.30 (2 H, m, ArCHHCH, ArCH2CHH), 3.30 – 3.40 (1 H, m, 
ArCH2CHH), 3.57 (1 H, dd, J 9, 2, CHCOOC2H5), 4.21 (2 H, q, J 7, COOCH2CH3), 
7.07 – 7.22 (4 H, CArH3,4,5,6); 
13C NMR (100 MHz, ppm) δ 14.2 (COOCH2CH3), 38.8 
(ArCH2CH2N), 41.4 (ArCH2CH), 46.5 (ArCH2CH2N), 59.8 (ArCH2CH), 61.2 
(COOCH2CH3), 126.3, 126.8, 129.2, 130.0 (ArC3,4,5,6), 138.8, 142.1 (ArC1,2), 172.7 
(COOC2H5); MS (ESI) m/z (%) 220 (MH
+, 100), 146 (M+ – COOC2H5, 5). Elemental 
NH
COOEt
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analysis calcd. (%) for C13H17NO2 (219.12): C 71.21, H 7.81, N 6.39 found: C 71.4, H 
7.7, N 6.3. 
 
Attempted Enzyme (CAL-B) dynamic kinetic resolution of 92 (see Scheme 25): 
Sic ethyl ester 92 (0.06 g, 0.3 mmol) was introduced in a test tube and dissolved in 
toluene/MeCN 4:1 (3 mL). H2O (5 µL, 0.3 mmol) and DIPE (9.7 µL, 0.07 mmol) were 
added followed by CAL-B enzyme (107 mg). Toluene/MeCN 4:1 (2 mL) was added to 
the reaction mixture and the test tube was sealed with a rubber septum and placed in a 
shaker at 25 °C for 2 days. More of CAL-B enzyme (107 mg) was then added and the 
test tube was placed back in the shaker for 6 days at 25 °C. The reaction contents were 
then filtered through Celite® and washed with DIPE and H2O (40 °C). The aqueous 
layer was separated and water was evaporated but no residue was obtained. The organic 
layer was dried over MgSO4 and the solvent evaporated to give back the starting 
material Sic ethyl ester 92 (42 mg, 71%).  
 
Camphor-10-sulfonyl 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylic acid 
(100): 
 
2,3,4,5-Tetrahydro-1H-benzo[d]azepine-2-carboxylic acid 32b (0.84 g, 4.4 mmol) and  
(–)-camphor-10-sulfonic acid (1.02 g, 4.4 mmol) were dissolved in 2:1 AcOH/methyl 
isobutyl ketone (30 mL) and the reaction mixture was stirred at 80 °C for 15 h. The 
NH2
COOH
H3C
CH3 S
O
O
O
O1 2
3
45
6
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product precipitated in the solution and was filtered through a sintered funnel and 
washed with methyl isobutyl ketone to give 100 as  a  white  solid  (1.68 g, 90%).    
M.p.  280-285 °C; [α] 
 = –10.19 (c 0.864, 1M dm-3 HCl); IR υmax(neat)/cm
-1  COOH 
2812 (br), C=O 1740 (s); 1H NMR (400 MHz, ppm, D2O) δ 0.68 and 0.88 (6 H, 2 × s, 2 
× CH3 of CSA), 1.21 – 1.36 [1 H, m, CHH of CSA, (C-6)], 1.39 – 1.55 [1 H, m, CHH 
of CSA, (C-6)], 1.77 – 2.06 [3 H, m, CH and CH2 of CSA, (C-4, 5)], 2.16 – 2.32 [2 H, 
m, CH2 of CSA, (C-3)], 2.71 [1 H, d, J 15, CHHSO3
- of CSA, (C-8)], 2.94 – 3.10 (3 H, 
m, ArCH2CH2N and ArCHHCH), 3.13 [1 H, d, J 15, CHHSO3
- of CSA, (C-8)], 3.18 – 
3.39 (2 H, m, ArCHHCH and ArCH2CHHN), 3.44 –3.60 (1 H, m, ArCH2CHHN), 3.95 
(1 H, dd, J 9, 2, ArCH2CH); 
13C NMR (100 MHz, ppm) δ 18.6 and 18.7 (2 × CH3 of 
CSA), 24.4 and 26.1 [2 × CH2 of CSA (C-5, 6)], 31.1 and 34.6 (ArCH2CH2N and 
ArCH2CH), 42.1 [CH of CSA, (C-4)], 42.4 [CH2 of CSA, (C-3)], 44.5 (ArCH2CH2N), 
47.0 [–CH2SO3
- of CSA, (C-8)], 48.1 [C(CH3)2 of CSA, (C-7), 58.1 (ArCH2CH), 58.4 
[CCH2SO3
- of CSA, (C-1)], 127.5, 127.9, 129.3, 130.0 (ArC3,4,5,6), 136.2 and 139.0 
(ArC1,2), 171.4 (COOH), 221.8 [C=O of CSA, (C-2)]; HRMS (ESI, +ve ion) calcd. for 
C11H14NO2
+ (192.1019), found 192.1021; HRMS (ESI,  –ve ion) calcd. for C10H15SO4
- 
(231.0697), found 231.0681; Elemental analysis calcd. (%) for C21H29NO6S (423.17): C 
59.55, H 6.90, N 3.31 found: C 59.6, H 6.7, N 3.2. 
 
Attempted fractional crystallization of CSA.Sic 100 (see Figure 39): 
CSA.Sic 100 (0.10 g, 0.2 mmol) was dissolved in minimum quantity of MeCN/H2O 1:1 
(0.8 – 1 mL) in a vial until a clear solution was obtained. The solution was allowed to 
stand at room temperature for 24 h. The crystals formed overnight were separated by 
removing the mother liquor and transferring it into another vial. The mother liquor was 
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allowed to recrystallize for another 24-48 h and the crystals obtained in the first batch 
were dried in vacuo (48 mg, 48%) and analysed for [α] 
 = -11.57 (c 0.864, 1M dm-3 
HCl). The crystals obtained in the second batch (after drying all the mother liquor) were 
dried in vacuo (42 mg, 42%) and analysed for [α] 
 = -7.81 (c 0.909, 1M dm-3 HCl). 
Procedure for hydrolysis of CSA.Sic 100 to give Sic 32b (see Scheme 29): 
Camphor-10-sulfonyl 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylic acid 100 
(0.10 g, 0.24 mmol) was dissolved in a minimum quantity of water (1.1 mL) until a 
clear solution was obtained. The solution was then warmed to 55 °C and KOH (2 M 
soln) was added drop-wise until the pH of the solution was in the range of 4-5. When 
the pH exceeded 5, it was lowered by addition of HCl (1M soln.) and maintained 
between 4 and 5. The solution was allowed to stand at 55 °C for 30 mins, while the Sic 
amino acid precipitated in the solution. The suspension was cooled to room temperature 
and filtered through a filter paper (H2O) and dried in vacuo to give Sic 32b (38 mg, 
82%) as a while crystalline solid. [α] 
 = 0 (c 0.864, 1M dm-3 HCl). The crystals 
obtained via fractional crystallization of CSA.Sic 100 were also hydrolysed by 
following the above procedure. Batch 1 crystals: [α] 
 = 0 (c 0.927, 1M dm-3 HCl). 
Batch 2 crystals: [α] 
 = 0 (c 1.273, 1M dm-3 HCl). Other analytical data concurred 
with 32b mentioned earlier.  
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6.3 Experimental for Chapter 3 
(E) and (Z)-2-Phenyl-1-methoxyethene (117)
[142]
:  
 
Potassium tert-butoxide (42.30 g, 0.4 mol) was added portionwise to a stirred 
suspension of (methoxymethyl)triphenylphosphonium chloride (146.00 g, 0.4 mol) in 
THF (400 mL) under nitrogen in an ice bath. After stirring the red solution at room 
temperature for 30 min, benzaldehyde 116 (20.00 g, 0.2 mol) in THF (100 mL) was 
added via a cannula. The reaction mixture was stirred at room temperature for 12 h and 
its colour was seen to change from dark red to an opaque yellow-brown. Saturated aq. 
NH4Cl (200 mL) was added with stirring. The organic layer was decanted and the 
aqueous layer was extracted with Et2O (3 × 100 mL), dried over MgSO4 and evaporated 
under reduced pressure to give a viscous brown oil. Vacuum distillation at 150 °C 
yielded compound 117 as a pale yellow oil (20.00 g, 79%). IR υmax(neat)/cm
-1 C=C 
1651 (s), 1640 (s), C-O-C 1098 (m); 
1H NMR (400 MHz, ppm, CDCl3) δ 3.72 (3 H, s, 
(E)- or (Z)-CH3), 3.81 (3 H, s, (E)- or (Z)-CH3), 5.27 (1 H, d, J 7, (Z)-CHOCH3), 5.86 
(1 H, d, J 13, (E)-CHOCH3), 6.18 (1 H, d, J 7, (Z)- ArCH=CHOCH3),  7.10 (1 H, d, J 
13, (E)- ArCH=CHOCH3), 7.16 – 7.18 (2 H, m, (E)- and (Z)- CArH4), 7.19 – 7.28 (4 H, 
m, (E)- and (Z)- CArH3,5), 7.61 – 7.62 (4 H, d, J 7,  (E)- and (Z)- CArH2,6); 
13C NMR 
(100 MHz, ppm) δ 56.5 [(E)-OCH3], 60.7 [(Z)-OCH3], 105.1 [(Z)-ArCH=CHOCH3], 
105.7 [(E)-ArCH=CHOCH3], 125.1, 125.7, 128.2 × 2, 128.6 × 2 [(E)- and (Z)-ArC3,4,5], 
136.0, 136.4 [(E)- and (Z)-ArC1], 148.0 [(Z)-ArCH=CHOCH3], 148.9 [(E)-
ArCH=CHOCH3]; MS (EI) m/z (%) 134 (M
+, 76), 119 (M+ – CH3, 14), 91 (M
+ – 
O
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=CHOMe, 100), 77 (M+ – CH=CHOMe, 14). The experimental data was consistent 
with the values reported in literature.[142] 
 
Phenylethanal (118)
[141]
:  
 
Formic acid (138.00 g, 2.9 mol) was added to a solution of (E)- and (Z)-2-phenyl-1-
methoxyethene 117 (20.00 g, 19.2 mmol) in DCM (100 mL). The reaction was stirred at 
room temperature in a foil-covered vessel for 64 h. Water (100 mL) was then added to 
the reaction mixture and the organic layer was separated. The aqueous layer was 
extracted with DCM (3 × 50 mL). The combined organic layers were washed with 
saturated aq. Na2CO3 (50 mL), brine (50 mL), dried over MgSO4 and evaporated under 
reduced pressure to give the title compound 118 as a brown oil (11.7 g, 73%). (SiO2; 
hexane/EtOAc 1:1; Rf = 0.58); IR υmax(neat)/cm
-1 C=O 1722 (s); 1H NMR (400 MHz, 
ppm, CDCl3) δ 3.72 (2 H, d, J 2.5, ArCH2), 7.27 – 7.46 (5 H, m, CArH2,3,4,5,6), 9.78 (1 H, 
t, J 2.5, CHO); 13C NMR (100 MHz, ppm) δ 50.6 (ArCH2), 127.5 (ArC4), 129.1 × 2 
(ArC2,6), 129.7 × 2 (ArC3,5), 132.0 (ArC1), 199.6 (CHO); MS (CI, NH3) m/z (%) 120 
(M+, 39), 91 (M+ – CHO, 100). The experimental data was consistent with the values 
reported in literature.[141] 
 
 
 
CHO
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N-[2-(Phenyl)ethyl]serine methyl ester (119): 
 
(±)-Serine methyl ester hydrochloride (5.28 g, 33.9 mmol), potassium acetate (3.27 g, 
33.3 mmol) and activated 3Å molecular sieves (10 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(100 mL) was added via a cannula and the reaction mixture was stirred for 15 min. A 
solution of 1-phenylethanal 118 (2.00 g, 16.7 mmol) was prepared in methanol (10 mL) 
and transferred to the reaction vessel via a syringe over 1 h. The mixture was stirred for 
2 h, and then a solution of sodium cyanoborohydride (2.10 g 33.4 mmol) in dry MeOH 
(10 mL) was slowly added over 30 min (evolution of gas was observed with small 
exotherm). The reaction mixture was then stirred at room temperature for 15 h. Excess 
sodium cyanoborohydride was quenched by adding 6M HCl (10 mL). The gas evolved 
was passed through 5M NaOH. When no more gas was seen to evolve, the mixture was 
rendered alkaline by careful addition of a saturated solution of Na2CO3 (25 mL). The 
mixture was filtered through a sintered funnel and the slurry was thoroughly washed 
with MeOH. The solvent was removed under reduced pressure leaving an aqueous 
slurry which was diluted with H2O (50 mL) and then extracted with Et2O (3 × 75 mL). 
The combined organic layers were dried over MgSO4 and evaporated in vacuo. 
Purification by column chromatography (SiO2; hexane/diethyl ether 1:1, then 0:1) 
afforded the title compound 119 as a white solid (0.77 g, 20 %). M.p. 61–63 °C; IR 
υmax(neat)/cm
-1 NH, OH 3129 (br), C=O 1725 (s), C-N 1217 (m); 
1H NMR (400 MHz, 
ppm, CDCl3) δ 2.39 (2 H, s, NH and OH), 2.74 – 2.84 (3 H, m, ArCHHCH2N), 2.97 – 
N
H
O
O
OH
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3.02 (1 H, m, ArCHHCH2N), 3.40 (1 H, dd, J 6, 4.5, CHCOOCH3)  3.63 (1 H, dd, J 11, 
6, CHHOH ), 3.75 (3 H, s, COOCH3), 3.79 (1 H, dd, J 11, 4.5, CHHOH ), 7.22 – 7.34 
(5 H, m, CArH2,3,4,5,6); 
13C NMR (100 MHz, ppm) δ 36.5 (ArCH2), 49.5 (ArCH2CH2), 
62.8 (CHCOOMe), 52.2 (COOCH3), 62.4 (CH2OH), 126.3 × 2 (ArC2,6), 128.6 × 3 
(ArC3,4,5), 139.5 (ArC1), 173.5 (COOMe); MS (CI, NH3) m/z (%) 224 (M
+, 100), 164 
(M+ – COOMe, 3); Elemental analysis calcd. (%) for C12H17NO3 (223.12): C 64.55, H 
7.67, N 6.27 found: C 64.6, H 7.8, N 6.1.  
 
4-Phenylbutan-1-ol (121)
[140]
:
   
 
4-Phenylbutanoic acid 120 (15.00 g, 91.4 mmol) was dissolved in dry THF (200 mL) 
and stirred in an ice bath for 10 mins. BF3.OEt2 (16.00 mL, 129.7 mmol) was carefully 
added to the solution over 1 h. A solution of NaBH4 (7.60 g, 200.9 mmol) was prepared 
in dry THF (20 mL) and carefully added to the reaction mixture using an addition 
funnel. The reaction mixture was then warmed to room temperature and stirred 
overnight (12 h). 1M HCl solution (50 mL) was carefully added to quench the excess 
NaBH4 followed by saturated solution of Na2CO3 (50 mL). The product mixture was 
filtered through sand and the solvent was removed under reduced pressure. The 
resulting slurry was extracted with Et2O (3 × 100 mL), dried over MgSO4 and the 
filtered solution was evaporated under reduced pressure to yield compound 121 (13.50 
g, 98%) as a colourless oil. (SiO2; hexane/Et2O/MeOH, 6:3:1; Rf = 0.31);                     
IR υmax(neat)/cm
-1 OH 3312 (br); 1H NMR (400 MHz, ppm, CDCl3) δ 1.62 – 1.80 (4 H, 
OH
1
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m × 2, ArCH2CH2CH2), 2.67 (1 H, s, OH), 2.71 (2 H, t, J 7.5, ArCH2), 3.67 (2 H, t, J 
6.5, CH2OH), 7.25 (3 H, m, CArH3,4,5), 7.38 (2 H, m, CArH2,6); 
13C NMR (100 MHz, 
ppm) δ 27.6 and 32.3 (ArCH2CH2CH2), 35.7 (ArCH2), 62.6 (CH2OH), 125.8 (ArC4), 
128.4 (ArC3,5), 128.5 (ArC2,6), 142.5 (ArC1); MS (CI,  NH3) m/z (%) 150 (M
+, 43), 132 
(M+ – OH, 10), 104 (M+ – CH2CH2OH, 100), 91 (M
+ – CH2CH2CH2OH, 28). The 
experimental data was consistent with the values reported in literature.[140] 
 
Attempted reactions for the oxidation of 122 (see Table 3) 
[Entry 1] 122 (1.00 g, 6.6 mmol) was dissolved in CHCl3 (20 mL) and MnO2 (11.57 g, 
133.1 mmol) was slowly added followed by stirring for 24 h. The reaction mixture was 
filtered over Celite® and the filtrate was evaporated in vacuo to give back 122 (1.00 g, 
100%). No oxidation was observed.  
[Entry 2] Oxalyl chloride (2 M soln. in DCM), (3.6 mL, 7.3 mmol) was diluted in DCM 
(25 mL) and the solution was cooled to -78 °C.  DMSO (1.04 mL, 14.6 mmol) was 
added to the solution and stirred for 10 mins. 122 (1.00 g, 6.6 mmol) was dissolved in 
DCM (5 mL) and slowly added to the reaction mixture via a syringe. After 15 mins., 
Et3N (4.7 mL, 3.6 mmol) was added via a syringe and the reaction vessel was warmed 
to room temperature over a 30 min period. H2O (25 mL) was added to the reaction 
mixture and the organic layer was separated, dried over MgSO4 and the solvent 
evaporated to give a crude oil which on NMR analysis indicated approx. 15% 
conversion to the aldehyde 123 but, with a strong presence of 122 (>80%).  
Entries 3-4 led to conditions in Entry 5 which is described below as the optimised 
synthesis for 122. 
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4-Phenylbutanal (122)
[139]
:  
 
4-Phenylbutanol 121 (5.00 g, 33.3 mmol) was weighed in a flask and dissolved in DCM 
(200 mL). MgSO4 (10 g) and pyridiniumchlorochromate (21.50 g, 99.8 mmol) were 
weighed and added to the reaction mixture with constant stirring. The reaction mixture 
was allowed to stir at room temperature for 4 h, and then filtered through a sintered 
funnel over a pad of silica (DCM). The solvent was evaporated under reduced pressure 
to yield compound 122 (4.12 g, 83%) as a colourless oil. (SiO2; hexane/Et2O 1:1;        
Rf = 0.61); IR υmax(neat)/cm
-1 C=O 1722 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.99 
(2 H, m, ArCH2CH2), 2.48 (2 H, td, J 7.5, 1.5, CH2CHO), 2.69 (2 H, t, J 7.5, ArCH2), 
7.22 (3 H, dd, J 7, CArH3,4,5), 7.34 – 7.31 (2 H, m, CArH2,6), 9.78 (1 H, t, J 1.5, CHO); 
13C NMR (100 MHz, ppm) δ 23.7 (ArCH2CH2), 35.1 (ArCH2), 43.2 (ArCH2CH2CH2), 
126.1 (ArC4), 128.5 (ArC2,3,5,6), 141.3 (ArC1), 202.4 (CHO); MS (CI, NH3) m/z (%) 148 
(M+, 12.3), 104 (M+ – CH2CHO, 100), 91 (M
+ – CH2CH2CHO, 40). The experimental 
data was consistent with the values reported in literature.[139] 
 
N-[4-Phenylbutyl]serine methyl ester (123):
  
 
(±)-Serine methyl ester hydrochloride (8.70 g, 55.7 mmol), potassium acetate (5.50 g, 
55.7 mmol) and activated 4Å molecular sieves (20 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
O
N
H
COOMe
HO
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(200 mL) was added via a cannula and the reaction mixture was stirred for 15 min. A 
solution of 4-phenylbutan-1-al 122 (4.13 g, 27.9 mmol) was prepared in methanol     
(10 mL) and transferred to the reaction vessel via a syringe. The mixture was stirred for 
2 h, and then a solution of sodium cyanoborohydride (3.50 g 55.7 mmol) in MeOH    
(10 mL) was slowly added over 30 min (evolution of gas was observed with small 
exotherm). The reaction mixture was then stirred at room temperature for 15 h. Excess 
sodium cyanoborohydride was quenched by adding 6M HCl (20 mL). The gas evolved 
was passed through 5M NaOH. When no more gas was seen to evolve, the mixture was 
rendered alkaline by careful addition of a saturated solution of Na2CO3 (50 mL). The 
mixture was filtered through a sintered funnel and the slurry was thoroughly washed 
with MeOH. The solvent was removed under reduced pressure leaving an aqueous 
slurry which was diluted with H2O (75 mL) and then extracted with Et2O (3 × 100 mL). 
The combined organic layers were dried over MgSO4 and evaporated in vacuo to give 
the title compound 123 (6.08 g, 86 %) as a colourless oil. IR υmax(neat)/cm
-1 OH, NH 
3320 (br), C=O 1735 (s);  1H NMR (400 MHz, ppm, CDCl3) δ 1.54 – 1.70 (4 H, m × 2, 
ArCH2CH2CH2), 2.50 – 2.59 (1 H, m, CHHNH), 2.65 (2 H, t, J 7.5, ArCH2), 2.68 – 
2.77 (3 H, m, CHHNH, OH), 3.37 (1 H, dd, J 6.5, 4.5, CHCOOCH3), 3.62 (1 H, dd, J 
10.5, 6.5, CHHOH ), 3.76 (3 H, s, COOCH3), 3.79 (1 H, dd, J 10.5, 4.5, CHHOH), 7.20 
(3 H, m, CArH3,4,5), 7.25 – 7.35 (2 H, m, CArH2,6); 
13C NMR (100 MHz, ppm) δ 29.0 and 
29.7 (ArCH2CH2CH2), 35.7 (ArCH2), 48.2 (CH2NH), 52.1 (COOCH3), 62.4 (CH2OH), 
62.8 (CHCOOMe), 125.7 (ArC2,6), 128.3 (ArC3,4,5), 142.3 (ArC1), 173.7 (COOMe); MS 
(EI) m/z  274 (MNa+, 13), 252 (MH+, 100), 220 (M+ – CH2OH, 7); Elemental analysis 
calcd. (%) for C14H21NO3 (251.15): C 66.91, H 8.42, N 5.57; found: C 67.0, H 8.5, N 
5.6.  
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Methyl 2-{N-[4-(phenyl)butyl]-N-(tert-butoxycarbonyl)-amino}prop-2-enoate 
(124):  
 
 
Di-tert-butyl dicarbonate (1.64 g, 7.5 mmol) was added to a solution of N-[4-(4-
phenyl)butyl]serine methyl ester 123 (1.57 g, 6.3 mmol) in DCM (10 mL) under N2. 
The mixture was stirred for 20 h at room temperature. Tosyl chloride (1.78 g,             
9.3 mmol) was dissolved in DCM (10 mL) and added to the reaction vessel followed by 
triethylamine (1.70 mL, 18.8 mmol). The mixture was stirred for 12 h before being 
diluted with DCM (25 mL), washed with HCl (20 mL), saturated soln. Na2CO3               
(20 mL), brine (10 mL), dried over MgSO4 and the solvent evaporated under vacuo. 
Column chromatography (SiO2; hexane/Et2O 7:3; Rf = 0.35) yielded compound 124 as a 
colourless oil (1.82 g 87%). IR υmax(neat)/cm
-1 C=O 1734 (s), C=C 1631 (s), C-N 1152 
(s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.44 [9 H, s, C(CH3)3], 1.64 (4 H, m, 
ArCH2CH2CH2), 2.66 (2 H, t, J 7, ArCH2), 3.52 (2 H, t, J 6, CH2N), 3.79 (3 H, s, 
COOCH3), 5.38 (1 H, s, =CHH), 5.91 (1 H, s, =CHH), 7.14 – 7.32 (5 H, m,  
CArH2,3,4,5,6); 
13C NMR (100 MHz, ppm) δ 27.9 and 28.5 (ArCH2CH2CH2), 28.2 
[C(CH3)3], 35.6 (ArCH2), 49.2 (CH2N), 52.2 (COOCH3), 80.9 [C(CH3)3], 128.4 
(ArC2,3,5,6), 117.2 (=CH2), 125.7 (ArC4), 142.4 (CCOOMe), 140.1 (ArC1), 153.9 (C=O, 
Boc), 165.1 (COOMe); MS (CI, NH3) m/z (%) 351 (MNH4
+, 42), 334 (MH+, 26), 295 
[MNH4
+ – C(CH3)3, 100], 234 [M
+ – COOC(CH3)3, 57]; Elemental analysis calcd. (%) 
for C19H27NO4 (333.19) C 68.44, H 8.16, N 4.20; found: C 68.4, H 8.1, N 4.3. 
 
N
Boc
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Attempted Fujiwara Addition of 124 (see Scheme 42 and Table 4): 
[Entry 1] Trifluoroacetic acid (1 mL) was taken in a tube and saturated with nitrogen. 
Pd(OAc)2 (2 mg, 7.5 × 10
-3 mmol) was added to the TFA and stirred for 10 mins. 124        
(250 mg, 0.75 mmol) was dissolved in DCM (0.5 mL) and carefully added using a 
syringe (mild effervescence was observed). The reaction mixture was stirred for 24 h 
followed by dilution with H2O (5 mL) and extraction with DCM (5 mL × 3). The 
organic layers were washed with saturated soln. of Na2CO3, dried over MgSO4 and the 
solvent evaporated to give a crude brown oil, which on NMR analysis, showed a 
complex pattern and indicated that decomposition had occurred. Entries 2 and 3 were 
performed by following the same procedure as described for Entry 1 and the reaction 
time was lowered to 12 h and 6 h respectively. The reagent quantities used in these 
reactions were same as in Entry 1. In all cases decomposition was observed.  
 
3-(1H-Indol-3-yl)-acrylic acid tert-butyl ester (127)
[90]
: 
 
Indole 126 (250 mg, 2.1 mmol), tert-butyl acrylate (547 mg, 4.3 mmol), Cu(OAc)2  
(697 mg, 3.8 mmol) and Pd(OAc)2 (48 mg, 0.2 mmol) were taken in a nitrogen flushed 
flask and stirred in a mixture of solvents (DMF:DMSO 9:1, 5.0 mL). The flask was then 
fitted with a reflux condenser and stirred at 70 oC for 18 h. The reaction mixture was 
cooled to room temperature and partitioned between water (10 mL) and ethyl acetate 
(20 mL) and filtered through a plug of Celite®. The organic layer was separated and the 
N
H
O
O
2
3
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aqueous layer was extracted with ethyl acetate (3 × 15mL). The combined organic 
layers were washed with brine (50 mL) and dried over MgSO4. The filtered solution 
was evaporated under reduced pressure to give 127 as a brown oil (267 mg, 52%).  
(SiO2; Et2O/hexane, 1:1; Rf = 0.27). IR υmax(neat)/cm
-1 NH 3381 (br), C=O 1708 (s), 
C=C 1621 (s), C-N 1146 (s); 
1H NMR (400 MHz, ppm, CDCl3) δ 1.59 [9 H, s, 
C(CH3)3], 6.44 (1 H, d, J 16, =CHCOOtBu), 7.24 – 7.49 (4 H, m, CArH × 4), 7.86 (1 H, 
d, J 16, CH=CHCOOtBu), 7.95 [1 H, dd, J 7, 1.5, NHCH= (C-2)], 8.71 (1 H, s, br, 
NH); 13C NMR (100 MHz, ppm) δ 28.4 [C(CH3)3], 79.9 [C(CH3)3], 111.8 [ArC (C-3)], 
113.6 (ArC), 115.4 (=CHCOOtBu), 120.5, 121.4, 123.2, 125.4 (ArC × 4), 128.5 [ArCH 
(C-2)], 137.1 (ArC), 137.2 (CH=CHCOOtBu), 168.0 (C=O, Boc); MS (CI, NH3) m/z 
(%) 243 (M+, 33), 187 [M+ – C(CH3)3, 100], 170 [M
+ – OC(CH3)3, 56], 141 [M
+ – 
COOC(CH3)3, 11]. The experimental data was consistent with the values reported in 
literature.[90] 
 
Attempted Gaunt oxidative Heck cyclization of 124 (see Scheme 46, Table 5): 
[Entry 1] 124 (250 mg, 0.75 mmol) was dissolved in solvent mixture DMF:DMSO 9:1 
(1.9 mL) and saturated with nitrogen. Cu(OAc)2 (273 mg, 1.5 mmol) was added to the 
solution followed by Pd(OAc)2 (16 mg, 0.07 mmol) and the reaction mixture was 
heated to 70 oC for 18 h. The reaction mixture was then cooled to room temperature and 
filtered through Celite® and the filtrate was diluted with H2O (5 mL) and extracted with 
DCM (5 mL × 3). The organic layers were dried over MgSO4 and the solvent 
evaporated to give back the starting material 124 (0.23 g, 90%). No product was 
observed. Subsequently, experiments were conducted at high temperatures (Entries 2 
and 3, Table 5) at temperatures 130 °C and 160 °C for 6 h and at 130 °C for 24 h (Entry 
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4). The reagent quantities used in these reactions were same as in Entry 1. In all cases, 
the starting material 124 was recovered (87-68%). No product was observed. 
 
4-(4-Methoxyphenyl)butan-1-ol (137)
[138]
:
 
 
4-(4-Methoxyphenyl)butanoic acid 136 (11.5 g, 58.9 mmol) was dissolved in dry THF 
(200 mL) and stirred in an ice bath for 10 mins. BH3-THF (1M soln. in THF) (100 mL, 
99.5 mmol) was carefully added to the solution over 1 h and then warmed to room 
temperature. The reaction mixture was heated under reflux for 3 h and then cooled to 
room temperature and stirred overnight (12 h). HCl (1M solution) (50 mL) was 
carefully added to quench the excess borane followed by saturated solution of Na2CO3 
(50 mL). The product mixture was filtered through sand and the solvent was evaporated 
under reduced pressure. The resulting slurry was extracted with Et2O (3 × 100 mL), 
dried over MgSO4 and the filtered solution was evaporated under reduced pressure to 
yield compound 137 (10.5 g, 99%) as a colourless oil. (SiO2; hexane/Et2O/MeOH, 
6;3:1; Rf  = 0.31); IR υmax(neat)/cm
-1 OH 3334 (br), C-O-C 1245 (s); 1H NMR (400 
MHz, ppm, CDCl3) δ 1.52 – 1.77 (4 H, m, ArCH2CH2CH2), 2.62 (2 H, t, J 7.5, ArCH2), 
2.81 (1 H, s, OH), 3.64 (2 H, t, J 6.5, CH2OH), 3.80 (3 H, s, OCH3), 6.87 and 7.14 (4 H, 
d × 2, J 8.5, CArH2,3,5,6); 
13C NMR (100 MHz, ppm) δ 27.9 and 32.3 (ArCH2CH2CH2), 
34.8 (ArCH2), 55.3 (ArOCH3), 62.5 (CH2OH), 113.8 (ArC3,5), 129.3 (ArC2,6), 134.6 
(ArC1), 157.7 (ArC4); MS (CI, NH3) m/z (%) 198 (MNH4
+, 100), 180 (M+, 18). The 
experimental data was consistent with the values reported in literature.[138] 
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4-(4-Methoxyphenyl)butan-1-al (138)
[136]
:
 
 
 4-(4-Methoxyphenyl)butan-1-ol 137 (500 mg, 2.8 mmol) was weighed in a dry tube 
and dissolved in DCM (20 mL). MgSO4 (2.00 g) and pyridiniumchlorochromate      
(1.79 g, 8.3 mmol) were added to the tube with constant stirring. The reaction mixture 
was allowed to stir at room temperature for 4 h, and then filtered through a sintered 
funnel over a pad of silica (DCM). The solvent was evaporated under reduced pressure 
to yield compound 138 (426 mg, 86%) as a colourless oil. (SiO2; hexane/Et2O, 1:1;     
Rf  = 0.61); IR υmax(neat)/cm
-1 C=O 1709 (s), C-O-C 1245 (s); 1H NMR (400 MHz, 
ppm,CDCl3) δ 1.95 (2 H, quin, J 7.5, ArCH2CH2), 2.45 (td, J 7.5, 1.5, CH2CHO), 2.62 
(2 H, t, J 7.5, ArCH2), 3.80 (3 H, s, OCH3), 6.86 (2 H, d, J 8.5, CArH3,5), 7.11 (2 H, d, J 
8.5, CArH2,6), 9.76 (1 H, t, J 1.5, CHO); 
13C NMR (100 MHz, ppm) δ 23.8 (ArCH2CH2), 
34.1 (ArCH2), 43.1 (CH2CHO), 55.3 (ArOCH3), 114.0 (ArC3,5), 129.4 (ArC2,6), 133.3 
(ArC1), 158.0 (ArC4), 202.4 (CHO); MS (EI) m/z (%) 121 (M
+ – CH2CH2CHO, 95), 
134 (M+ – CH2CHO, 100), 178 (M
+, 30). The experimental data was consistent with the 
values reported in literature.[136] 
 
N-[4-(4-Methoxyphenyl)butyl]serine methyl ester (139):
 
 
(±)-Serine methyl ester hydrochloride (4.90 g, 31.5 mmol), potassium acetate (3.10 g, 
31.5 mmol) and activated 4Å molecular sieves (10 g) were successively introduced into 
O
MeO
N
H
COOMe
HOMeO
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a reaction vessel which was then evacuated and filled with nitrogen. Methanol (200 
mL) was added via a cannula and the reaction mixture was stirred for 15 min. A 
solution of 4-(4-methoxyphenyl)butan-1-al 138 (2.80 g, 15.7 mmol) was prepared in 
methanol (10 mL) and transferred to the reaction vessel via a syringe. The mixture was 
stirred for 2 h, and then a solution of sodium cyanoborohydride (2.00 g 31.5 mmol) in 
MeOH (10 mL) was slowly added over 30 min (evolution of gas was observed with 
small exotherm). The reaction mixture was then stirred at room temperature for 15 h. 
Excess sodium cyanoborohydride was hydrolysed by adding 6M HCl (20 mL). The gas 
evolved was passed through 5M NaOH. When no more gas was seen to evolve, the 
mixture was rendered alkaline by careful addition of saturated solution of Na2CO3     
(25 mL). The mixture was filtered through a sintered funnel and the slurry was 
thoroughly washed with MeOH. The solvent was removed under reduced pressure 
leaving an aqueous slurry which was diluted with H2O (75 mL) and then extracted with 
Et2O (3 × 100 mL). The combined organic layers were dried over MgSO4 and 
evaporated in vacuo to give the title compound 139 (3.59 g, 81%) as a colourless oil. IR 
υmax(neat)/cm
-1 OH, NH 3303 (br), C=O 1734 (s), C-O-C 1242 (s); 1H NMR (400 MHz, 
ppm, CDCl3) δ 1.44 – 1.67 (4 H, m × 2, ArCH2CH2CH2), 2.47 – 2.74 (4 H, m × 2, 
ArCH2, CH2NH) 2.79 (2 H, s, NH and OH), 3.35 (1 H, dd, J 6, 4.5, CHCOOCH3), 3.62 
(1 H, dd, J 11, 6, CHHOH ), 3.74 (3 H, s, COOCH3), 3.77 (1 H, dd, J 11, 4.5, 
CHHOH), 3.78 (3 H, s, ArOCH3), 6.83 (2 H, d, J 8.5, CArH3,5), 7.09 (2 H, d, J 8.5, 
CArH2,6); 
13C NMR (100 MHz, ppm) δ 29.2 and 29.6 (ArCH2CH2CH2), 34.8 (ArCH2), 
48.2 (CH2NH), 52.1 (COOCH3), 55.2 (OCH3), 62.4 (CH2OH), 62.7 (CHCOOMe), 
113.7 × 2 (ArC3,5), 129.4 × 2 (ArC2,6), 134.4 (ArC1), 158.0 (ArC4), 173.6 (COOMe); 
MS (CI, NH3) m/z (%) 264 (M
+ – OH, 14), 222 (M+ – COOMe, 3), 282 (MH+, 100); 
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Elemental analysis calcd. (%) for C15H23NO4 (281.16): C 64.03, H 8.24, N 4.98; found: 
C 64.13, H 8.32, N 4.85.  
 
Methyl 2-{N-[4-(4-methoxyphenyl)butyl]-N-(tert-butoxycarbonyl)-amino}prop-2-
enoate (140):  
 
 
Di-tert-butyl dicarbonate (3.40 g, 15.3 mmol) was added to a solution of N-[4-(4-
methoxyphenyl)butyl]serine methyl ester 139 (3.60 g, 12.8 mmol) in DCM (20 mL) 
under N2. The mixture was stirred for 20 h at room temperature. Tosyl chloride (3.65 g, 
19.2 mmol) was dissolved in dry DCM (10 mL) and added to the reaction vessel 
followed by triethylamine (5.40 mL, 38.3 mmol). The mixture was stirred for 12 h 
before being diluted with DCM (50 mL), washed with 1M HCl (50 mL), saturated soln. 
Na2CO3 (50 mL), brine (50 mL), dried over MgSO4 and the solvent evaporated in 
vacuo. Column chromatography (SiO2; hexane/Et2O 7:3; Rf = 0.35) yielded compound 
140 as a colourless oil (3.82 g 87%). IR υmax(neat)/cm
-1 C=O 1734 (s), C=C 1631 (s), C-
O-C 1245 (s), C-N 1154 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.43 [9 H, s, 
C(CH3)3], 1.58 – 1.67 (4 H, m, ArCH2CH2CH2), 2.59 (2 H, t, J 7, ArCH2), 3.51 (2 H, t, 
J 6.5, CH2N), 3.78 (3 H, s, Ar-OCH3), 3.79 (3H, s, COOCH3), 5.37 (1 H, s, =CHH), 
5.90 (1 H, s, =CHH ), 6.83 (2 H, d, J 8.5, CArH3,5), 7.09 (2 H, d, J 8.5, CArH2,6); 
13C 
NMR (100 MHz, ppm) δ 27.8 and 28.7 (ArCH2CH2CH2), 28.1 [C(CH3)3], 34.6 
(ArCH2), 49.2 (CH2N), 52.2 (COOCH3), 55.2 (OCH3), 80.9 [C(CH3)3], 113.7 (ArC3,5), 
117.1 (=CH2), 129.2 (ArC2,6), 134.4 (CCOOMe), 140.1 (ArC1), 153.9 (C=O, Boc), 
N
Boc
COOMe
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158.0 (ArC4), 165.6 (COOMe); MS (CI, NH3) m/z (%) 381 (MNH4
+, 82), 364 (MH+, 
24), 325 [MNH4
+ – C(CH3)3, 100], 264 [M
+ – COOC(CH3)3, 82]; Elemental analysis 
calcd. (%) for C20H29NO5 (363.44): C 66.09, H 8.04, N 3.85; found: C 66.15, H 7.98, N 
3.84. 
 
Attempted Gaunt oxidative Heck cyclization of 140 (see Scheme 51, Table 6): 
[Entry 1] 140 (250 mg, 0.69 mmol) was dissolved in solvent mixture DMF:DMSO 9:1 
(2 mL) and saturated with nitrogen. Cu(OAc)2 (250 mg, 1.4 mmol) was added to the 
solution followed by Pd(OAc)2 (16 mg, 0.07 mmol) and the reaction mixture was 
heated to 70 oC for 18 h. The reaction mixture was then cooled to room temperature and 
filtered through Celite® and the filtrate was diluted with H2O (5 mL) and extracted with 
DCM (5 mL × 3). The organic layers were dried over MgSO4 and the solvent 
evaporated to give back the starting material 140 (0.21 g, 84%). No product was 
observed. Subsequently, experiments were conducted at high temperatures (Entries 2 
and 3, Table 6) at temperatures 130 °C and 160 °C for 6 h. The reagent quantities were 
same as in Entry 1. In all cases, the starting material 140 was recovered (90-84%). No 
product development was observed. 
 
4-(3,4-Dimethoxyphenyl)butan-1-ol (143)
[137]
: 
 
4-(3,4-Dimethoxyphenyl)butanoic acid 142 (5.00 g, 22.3 mmol) was dissolved in THF 
(100 mL) and stirred in an ice bath for 10 mins. BH3-THF (1M soln. in THF) (45 mL, 
OH
MeO
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44.6 mmol) was carefully added to the solution over 1 h and the reaction was warmed 
to room temperature. The reaction mixture was heated under reflux for 3 h and then 
cooled to room temperature and stirred overnight (12 h). 1M HCl solution (25 mL) was 
carefully added to quench the excess borane followed by saturated solution of Na2CO3 
(25 mL). The product mixture was filtered through sand and the solvent was evaporated 
under reduced pressure. The resulting slurry was extracted with Et2O (3 × 100 mL), 
dried over MgSO4 and the filtered solution was evaporated under reduced pressure to 
yield compound 142 (4.83 g, 96%) as a colourless oil. (SiO2; hexane/Et2O, 6:3;            
Rf  = 0.17); IR υmax(neat)/cm
-1 3323 OH, (br); 1H NMR (400 MHz, ppm, CDCl3) δ 1.45 
– 1.75 (4 H, m, ArCH2CH2CH2), 2.29 (1 H, s, br, OH), 2.58 (2 H, t, J 7.5, ArCH2), 3.63 
(2 H, m, CH2OH), 3.84 and 3.86 (6 H, s × 2, OCH3 × 2), 6.67 – 6.74 (2 H, m, CArH2,3), 
6.78 (1 H, d, J 8 CArH6); 
13C NMR (100 MHz, ppm) δ 27.8 and 31.1 (ArCH2CH2CH2), 
35.3 (ArCH2), 55.6 and 55.9 (OCH3 × 2), 62.57 (CH2OH), 111.21, 111.75 (ArC3,6), 
120.2 (ArC2), 135.1 (ArC1), 147.1 and 148.8 (ArC4,5); MS (EI) m/z (%) 210 (M
+, 62), 
193 (M+ – HO, 21), 151 (M+ – CH2CH2CH2OH, 28), 91 (M
+ – CH2CH2CH2OH – OCH3 
– OCH3, 100); HRMS (EI): Calcd. for C12H18O3
+ (210.1256), found 210.1261. The 
experimental data was consistent with the values reported in literature.[137] 
 
4-(3,4-Dimethoxyphenyl)butanal (144)
[137]
: 
 
4-(3,4-Dimethoxyphenyl)butan-1-ol 143 (4.80 mg, 23.6 mmol) was weighed in a flask 
and dissolved in DCM (50 mL). MgSO4 (10 g) and pyridiniumchloro chromate (15.00 
O
MeO
MeO
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g, 69.2 mmol) were added to the flash with constant stirring. The reaction mixture was 
allowed to stir at room temperature for 4 h, and then filtered through a sintered funnel 
over a pad of silica (DCM). The solvent was evaporated under reduced pressure to yield 
compound 143 (3.61 mg, 76%) as a colourless oil. (SiO2; hexane/Et2O, 1:1; Rf  = 0.24); 
IR υmax(neat)/cm
-1 C=O 1711 (s), C–O–C 1241 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 
1.96 (2 H, quin, J 7.5, ArCH2CH2), 2.47 (2 H, td, J 7.5, 1.5, CH2CHO), 2.62 (2 H, t, J 
7.5, ArCH2), 3.87 and 3.89 (6 H, s × 2, OCH3 × 2), 6.72 (2 H, m, CArH2,3), 6.81 (1 H, d, 
J 8, CArH6), 9.78 (1 H, t, J 1.5, CHO); 
13C NMR (100 MHz, ppm) δ 23.2 (ArCH2CH2), 
34.6 (ArCH2), 43.1 (CH2CHO), 55.8 and 55.9 (OCH3 × 2), 111.2, 111.5 (ArC3,6), 
120.31 (ArC2),  133.8 (ArC1), 147.4 and 148.9 (ArC4,5), 209.4 (CHO); MS (EI) m/z (%) 
209 (M+, 40), 179 (M+ – CHO, 25), 151 (M+ – CH2CH2CHO, 32), 91 (M
+ – 
CH2CH2CHO – OCH3 – OCH3, 100); HRMS (EI): Calcd for C12H17O3
+ (209.1099), 
found 209.1102. The experimental data was consistent with the values reported in 
literature.[137] 
 
Methyl 2-[4-(3,4-dimethoxyphenyl)butylamino]-3-hydroxypropanoate (145): 
 
(±)-Serine methyl ester hydrochloride (5.40 g, 34.6 mmol), potassium acetate (3.40 g, 
34.6 mmol) and activated 4Å molecular sieves (10 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(150 mL) was added via a cannula and the reaction mixture was stirred for 15 min. A 
solution of 4-(3,4-dimethoxyphenyl)butan-1-al 144 (3.60 g, 17.3 mmol) was prepared in 
N
H
COOMe
HOMeO
MeO
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methanol (10 mL) and transferred to the reaction vessel via a syringe. The mixture was 
stirred for 2 h, and then a solution of sodium cyanoborohydride (2.20 g 34.6 mmol) in 
dry MeOH (10 mL) was slowly added over 30 min (evolution of gas was observed with 
small exotherm). The reaction mixture was then stirred at room temperature for 15 h. 
Excess sodium cyanoborohydride was hydrolysed by adding 6M HCl (20 mL). The gas 
evolved was passed through 5M NaOH. When no more gas was seen to evolve, the 
mixture was rendered alkaline by careful addition of saturated solution of Na2CO3 (25 
mL). The mixture was filtered through a sintered funnel and the slurry was thoroughly 
washed with MeOH. The solvent was removed under reduced pressure leaving an 
aqueous slurry which was diluted with H2O (75 mL) and then extracted with Et2O (3 × 
100 mL). The combined organic layers were dried over MgSO4 and evaporated in 
vacuo. Purification by column chromatography (SiO2; hexane/diethyl ether 1:1, then 
0:1) afforded the title compound 145 as a colorless oil (3.11 g, 58%). IR υmax(neat)/cm
-1 
3331 NH, OH (br), 1732 C=O (s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.47 – 1.73 (4 
H, m × 2, ArCH2CH2CH2), 2.42 – 2.78 (6 H, m × 2, ArCH2, CH2NH and OH), 3.35 (1 
H, dd, J 6.5, 4.5, CHCOOCH3), 3.59 (1 H, dd, J 11, 6.5, CHHOH), 3.75 (3 H, s, 
COOCH3), 3.78 (1 H, dd, J 11, 4.5, CHHOH), 3.85 and 3.88 (6 H, s × 2, OCH3 × 2), 
6.71 (2 H, dd, J 6, 2 CArH2,3), 6.79 (1 H, d, J 8, CArH6); 
13C NMR (100 MHz, ppm) δ 
28.54 and 29.70 (ArCH2CH2CH2), 35.3 (ArCH2), 48.1 CH2NH), 62.2 (CH2OH), 62.5 
(CHCH2OH), 51.1 (COOCH3), 55.8 and 55.9 (OCH3 × 2), 111.2, 111.7 (ArC3,6), and 
120.1 (ArC2), 134.9 (ArC1), 147.1 and 148.8 (ArC4,5), 173.5 (COOCH3); MS (ESI) m/z 
(%) 334 (MNa+, 50), 312 (MH+, 100); Elemental analysis calcd. (%) for C16H25NO5 
(311.37): C 61.72, H 8.09, N 4.50 found C 61.7, H 8.1, N 4.5. 
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Benzyl 1-(methoxycarbonyl)vinyl4-(3,4-dimethoxyphenyl)butylcarbamate (146): 
 
CbzCl (2.31 g, 13.5 mmol) was added to a solution of N-[4-(3,4-
dimethoxyphenyl)butyl]serine methyl ester 145 (2.80 g, 9.0 mmol) in DCM (10 mL) 
under N2 at 0 °C. The mixture was then warmed to room temperature and stirred for    
20 h. Tosyl chloride (2.60 g, 13.5 mmol) was dissolved in DCM (10 mL) and added to 
the reaction vessel followed by triethylamine (3.8 mL, 27.0 mmol). The mixture was 
stirred for 12 h before being diluted with DCM (50 mL), washed with HCl (20 mL), 
saturated soln. Na2CO3 (20 mL), brine (25 mL), dried over MgSO4 and the solvent 
evaporated under vacuo. Column chromatography (SiO2; hexane/Et2O 1:1; Rf = 0.13) 
yielded compound 146 as a colourless oil (2.65 g 69%). IR υmax(neat)/cm
-1 1768, 1731 
C=O (s), 1633 C=C (w), 1244 C–O-C (w); 1H NMR (400 MHz, ppm, CDCl3) δ 1.59 – 
1.70 (4 H, m, ArCH2CH2CH2), 2.58 (2 H, t, J 6.5, ArCH2), 3.57 (2 H, t, J 6.5, CH2N), 
3.81 (3 H, s, COOCH3), 3.87 and 3.88 (6 H, s × 2, OCH3 × 2), 5.13 (2 H, s, 
COOCH2C6H5), 5.51 (1 H, s, =CHH), 6.09 (1 H, s, =CHH), 6.64 – 6.75 (2 H, m, 
CArH2,3), 6.79 (1 H, d, J 8.5, CArH6), 7.22 – 7.52 (5 H, m, COOC6H5); 
13C NMR (100 
MHz, ppm) δ 28.7 and 29.5 (ArCH2CH2CH2), 35.1 (ArCH2), 49.6 (CH2N), 52.3 
(COOCH3), 55.8 and 55.9 (OCH3 × 2), 67.5 (COOCH2C6H5 from Cbz), 111.2, 111.8 
(ArC3,6), 120.1 (ArC2), 120.3 (=CH2), 127.9 × 2, 128.1, 128.4 × 2 (ArCH of Cbz, CH × 
5), 134.8 (ArC1), 136.2 (ArC of Cbz), 139.2 (C=CH2), 147.1 and 148.8 (ArC4,5), 154.9 
(COOC6H5), 164.9 (COOCH3); MS (EI) m/z (%) 427 (M
+, 46), 292 (M+ – 
COOCH2C6H5, 28), 151 (M
+ – CH2CH2CH2N(Cbz)C(COOCH3)CH2, 47), 91 (M
+ – 
N
Cbz
COOMe
MeO
MeO
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CH2CH2CH2N(Cbz)C(COOCH3)CH2 – OCH3 – OCH3, 100); Elemental analysis calcd. 
(%) for C24H29NO6 (427.49): C 67.43, H 6.84, N 3.28 found C 66.9, H 6.5, N 3.3. 
 
Attempted Gaunt oxidative Heck cyclization of 146 (see Table 7, Scheme 56): 
[Entry 1] 146 (115 mg, 0.27 mmol) was dissolved in solvent mixture DMF:DMSO 9:1 
(2 mL) and saturated with nitrogen. Cu(OAc)2 (100 mg, 0.5 mmol) was added to the 
solution followed by Pd(OAc)2 (6 mg, 0.03 mmol) and the reaction mixture was heated 
to 70 oC for 12 h. The reaction mixture was then cooled to room temperature and 
filtered through Celite® and the filtrate was diluted with H2O (5 mL) and extracted with 
DCM (5 mL × 3). The organic layers were dried over MgSO4 and the solvent 
evaporated to give back the starting material 146 (80 mg, 68%). No product 
development was observed. Subsequently, experiments were conducted at high 
temperatures  
[Entry 2] Procedure followed as per Entry 1. 146 (102 mg, 0.24 mmol), Cu(OAc)2       
(87 mg, 0.48 mmol) and Pd(OAc)2 (5 mg, 0.023 mmol) were used. The reaction was 
heated to 130 °C for 6 h. After workup, the starting material 146 was recovered (71 mg, 
70%). No product development was observed. 
[Entry 3] Procedure followed as per Entry 1. 146 (128 mg, 0.3 mmol), Cu(OAc)2      
(109 mg, 0.6 mmol) and Pd(OAc)2 (7 mg, 0.03 mmol) were used. The reaction was 
heated to 160 °C for 6 h. After workup, the starting material 146 was recovered (91 mg, 
71%). No product development was observed. 
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Attempted Fujiwara Addition of 146 (see Scheme 57 and Table 8): 
[Entry 1] A 1% solution of Pd(OAc)2 was prepared in TFA (5 mg in 0.5 mL) and       
0.2 mL of this solution was taken in a tube and saturated with nitrogen. A solution of 
146 (0.1 g, 0.2 mmol) in DCM (0.1 mL) was added to the TFA solution and the reaction 
mixture was stirred for 24 h followed by dilution with H2O (2 mL) and extraction with 
DCM (2 mL × 3). The organic layers were washed with saturated soln. of Na2CO3, 
dried over MgSO4 and the solvent evaporated to give back the starting material 146     
(82 mg, 82%). No product development was observed.  
[Entry 2] Procedure followed as per Entry 1. 146 (0.10 g, 0.23 mmol), Pd(OAc)2 (5 mg, 
0.023 mmol)  and TFA (2 mL) were used. The reaction mixture was heated to 80 °C for 
6 h. After workup, a black residue was obtained which showed a very complex NMR 
pattern and indicated towards decomposition.  
 
Attempted Glorius oxidative Heck cyclization of 124, 140 and 146 (see Table 9, 
Scheme 59): 
[Entry 1] 124 (0.25 g, 0.75 mmol) was dissolved in DMF (15 mL) and saturated with 
nitrogen. Cu(OAc)2 (409 mg, 2.25 mmol) and K2CO3 (311 mg, 2.25 mmol) were added 
followed by Pd(OAc)2 (17 mg, 0.08 mmol). The reaction mixture was heated to 80 °C 
for 12 h and then cooled to room temperature and filtered through Celite®. The filtrate 
was diluted with H2O (25 mL) and the aqueous layer was extracted with DCM (25 mL 
× 3). The organic layers were dried over MgSO4 and the solvent was evaporated to give 
back the starting material 124 (0.22 g, 88%). No product development was observed. 
Subsequently, experiments were conducted at high temperatures. 
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[Entry 2] Procedure followed as per Entry 1.  124 (0.21 g, 0.6 mmol), Cu(OAc)2      
(343 mg, 1.9 mmol), K2CO3 (262 mg, 1.9 mmol) and Pd(OAc)2 (14 mg, 0.06 mmol) 
were used. The reaction was heated to 140 °C for 6 h. After workup, the starting 
material 124 was recovered (0.18 g, 84%). No product development was observed. 
[Entry 3] Procedure followed as per Entry 1. 124 (0.23 g, 0.7 mmol), Cu(OAc)2       
(376 mg, 2.0 mmol), K2CO3 (286 mg, 2.0 mmol) and Pd(OAc)2 (15 mg, 0.07 mmol) 
were used. The reaction was heated to 160 °C for 6 h. After workup, the starting 
material 124 was recovered (0.19 g, 81%). No product development was observed. 
[Entry 4] Procedure followed as per Entry 1. 140 (0.25 g, 0.7 mmol), Cu(OAc)2       
(375 mg, 2.1 mmol), K2CO3 (285 mg, 2.06 mmol) and Pd(OAc)2 (15 mg, 0.07 mmol) 
were used. After workup, the starting material 140 was recovered (0.20 g, 80%).  
[Entry 5] Procedure followed as per Entry 1. 140 (0.25 g, 0.7 mmol), Cu(OAc)2       
(375 mg, 2.1 mmol), K2CO3 (285 mg, 2.06 mmol) and Pd(OAc)2 (15 mg, 0.07 mmol) 
were used. The reaction was heated to 140 °C for 6 h. After workup, the starting 
material 140 was recovered (0.22 g, 87%).  
[Entry 6] Procedure followed as per Entry 1. 140 (0.25 g, 0.7 mmol), Cu(OAc)2       
(375 mg, 2.1 mmol), K2CO3 (285 mg, 2.06 mmol) and Pd(OAc)2 (15 mg, 0.07 mmol) 
were used. The reaction was heated to 160 °C for 6 h. After workup, the starting 
material 140 was recovered (0.21 g, 83%).  
[Entry 7] Procedure followed as per Entry 1. 146 (0.11 g, 0.3 mmol), Cu(OAc)2          
(145 mg, 0.8 mmol), K2CO3 (111 mg, 0.8 mmol) and Pd(OAc)2 (6 mg, 0.03 mmol) 
were used. After workup, the starting material 146 was recovered (89 mg, 78%). 
Subsequently, experiments were conducted at high temperatures. 
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[Entry 8] Procedure followed as per Entry 1.  146 (0.11 g, 0.3 mmol), Cu(OAc)2      
(136 mg, 0.7 mmol), K2CO3 (104 mg, 0.7 mmol) and Pd(OAc)2 (6 mg, 0.03 mmol) 
were used. The reaction was heated to 140 °C for 6 h. After workup, the starting 
material 146 was recovered (85 mg, 80%).  
[Entry 9] Procedure followed as per Entry 1.  146 (0.10 g, 0.2 mmol), Cu(OAc)2        
(128 mg, 0.7 mmol), K2CO3 (97 mg, 0.7 mmol) and Pd(OAc)2 (5 mg, 0.02 mmol) were 
used. The reaction was heated to 160 °C for 6 h. After workup, the starting material 146 
was recovered (76 mg, 76%).  
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6.4 Experimental for Chapter 4 
5-Phenyl-3H-furan-2-one (187)
[104]
: 
 
4-Oxo-4-phenylbutanoic acid 185 (8.30 g, 46.6 mmol) was weighed in a flask. Ac2O 
(13 mL, 140.0 mmol) and AcOH (6.5 mL, 113.7 mmol) were added and stirred to form 
a slurry. TsOH.H2O (0.05 g, 0.26 mmol) was added the reaction mixture and stirred for 
5 h. The reaction mixture was diluted with H2O (25 mL) and extracted in DCM (50 mL 
× 3). The organic layers were washed with saturated solution of Na2CO3 (100 mL) and 
brine (100 mL) and dried over MgSO4. The solvent was evaporated and the product 187 
was obtained as a white solid (7.75 g, 98%). (SiO2; Hexane/Et2O, 1:1; Rf  = 0.50);    
M.p.  52 – 54 oC; IR υmax(neat)/cm
-1 C=O 1801, (s), C=C 1630 (w);  1H NMR (400 
MHz, ppm, CDCl3) δ 3.44 (2 H, d, J 3, CH2CO), 5.82 (1 H, t, J 3, =CHCH2), 7.37 – 
7.47 (3 H, m, CArH3,4,5), 7.63 (2 H, d, J 3, CArH2,6); 
13C NMR (100 MHz, ppm) δ 34.7 
(CH2), 97.7 (=CH), 124.7 × 2 (ArC2,6), 128.7 and 129.6 × 2  (ArC3,4,5), 134.2 (ArC1), 
154.0 (=C), 175.9 (C=O); MS (CI, NH3) m/z (%) 178 (MNH4
+  , 12), 105 (M+ – 
COCH2CH=, 100), 77 (M
+ – C4H3O2, 60). The experimental data was consistent with 
the values reported in literature.[104] 
 
 
 
 
O
O
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4-Oxo-4-phenylbutanal (188)
[104]
: 
 
5-Phenyl-3H-furan-2-one 187 (1.50 g, 9.4 mmol) was dissolved in toluene (25 mL) and 
cooled to –70°C. DIBAL-H (1M soln) (10.5 mL, 10.3 mmol) was added slowly with a 
syringe. The reaction mixture was stirred for 3 h and then quenched with AcOH (3 mL) 
at –78 °C. The reaction mixture was warmed to room temperature and H2O (25 mL) 
was added. The organic layer was separated and the aqueous layer was extracted with 
diethyl ether (25 mL × 3). The combined organic layers were washed with saturated 
solution of Na2CO3 (50 mL) and brine (50 mL) and dried over MgSO4. The solvent was 
evaporated and the product 188 was obtained as a red oil after column chromatography 
(0.71 g, 46%). (SiO2; Hexane/Et2O, 7:3; Rf  = 0.12); IR υmax(neat)/cm
-1 C=O 1702, 1682 
(s);  1H NMR (400 MHz, ppm, CDCl3) δ 2.82 (2 H, t, J 6, ArCOCH2), 3.23 (2 H, t, J 6, 
CH2CHO), 7.39 (2 H, t, J 7.5, CArH3,5), 7.50 (1 H, t, J 7, CArH4), 7.91 (2 H, d, J 7, 
CArH2,6), 9.80 (1 H, s, CHO); 
13C NMR (100 MHz, ppm) δ 30.76 (CH2CHO), 37.7 
(CH2CH2CHO), 128.0 × 2 (ArC2,6), 128.6× 2  (ArC3,5), 133.3 (ArC4), 198.0 (ArC=O), 
200.7 (CHO); MS (EI) m/z (%) 162 (M+, 13), 133 (M+ – CHO, 31), 105 (M+ – 
CH2CH2CHO, 100). The experimental data was consistent with the values reported in 
literature.[104] 
 
 
 
CHO
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Methyl 3-hydroxy-2-(2-phenyl-1H-pyrrol-1-yl)propanoate (191): 
 
A solution of 4-oxo-4-phenylbutanal 188 in MeOH (10 mL) was added to a flask 
containing (±)-serine methyl hydrochloride (0.72 g, 4.6 mmol), potassium acetate (0.45 
g, 4.6 mmol) and 4 Å molecular sieves (2 g). The reaction mixture was stirred for       
15 mins. And a solution of NaBH3CN (0.30 g, 4.6 mmol) in MeOH (2 mL) was added 
using a syringe followed by stirring for 12 h. Excess sodium cyanoborohydride was 
hydrolysed by adding 6 M HCl (5 mL). The gas evolved was passed through 5 M 
NaOH. When no more gas was seen to evolve, the mixture was rendered alkaline by 
careful addition of saturated solution of Na2CO3 (10 mL). The mixture was filtered 
through a sintered funnel and the slurry was washed thoroughly with MeOH (50 mL). 
The solvent was removed under reduced pressure leaving an aqueous slurry which was 
diluted with H2O (25 mL) and then extracted with Et2O (3 × 25 mL). The combined 
organic layers were dried over MgSO4 and evaporated in vacuo to give a crude product. 
Column chromatrography (SiO2; hexane:Et2O 1:1; Rf = 0.32) gave product 191 (0.13 g, 
17%). 1H NMR (400 MHz, ppm, CDCl3) δ 3.71 (3 H, s, COOCH3), 3.78 (1 H, dd, J 11, 
6.5, CHHOH), 3.98 (1 H, dd, J 11, 6.5, CHHOH), 5.07 (1 H, t, J 6.5, CHCH2OH), 6.27 
(1 H, dd, J 3, 2, NCH=), 6.33 (1 H, t, J 3, NCH=CH), 7.02 (1 H, dd, J 3, 2, NC=CH), 
7.15 – 7.56 (5 H, m, CArH2,3,4,5,6);
 13C NMR (100 MHz, ppm) δ 52.61 (COOCH3), 59.8 
(CHCH2OH), 63.2 (CH2OH), 109.04 and 109.2 (NC=CH and NC=CH–CH=), 120.1 
(NCH=CH), 127.4, 127.5, 127.7, 128.7 and 129.5 (ArC2,3,4,5,6), 135.5 (ArC1), 142.9 
(NC=), 170.3 (COOCH3); 
N
OH
COOMe
Chapter 6 
~ 178 ~ 
 
Methyl 4-oxo-4-phenylbutanoate (194)
[135]
: 
 
4-Oxo-4-phenylbutanoic acid 185 (2.00 g, 11.2 mmol) was dissolved in MeOH (25 mL) 
and H2SO4 (conc.) (0.1 mL, 10% w/v) was carefully added and the reaction mixture 
followed by reflux for 12 h. The flask was cooled to room temperature and the acidic 
solution was quenched with a saturated solution of Na2CO3 (20 mL). The contents were 
then extracted with DCM (25 mL × 3), dried over MgSO4 and the solvent was 
evaporated in vacuo to give compound 194 as a colourless oil (2.01 g, 93%). (SiO2; 
Hexane/Et2O, 1:1; Rf  = 0.48); IR υmax(neat)/cm
-1 C=O 1733 (s), 1683 (s);  1H NMR 
(400 MHz, ppm, CDCl3) δ 2.80 (2 H, t, J 6.5, ArCOCH2), 3.35 (2 H, t, J 6.5, 
CH2COOMe), 3.73 (3 H, s, CH3), 7.50 (2 H, t, J 7.5, CArH3,5), 7.60 (1 H, t, J 7.5, 
CArH4), 8.01 (2 H, d, J 7.5, CArH2,6); 
13C NMR (100 MHz, ppm) δ 28.0 (ArCOCH2), 
33.4 (ArCOCH2CH2), 51.9 (CH3), 128.1 (ArC2,6), 128.6 (ArC3,5), 133.3 (ArC4), 136.5 
(ArC1), 173.4 (COOMe), 198.1 (ArC=OCH2-); MS (CI, NH3) m/z (%) 210 (MNH4
+, 
39), 193 (MH+, 100), 161 (M+ – OMe, 19);  Elemental analysis calcd. (%) for C11H12O3 
(192.08): C 68.74, H 6.29, found: C 68.7, H 6.2. The experimental data was consistent 
with the values reported in literature.[135] 
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Methyl 3-(2-phenyl-1,3-dithiolan-2-yl)propanoate (195)
[134]
: 
 
A dry Schlenk tube was charged with methyl 4-oxo-4-phenylbutanoate 194 (5.10 g, 
26.7 mmol) and ethane-1,2-dithiol (2.50 mL, 29.3 mmol). BF3.OEt2 (1.7 mL, 13.3 
mmol) was added slowly using a syringe and the reaction mixture was stirred for 12 h. 
The reaction mixture was diluted with Et2O (25 mL) and quenched with a saturated 
solution of Na2CO3 (25 mL). The organic layer was separated and the aqueous layer 
was extracted with Et2O (25 mL × 3). The combined organic layers were dried over 
MgSO4 and the solvent evaporated in vacuo to give compound 195 as a colourless oil 
(6.20 g, 86%). (SiO2; Hexane/Et2O, 1:1; Rf  = 0.64); IR υmax(neat)/cm
-1 C=O 1733 (s), 
C-O-C 1171 (s);  1H NMR (400 MHz, ppm, CDCl3) δ 2.42 [2 H, t, J 8, 
ArC(SCH2CH2S)CH2], 2.67 [2 H, t, J 8, ArC(SCH2CH2S)CH2CH2], 3.30 – 3.36 (2 H, 
m, SCH2), 3.38 – 3.45 (2 H, m, SCH2CH2S), 3.64 (3 H, s, CH3), 7.24 – 7.28 (1 H, t, J 
7.5, CArH4), 7.32 – 7.35 (2 H, t, J 7.5, CArH3,5),   7.69 (2 H, d, J 7.5, CArH2,6); 
13C NMR 
(100 MHz, ppm) δ 32.37 [ArC(SCH2CH2S)CH2CH2], 39.5 (SCH2CH2S), 40.7 
[ArC(SCH2CH2S)CH2], 51.7 (CH3), 73.2 [ArC(SCH2CH2S)], 127.0 (ArC2,6), 127.3 
(ArC4), 128.2 (ArC3,5), 144.0 (ArC1), 173.4 (COOMe); MS (ESI) m/z (%) 269 (MH
+, 
80), 237 (M+ – OMe, 100), 195 (M+ – CH2COOMe, 12); Elemental analysis calcd. (%) 
for C13H16O2S2 (268.06): C 58.18, H 6.01, found: C 58.3, H 5.9. The experimental data 
was consistent with the values reported in literature.[134] 
 
 
SS
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3-(2-Phenyl-1,3-dithiolan-2-yl)propan-1-ol (196): 
 
Methyl 3-(2-phenyl-1,3-dithiolan-2-yl)propanoate 195 (6.10 g, 22.8 mmol) was 
weighed in a flask and dissolved in Et2O (200 mL). The flask was cooled to 0 
oC and 
fitted with a reflux condenser. LiAlH4 (2 M in Et2O), (14.3 mL, 25.2 mmol) was 
carefully added with a syringe in 2 mL portions over 30 mins. The reaction mixture was 
allowed to warm to room temperature and stirred for 2 h. Excess LiAlH4 was quenched 
by careful addition of H2O (50 mL) dropwise initially, followed by 2 mL portions. The 
slurry was diluted with 50 mL Et2O. The organic layer was separated and the aqueous 
layer was extracted with Et2O (50 mL × 3). The combined organic layers were dried 
over MgSO4 and the solvent evaporated in vacuo to give compound 196 as a white solid 
(5.80 g, 100%). (SiO2; Hexane/Et2O, 1:1; Rf = 0.25); M.p.  45 – 48 
oC; IR υmax(neat)/cm
-
1 OH 3247 (br), C-O-C 1063 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.54 – 1.61 [2 H, 
m, ArC(SCH2CH2S)CH2CH2], 2.45 [2 H, t, J 8, ArC(SCH2CH2S)CH2], 3.26 – 3.33 (2 
H, m, SCH2), 3.40 – 3.42 (2 H, m, SCH2CH2), 3.60 (2 H, t, J 6.5, CH2OH), 7.25 (1 H, t, 
J 7.5, CArH4), 7.33 (2 H, t, J 7.5, CArH3,5) 7.71 (2 H, d, J 7.5, CArH2,6); 
13C NMR (100 
MHz, ppm) δ 30.9 [ArC(SCH2CH2)CH2CH2], 39.3 (SCH2CH2S), 42.4 
[ArC(SCH2CH2)CH2], 62.6 (CH2OH), 73.9 [ArC(SCH2CH2S)], 127.1 (ArC4), 127.1 
(ArC3,5), 128.1 (ArC2,6), 144.8 (ArC1); MS (CI, NH3) m/z (%) 258 (MNH4
+, 4), 240 
(MH+ 3), 181 (M+ – CH2CH2CH2OH, 26), 147 (M
+ – SCH2CH2S, 100); Elemental 
analysis calcd. (%) for C12H16OS2 (240.06): C 59.96, H 6.71, found: C 60.0, H 6.6. 
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3-(2-Phenyl-1,3-dithiolan-2-yl)propanal (197): 
 
3-(2-phenyl-1,3-dithiolan-2-yl)propan-1-ol 196 (5.23 g, 21.8 mmol) was dissolved in 
DCM (50 mL). MgSO4 (5.00 g) was added to the solution and stirred vigorously. 
Pyridinium chlorochromate (14.10 g, 65.4 mmol) was carefully added the solution 
turned from deep orange to dark brown after a few minutes. After stirring for               
30 mins., the reaction mixture was filtered over a thick pad of dry silica and washed 
with DCM (200 mL). The solvent was evaporated in vacuo to give 197 as a colourless 
oil (3.34 g, 65%). (SiO2; Hexane/Et2O, 1:1; Rf  = 0.64); IR υmax(neat)/cm
-1 C=O 1718 
(s); 1H NMR (400 MHz, ppm, CDCl3) δ 2.58 [2 H, t, J 7.5, ArC(SCH2CH2S) CH2], 2.67 
[2 H, td, J 7.5, 1.5, CH2CHO], 3.28 – 3.37 (2 H, m, SCH2), 3.37 – 3.46 (2 H, m, 
SCH2CH2), 7.27 (1 H, t, J 7.5 CArH4), 7.35 (2 H, t, J 7.5 CArH3,5), 7.69 (2 H, d, J 7.5 
CArH2,6), 9.73 (1 H, t, J 1.5, CHO); 
13C NMR (100 MHz, ppm) δ 38.1 
[ArC(SCH2CH2)CH2CH2], 39.6 (SCH2CH2S), 42.2 [ArC(SCH2CH2)CH2], 73.2 
[ArC(SCH2CH2S], 127.0 (ArC3,5), 127.41(ArC4),  128.3 (ArC2,6), 144.3 (ArC1), 201.0 
(CHO); MS (EI) m/z (%) 238 (M+, 18), 240 (M+ – CH2CH2CHO, 100); Elemental 
analysis calcd. (%) for C12H16OS2 (238.37): C 60.46, H 5.92, found: C 60.5, H 5.9. 
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CHO
Chapter 6 
~ 182 ~ 
 
Methyl 2-(3-(2-phenyl-1,3-dithiolan-2-yl)propylamino)-3-hydroxypropanoate 
(198): 
 
(±)-Serine methyl ester hydrochloride (4.50 g, 28.7 mmol), potassium acetate (2.80 g, 
28.7 mmol) and activated 4Å molecular sieves (20 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(200 mL) was added via a canulla and the reaction mixture was stirred for 15 min. A 
solution of 3-(2-phenyl-1,3-dithiolan-2-yl)propanal 197 (3.40 g, 14.3 mmol) was 
prepared in DCM (10 mL) and transferred to the reaction vessel via a syringe (197 was 
insoluble in MeOH). The mixture was stirred for 2 h, and then a solution of sodium 
cyanoborohydride (1.80 g 28.7 mmol) in MeOH (10 mL) was slowly added over 30 min 
(evolution of gas was observed with mild exotherm). The reaction mixture was then 
stirred at room temperature for 15 h. Excess sodium cyanoborohydride was hydrolysed 
by adding 6 M HCl (10 mL). The gas evolved was passed through 5 M NaOH. When 
no more gas was seen to evolve, the mixture was rendered alkaline by careful addition 
of saturated solution of Na2CO3 (25 mL). The mixture was filtered through a sintered 
funnel and the slurry was washed thoroughly with MeOH (100 mL). The solvent was 
removed under reduced pressure leaving an aqueous slurry which was diluted with H2O 
(100 mL) and then extracted with Et2O (3 × 100 mL). The combined organic layers 
were dried over MgSO4 and evaporated in vacuo to give 198 as a colourless oil (4.70 g, 
96%). IR υmax(neat)/cm
-1 NH, OH 3333 (br), C=O 1735 (s), C–O 1199 (s); 1H (400 
MHz, ppm, CDCl3) δ 1.41 – 1.55 (2 H, m, CH2CH2NH), 2.07 (2 H, s, br, NH, OH), 
2.31 – 2.54 (3 H, m, ArC(SCH2CH2S)CH2 and CHHNH), 2.57 – 2.76 (1 H, m, 
SS H
N COOMe
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CHHNH), 3.22 – 3.34 (3 H, m, SCH2CH2 and CHCOOCH3), 3.34 – 3.45 (2 H, m, 
SCH2), 3.44 – 3.63 (1 H, m, CHHOH ), 3.74 (3 H, s, COOCH3 ), 3.69 – 3.80 (1 H, m, 
CHHOH ), 7.19 – 7.27 (1 H, m, CArH4), 7.32 (2 H, t, J 7.5, CArH3,5), 7.69 (2 H, d, J 7.5, 
CArH2,6); 
13C NMR (100 MHz, ppm) δ 28.4 (ArC(SCH2CH2S)CH2CH2), 39.2 
(SCH2CH2S), 43.6 (Ar(SCH2CH2S)CH2), 48.0 (ArC(SCH2CH2S)CH2CH2CH2), 52.2 
(COOCH3), 62.2 (CH2OH), 62.5 (CHCOOCH3), 74.0 (ArC(SCH2CH2S)), 127.1 
(ArC2,4,6), 128.0 (ArC3,5), 144.8 (ArC1), 173.4 (COOCH3);  MS (ESI) m/z (%) 364 
(MNa+, 34), 342 (MH+, 100), 223 (M+ – NH(COOCH3)CH2OH, 8); Elemental analysis 
calcd. (%) for C16H23NO3S2 (240.06): C 56.27, H 6.79, N 4.10, found: C 56.3, H 6.7, N 
4.1. 
 
tert-Butyl 1-(methoxycarbonyl)vinyl-3-(2-phenyl-1,3-dithiolan-2-yl) propyl 
carbamate (199): 
 
Di-tert-butyl dicarbonate (0.78 g, 3.5 mmol) was added to a solution of methyl 2-(3-(2-
phenyl-1,3-dithiolan-2-yl)propylamino)-3-hydroxypropanoate 198 (1.01 g, 2.9 mmol) 
in DCM (5 mL). The mixture was stirred for 20 h at room temperature. Tosyl chloride 
(0.68 g, 3.5 mmol) was added to the reaction mixture followed by triethylamine      
(0.65 mL, 5.9 mmol). The mixture was stirred for 12 h and diluted with DCM (25 mL), 
washed with H2O (10 mL), HCl (20 mL), saturated solution of Na2CO3 (20 mL), brine 
(10 mL), dried over MgSO4 and the solvent evaporated in vacuo. Column 
chromatography (SiO2; Hexane/ Et2O 7:3; Rf = 0.38) yielded compound 199 as a 
N COOMe
Boc
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colourless oil (0.837 g 68%). IR υmax(neat)/cm
-1 C=O 1713 (s), C=C 1632 (w), C-O-C 
1242 (s);  1H (400 MHz, ppm, CDCl3) δ 1.41 (9 H, s, (CH3)3), 1.58 [2 H, quin, J 7.5, 
ArC(SCH2CH2S)CH2CH2], 2.40 [2 H, t, J 8, ArC(SCH2CH2S)CH2CH2CH2], 3.22 – 
3.32 (SCH2CH2S), 3.35 – 3.52 [4 H, m, SCH2CH2S and ArC(SCH2CH2S)CH2], 3.78 (3 
H, s, COOCH3), 5.30 (1 H, s, =CHH), 5.88 (1 H, s, =CHH), 7.23 (1 H, t, J 7.5, CArH4), 
7.28 – 7.34 (2 H, m, CArH3,5), 7.69 (2 H, d, J 7.5, CArH2,6); 
13C NMR (100 MHz, ppm) δ 
22.7  (ArCOCH2CH2), 28.1 (C(CH3)3), 31.6 (SCH2CH2S), 43.0 
(ArC(SCH2CH2S)CH2CH2CH2), 45.8 (ArC(SCH2CH2S)CH2), 52.2 (COOCH3), 73.9 
(ArC(SCH2CH2S), 81.0 (C(CH3)3, 117.6 (=CH2), 127.1 (ArC2,4,6), 128.0 (ArC3,5), 139.8 
(C=CH2), 144.8 (ArC1), 153.8 (COOC(CH3)3), 165.5 (COOCH3); MS (EI) m/z (%) 423 
(M+, 3), 366 (M+ – C(CH3)3, 14), 350 (M
+ – OC(CH3)3, 6), 322 (M
+ – COOC(CH3)3, 4), 
263 (M+ – COOC(CH3)3, – COOCH3, 21), 181 (M
+ – 
CH2CH2CH2N(COOC(CH3)3)C(COOCH3)CH2, 100); Elemental analysis calcd. (%) for 
C21H29NO4S2 (341.11): C 59.54, H 6.90, N 3.31, found: C 59.8, H 7.1, N 3.5. 
 
Attempted reactions for the deprotection of the dithiolane 199 (see Table 10): 
[Entry 1] 199 (0.12 g, 0.3 mmol) was dissolved in CHCl3 (5 mL). A solution of 
Hg(ClO4)2 (0.35 g, 0.9 mmol) was prepared in MeOH (2 mL) and added to the flask 
and stirred for 30 mins. The solution was then filtered through a pad of silica and 
washed with CHCl3 and the solvent was evaporated to give a crude residue which could 
not be purified and indicated that decomposition of the product had occured. 
[Entry 2] 199 (0.11 g, 0.2 mmol) was dissolved in DMSO (3 mL) and heated to 150 °C 
for 6 h. The solution was then cooled and partitioned between H2O  (5 mL) and Et2O   
(5 mL). The aqueous layer was extracted with Et2O (5 mL × 3) and the organic layers 
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were dried over MgSO4 and the solvent evaporated to give the starting material 199 in 
68% recovery. 
[Entry 3] 199 (0.11 g, 0.2 mmol) was dissolved in a solvent mixture (MeCN/H2O 3:1) 
(3 mL) and cerric ammonium nitrate (0.55 g, 1.0 mmol) was added followed by stirring 
for 30 mins. The reaction mixture was diluted with H2O (5 mL) and extracted with Et2O 
(10 mL × 3). The organic extract was dried over MgSO4 and the solvent evaporated in 
vacuo to give a crude residue which could not be purified and indicated towards a 
possible decomposition. 
[Entry 4] CuO (240 mg, 3.0 mmol) and CuCl2 (677 mg, 5 mmol) were taken in acetone 
(25 mL) and heated to reflux. A solution of 199 (1.06 g, 2.5 mmol) in solvent mixture 
(acetone/DMF 9:1) (5 mL) was prepared and carefully added to the refluxing reaction 
mixture. The reaction mixture was refluxed for 12 h, and filtered over Celite® (Et2O). 
The solvent was evaporated in vacuo and the NMR of the residue indicated 5% product 
186 and 95% starting material 199. 
[Entry 5] 199 (0.10 g, 0.25 mmol) was dissolved in acetone (7 mL) and tBuOOH      
(0.06 mL, 0.5 mmol) was carefully added using a syringe. The reaction mixture was 
refluxed for 12 h. H2O (10 mL) was added and the aqueous layer was extracted in Et2O 
(10 mL × 3). The organic extracts were dried over MgSO4 and the solvent evaporated in 
vacuo to give a crude residue. The NMR spectrum of the residue indicated about 8-10% 
conversion to 186 and a 90% recovery of the starting material 199. 
[Entry 6] Procedure followed as per Entry 5. 199 (0.10 g, 0.25 mmol), tBuOOH      
(0.06 mL, 0.5 mmol) and EtOH (7 mL) was used instead of acetone. After workup, the 
NMR spectrum of the crude residue indicated about 8% conversion to 186 while a 
significant amount of 199 remained unreacted. 
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Entries 7-10 led to conditions used in Entry 11 which is described below as the 
optimised synthesis of 186. 
 
tert-Butyl 1-(methoxycarbonyl)vinyl-4-oxo-4-phenylbutylcarbamate (186): 
 
tert-Butyl 1-(methoxycarbonyl)vinyl-3-(2-phenyl-1,3-dithiolan-2-yl)propylcarbamate 
199 (2.03 g, 4.8 mmol) was dissolved in a solvent mixture of acetone and H2O (3:1)  
(60 mL). K2CO3 (2.00 g, 14.5 mmol) was added followed by MeI (0.90 mL,             
14.4 mmol) and the reaction mixture was stirred for 10 days. K2CO3 (0.67 g, 4.8 mmol) 
was added followed by MeI (0.30 mL, 4.8 mmol) and the reaction mixture was stirred 
for another 10 days. The solvent was evaporated and the aqueous slurry was extracted 
with Et2O (25 mL × 3) dried over MgSO4 and the solvent evaporated in vacuo. Column 
chromatography (SiO2; Hexane/Et2O 7:3; Rf = 0.26) yielded compound 186 as a 
colourless oil (1.12 g, 68%).  IR υmax(neat)/cm
-1 C=O 1733 (s), C=O, 1683 (s), C=C 
1633 (w), C-O-C 1162 (s), 1136 (s); 1H (400 MHz, ppm, CDCl3) δ 1.40 (9 H, s, 
(CH3)3), 2.02 (2 H, quin, J 7, ArCOCH2CH2 ), 3.11 (2 H, t, J 7, ArCOCH2CH2CH2), 
3.64 (2 H, t, J 7, ArCOCH2), 3.77 (3 H, s, COOCH3), 5.48 (1 H, s, =CHH), 5.93 (1 H, s, 
=CHH), 7.46 (2 H, t, J 7.5, CArH3,5), 7.56 (1 H, t, J 7.5, CArH4), 7.97 (2 H, d, J 7.5, 
CArH2,6); 
13C NMR (100 MHz, ppm) δ 22.5 (ArCOCH2CH2), 28.1 (C(CH3)3), 35.2 
(ArCOCH2CH2CH2), 48.4 (ArCOCH2), 52.2 (COOCH3), 81.1 (C(CH3)3, 117.0 (=CH2), 
128.0 (ArC2,6), 128.5 (ArC3,5), 133.0 (ArC4), 136.9 (ArC1), 139.8 (C=CH2), 153.9 
(COOC(CH3)3), 165.6 (COOCH3), 199.7 (ArCO); MS (ESI) m/z (%) 717 (2MNa
+, 
N COOMe
BocO
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100), 370 (MNa+, 100), 246 (M+ – COOC(CH3)3, 74); Elemental analysis calcd. (%) for 
C19H25NO5 (347.41): C 65.69, H 7.25, N 4.03, found: C 65.7, H 7.4, N 3.9. 
 
1-[2-Methyl-6-(3,3-dimethylbutyl)phenyl]ethanone (170)
[97]
: 
 
RuH2(CO)(PPh3)3 catalyst (37 mg, 0.04 mmol) was added to a flask containing a 
solution of 2-methylacetophenone 154 (0.26 mL, 2.0 mmol) and 1,1-dimethylbutene 
(1.3 mL, 10.0 mmol) in toluene (3 mL). The reaction mixture was refluxed for 8 h and 
then cooled to room temperature. The contents were filtered through a pad of silica 
(Et2O) and the solvent was evaporated to give compound 170 as a red oil (0.40 g, 91%). 
IR υmax(neat)/cm
-1 C=O 1677 (s); 1H (400 MHz, ppm, CDCl3) δ 0.96 (6 H, s, C(CH3)3), 
1.48 (2 H, t, J 9, ArCH2CH2), 2.27 (3 H, ArCH3), 2.48 (2 H, t, J 9, ArCH2), 2.52 
(ArCOCH3), 7.07 (2 H, dd, J 12, 7.5, CArH3,5), 7.21 (1 H, t, J 7.5, CArH4); 
13C NMR 
(100 MHz, ppm) δ 19.2 (C=OCH3), 28.5 (ArCH2), 29.2 (C(CH3)3), 30.6 (C(CH3)3), 
32.6 (C=OCH3), 46.6 (ArCH2CH2), 126.8, 127.7, 128.6 (ArC3,4,5), 132.1 (ArC6), 137.9 
(ArC1), 142.3 (ArC2), 208.4 (C=OCH3). HRMS (ESI) calcd. for C15H22O (218.1671), 
found 218.1673. The experimental data was consistent with the values reported in 
literature.[97] 
 
 
 
O
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Attempted chelation assisted ortho-selective coupling of 186 (See Scheme 88, Table 
11): 
[Entry 1] A solution of 186 (0.1 g, 0.3 mmol) in toluene (3 mL) was charged with the 
catalyst RuH2(CO)(PPh3)3 (13 mg, 0.014 mmol) and the reaction mixture was refluxed 
for 12h. Work-up was done by filtering the cooled reaction mixture through a pad of 
silica and washing with Et2O followed by evaporation of the solvent under reduced 
pressure. The starting material 186 was recovered in (90 mg, 90%). No product 
formation was observed.  
[Entry 2] Procedure followed as per Entry 1. The reagents were taken in the same 
proportion as in Entry 1. The reaction time was increased to 24 h. After work-up, the 
starting material 186 was recovered (95mg, 95%). 
[Entry 3] Procedure followed as per Entry 1. 186 (103 mg, 0.3 mmol), catalyst 
Ru(CO)12 (10 mg, 0.015 mmol) and toluene (3 mL) were used. The reaction was 
refluxed for 24 h. After workup, the starting material 186 was recovered (98 mg, 95%) 
and no product formation was observed.  
[Entry 4] Procedure followed as per Entry 1. 186 (127 mg, 0.4 mmol), catalyst 
Rh(Cl)(PPh3)3 (17 mg, 0.02 mmol) and toluene (3 mL) were used. The reaction was 
refluxed for 24 h. After workup, the starting material 186 was recovered (0.12 g, 98%) 
and no product formation was observed. 
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6.5 Experimental for Chapter 5 
2-Phenoxyethanol (218)
[133]
: 
 
Methyl 2-phenoxyacetate 217 (11.50 g, 67.1 mmol) was taken in a flask and dissolved 
in Et2O (200 mL). The flask was cooled to 0 
oC and fitted with a reflux condenser. 
LiAlH4 (2 M soln. in Et2O), (20.0 mL, 40.0 mmol) was added with a syringe in 2 mL 
portions over 30 mins. The reaction mixture was allowed to warm to room temperature 
and stirred for 2 h. Excess LiAlH4 was quenched by careful addition of H2O (50 mL) 
drop wise initially, followed by 2 mL portions. The slurry was diluted with Et2O        
(50 mL). The organic layer was separated and the aqueous layer was extracted with 
Et2O (50 mL × 3). The combined organic layers were dried over MgSO4 and the solvent 
evaporated in vacuo to give compound 218 as a colourless oil (8.43 g, 88%).  (SiO2; 
hexane/Et2O, 1:1; Rf  = 0.31);  IR υmax(neat)/cm
-1
  3335 OH (br); 1H NMR (400 MHz, 
ppm, CDCl3) δ 2.62 (1 H, s, br, OH), 3.98 (2 H, t, J 4.5, CH2OH), 4.10 (2 H, t, J 4.5, 
ArOCH2), 6.95 (2 H, d, J 8, CArH3,5), 7.00 (1 H, t, J 7.5, CArH4), 7.32 (2 H, t, J 8, 
CArH2,6); 
13C NMR (100 MHz, ppm) δ 61.4 (CH2OH), 69.2 (ArOCH2), 114.6 (ArC3,5), 
121.1 (ArC4), 129.6 (ArC2,6), 158.6 (ArC1); MS (EI) m/z (%) 138 (M
+, 42), 121 (M+ – 
OH, 2), 107 (M+ – CH2OH, 8), 94 (M
+ – CH2CH2OH, 100);  HRMS (ESI) calcd. for 
C8H10O2
+ (138.0681), found 138.0678. The experimental data was consistent with the 
values reported in literature.[133] 
 
 
O
OH
Chapter 6 
~ 190 ~ 
 
Attempted PCC oxidation of 218: 
2-Phenoxyethanol 218 (3.01 g, 21.8 mmol) was dissolved in DCM (100 mL) and 
MgSO4 (10 g) was added to the solution with vigorous stirring. Pyridinium 
chlorochromate (14.10 g, 65.4 mmol) was added to the reaction mixture and stirring 
was continued for 2 h. The reaction mixture was filtered through a pad of silica (DCM) 
and the solvent was removed in vacuo to yield a crude brown oil which on analysis 
could not be characterised as 219 and the NMR spectrum showed a complex pattern 
which indicated that the compound had decomposed. Subsequently an alternative 
reaction pathway was followed wherein 1-(2,2-dimethoxyethoxy)benzene 220 was 
hydrolysed using 2 M H2SO4 to synthesise 219. 
 
2-Phenoxyethanal (219)
[132]
: 
 
1-(2,2-Dimethoxyethoxy)benzene 220 (8.20 g, 45.0 mmol) was weighed in a flask and 
dissolved in THF (170 mL). A solution of 2 M H2SO4 was prepared and 60 mL was 
added to the flask followed by reflux for 1 h. The reaction mixture was diluted with 
H2O (100 mL) and the organic layer separated and the aqueous layer was extracted with 
diethyl ether (50 mL × 3). The combined organic layers were washed with saturated 
solution of Na2CO3 (100 mL), brine (100 mL) and dried over MgSO4 and the solvent 
evaporated in vacuo to give compound 219 as a colourless oil (7.92 g, 98%).  (SiO2; 
Hexane/Et2O, 1:1; Rf  = 0.37);  IR υmax(neat)/cm
-1 C=O 1708 (s), C-O-C 1243 (s);        
1H NMR (400 MHz, ppm, CDCl3) δ 4.13 (2 H, d, J 1, ArOCH2), 6.89 – 7.02 (3 H, m, 
O CHO
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CArH3,4,5), 7.24 – 7.40 (2 H, m, CArH2,6), 9.89 (1 H, t, J 1, CHO);
 13C NMR (100 MHz, 
ppm) δ 72.5 (CH2CHO), 114.71 (ArC3,5), 122.0 (ArC4), 129.79 (ArC2,6), 158.32 (ArC1), 
199.53 (CHO); MS (EI) m/z (%) 136 (M+, 61), 107 (M+ – CHO, 72), 77 (M+ – 
OCH2CHO, 100); HRMS (ESI) calcd. for C8H8O2
+ (136.0524), found 136.0523. The 
experimental data was consistent with the values reported in literature.[132] 
 
Methyl 2-(2-phenoxyethylamino)-3-hydroxypropanoate (221): 
 
(±)-Serine methyl ester hydrochloride (11.51 g, 73.4 mmol), potassium acetate (7.21 g, 
73.4 mmol) and activated 4 Å molecular sieves (25 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(200 mL) was added via a canula and the reaction mixture was stirred for 15 min. A 
solution of 2-phenoxy ethanal 219 (5.00 g, 36.7 mmol) was prepared in DCM (10 mL) 
and transferred to the reaction vessel via a syringe. The mixture was stirred for 2 h, and 
then a solution of sodium cyanoborohydride (4.62 g 73.4 mmol) in MeOH (10 mL) was 
slowly added over 30 min (evolution of gas was observed with mild exotherm). The 
reaction mixture was then stirred at room temperature for 15 h. Excess sodium 
cyanoborohydride was hydrolysed by adding 6M HCl (20 mL). The gas evolved was 
passed through 5M NaOH. When no more gas was seen to evolve, the mixture was 
rendered alkaline by careful addition of saturated solution of Na2CO3 (30 mL). The 
mixture was filtered through a sintered funnel and the slurry was washed thoroughly 
with MeOH (100 mL). The solvent was removed under reduced pressure leaving an 
O
N
H
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aqueous slurry which was diluted with H2O (100 mL) and then extracted with Et2O 
(100 mL × 3). The combined organic layers were dried over MgSO4 and evaporated in 
vacuo to give 221 as a colourless oil (5.16 g, 63%). (SiO2; hexane/Et2O/EtOH, 1:1:0.4; 
Rf  = 0.23); IR υmax(neat)/cm
-1 3314 NH,OH (br), C=O 1729 (s); 1H NMR (400 MHz, 
CDCl3) δ  2.78 (2 H, s, br, NH, OH), 2.93 (1 H, dt, J 13, 5, ArOCH2CHH), 3.15 (1 H, 
dt, J 13, 5, ArOCH2CHH), 3.50 (1 H, dd, J 6, 4, CHCH2OH), 3.66 (1 H, dd, J 11, 6, 
CHHOH), 3.73 (3 H, s, COOCH3), 3.83 ( 1 H, dd, J 11, 4, CHHOH), 4.06 (2 H, t, J 5, 
ArOCH2), 6.92 (2 H, d, J 8, CArH3,5), 6.96 (1 H, t, J 7.5 CArH4), 7.29 (2 H, t, J 8, 
CArH2,6); 
13C NMR (100 MHz, ppm) δ 47.2 (ArOCH2CH2), 52.2 (COOCH3), 62.5 
(CH2OH), 62.8 (CHCH2OH), 67.6 (ArOCH2), 114.5 (ArC3,5), 121.0 (ArC4), 129.5 
(ArC2,6), 158.61 (ArC1), 173.5 (COOCH3); MS (EI) m/z (%) 239 (M
+, 8), 208 (M+ – 
OCH3, 65), 180 (M
+ – COOCH3, 100), 121 (M
+ – NH(COOCH3)CH2OH). Elemental 
analysis calcd. (%) for C12H17NO4: C 60.24, H 7.16, N 5.85 found C 60.3, H 7.2, N 5.6. 
 
tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-2-phenoxyethylcarbamate (222): 
 
Methyl 2-(2-phenoxyethylamino)-3-hydroxypropanoate 221 (3.73g, 17.8 mmol) and 
NaHCO3 (4.50 g, 53.5 mmol) were taken in a Schlenk tube and dissolved in MeOH   
(10 mL). The tube was subjected to sonication for 10 mins and a solution of (Boc)2O 
(4.30 g, 19.6 mmol) in MeOH (10 mL) was added. The tube was then sonicated and the 
reaction was monitored by TLC. After 12 h, the solvent was evaporated in vacuo and 
the slurry was extracted with Et2O (25 mL × 3). The organic extracts were washed with 
O
N
COOMe
OHBoc
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H2O (50 mL) and brine (50 mL) and dried over MgSO4. The solvent was evaporated in 
vacuo to give the compound 222 as a colorless oil (5.27 g, 98%). (SiO2; 
hexane/Et2O/EtOH, 1:1:0.4; Rf = 0.53); IR υmax(neat)/cm
-1 NH,OH 3314 (br), C=O 
1733 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 1.37 and 1.43 (18 H, 2 × s, C(CH3)3 
rotamers), 3.25 (1 H, s, br, OH), 3.36 – 3.55 (2 H, m, ArOCH2CHH rotamers), 3.58 and 
3.61 (6 H,  s × 2, COOCH3 rotamers), 3.66 – 3.80 and 3.81 – 4.01 (6 H, m × 2, 
ArOCH2CHH and CH2OH rotamers), 4.06 – 4.22 (4 H, m × 2, ArOCH2 rotamers), 4.24 
– 4.34 and 4.42 – 4.52 (2 H, m × 2, CHCH2OH rotamers), 6.85 (4 H, d, J 7.5, CArH3,5 
rotamers), 6.90 (2 H, d, J 7, CArH4 rotamers), 7.22 (4 H, d, J 7.5, CArH2,6 rotamers); 
13C 
NMR (100 MHz, ppm) δ 28.1, 28.3 [C(CH3)3 rotamers], 47.4, 47.9 (ArOCH2CH2 
rotamers), 51.9 (COOCH3), 61.2, 61.5 (CH2OH rotamers), 62.8, 63.3 (CHCH2OH 
rotamers), 66.7, 66.8 (ArOCH2 rotamers), 81.0 [C(CH3)3], 114.3 (ArC2,6) 121.0 (ArC4), 
129.5 (ArC3,5), 154.9, 155.9 [COOC(CH3)3 rotamers], 158.3 (ArC1), 170.8, 171.3 
(COOCH3 rotamers); MS (ESI) m/z (%) 362 (MNa
+, 3), 345 (MNa+ – OH, 15), 289 
(MNa+ – OH, – C(CH3)3, 9), (M
+ – OH, – COOC(CH3)3); Elemental analysis calcd. (%) 
for C17H25NO6: C 60.16, H 7.42, N 4.13 found C 60.2, H 7.2, N 4.1. 
 
Attempted triflation of 222 (see Scheme 101, Table 12): 
[Entry 1] tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-2-phenoxyethylcarbamate 
222 (0.10 g, 0.5 mmol) was dissolved in DCM (5 mL) followed by the addition of 
pyridine (0.08 mL, 1.0 mmol) and 4Å molecular sieves (1 g). The reaction mixture was 
cooled to 0 °C and triflic anhydride (0.1 mL, 0.6 mmol) was slowly added using a 
syringe. The reaction was stirred for 2 h and warmed to room temperature. The reaction 
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contents were filtered through a sinter funnel and the solvent was evaporated under 
reduced pressure to give a crude oil (77 mg, 81%) which was characterised as 223. 
[Entry 2] 222 (0.2 mmol, 0.7 mmol) was dissolved in DMF (3 mL) and the flask was 
cooled to 0 °C. PhNTf2 (0.25 g, 0.7 mmol) was added followed by KO
tBu (88 mg,     
0.8 mmol) and the reaction mixture was stirred for 1 h. The contents were then diluted 
with Et2O (5 mL) and washed with H2O (5 mL) and the aqueous layer was extracted 
with Et2O (5 mL × 3). The organic layers were dried over MgSO4 and the solvent 
evaporated in vacuo to yield a crude oil (0.15 g, 78%) which was characterised as 223. 
[Entry 3] 222 (0.16 g, 0.5 mmol) was dissolved in DMF (3 mL) and the flask was 
cooled to 0 °C. PhNTf2 (0.25 g, 0.7 mmol) was added followed by Et3N (0.09 mL,     
0.6 mmol) and the reaction mixture was stirred for 1 h. The contents were then diluted 
with Et2O (5 mL) and washed with H2O (5 mL) and the aqueous layer was extracted 
with Et2O (5 mL × 3). The organic layers were dried over MgSO4 and the solvent 
evaporated in vacuo to yield a crude oil (0.15 g, 78%) which was characterised as 223. 
 
Attempted tosylation of 222 (See Scheme 101, Table 12): 
[Entry 4] tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-2-phenoxyethylcarbamate 
222 (0.26 g, 0.8 mmol) was dissolved in DCM (10 mL) and Et3N (0.11 mL, 0.8 mmol) 
was added followed by tosyl chloride (0.15 g, 0.8 mmol). The reaction mixture was 
stirred at room temperature for 12 h and diluted with DCM (10 mL). The reaction 
contents were washed with H2O (20 mL) and 2 M HCl (20 mL) and the organic layer 
was dried over MgSO4 and the solvent evaporated in vacuo to give a crude oil (0.19 g, 
80%) which was characterised as 223.  
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Attempted mesylation of 222 (See Scheme 101, Table 12): 
[Entry 5] tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-2-phenoxyethylcarbamate 
222 (0.20 g, 0.6 mmol) was dissolved in DCM (10 mL) and Et3N (0.09 mL, 0.6 mmol) 
was added followed by mesyl chloride (0.05 mL, 0.6 mmol). The reaction mixture was 
stirred at room temperature for 12 h and diluted with DCM (10 mL). The reaction 
contents were washed with H2O (20 mL) and 2 M HCl (20 mL) and the organic layer 
was dried over MgSO4 and the solvent evaporated in vacuo to give a crude oil (0.13 g, 
71%) which was characterised as 223. 
 
Methyl 3-(2,4,6-trimethoxyphenyl)propanoate (225)
[125]
: 
 
1,3,5-Trimethoxybenzene 224 (0.20 g, 1.2 mmol) and methyl acrylate (0.11 mL, 1.2 
mmol) were dissolved in DCE (3.5 mL) in a test tube. AgOTf (46 mg, 0.2 mmol) and 
AuCl3 (18 mg, 0.06 mmol) were added to the tube and stirred for 1 h. The reaction 
mixture was then filtered through a pad of silica (Et2O) and the solvent was evaporated 
under reduced pressure to give the product 225 as a white solid. (SiO2; hexane:Et2O 
7:3;       Rf = 0.28); M.p. 58 – 61 °C;  IR υmax(neat)/cm
-1 C-O-C 1153 (s), C=O 1738 (s); 
1H NMR (400 MHz, ppm, CDCl3) δ 2.47 (2 H, t, J 8, CH2COOCH3), 2.92 (2 H, t, J 8, 
CH2CH2COOCH3), 3.70 (3 H, s, COOCH3), 3.81 (6 H, s, ArOCH3 × 2), 6.08 – 6.21 (2 
H, m, CArH3,5); 
13C NMR (100 MHz, ppm) δ 18.4 (CH2COOCH3), 33.7 
(CH2CH2COOCH3), 51.4 (COOCH3), 55.3 and 55.6 (ArOCH3 × 2), 90.4 (ArC3,5), 
109.3 (ArC1), 158.8 and 159.6 (ArC2,4,6), 174.3 (COOCH3); HRMS (ESI) calcd. for 
OMe
MeO OMe
COOMe
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C13H18O5 (254.1154), found 254.1156. The experimental data was consistent with the 
values reported in literature.[125] 
 
tert-Butyl 1-(methoxycarbonyl)vinyl2-phenoxyethylcarbamate (223): 
 
tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl2-phenoxyethylcarbamate 222 (3.40 g, 
10.0 mmol) was weighed in a Schlenk tube and dissolved in DCM (25 mL). TsCl    
(2.30 g, 12.1 mmol) was added to the tube followed by Et3N (4.30 mL, 30.1 mmol) and 
the reaction mixture was stirred for 12 h. The reaction mixture was then diluted with 
DCM (10 mL) and washed with H2O (50 mL), dil. HCl (25 mL), saturated solution of 
Na2CO3 (25 mL). The organic extract was dried over MgSO4 and the solvent 
evaporated to give the crude product as a red oil. Column chromatography (SiO2; 
hexane/ Et2O, 1:1) gave 223 as a colorless oil (3.09 g, 68%). (SiO2; Hexane/ Et2O, 1:1; 
Rf = 0.65); IR υmax(neat)/cm
-1 3314 NH,OH (br), C=O 1733 (s), C=C 1661 (m,w), C-O-
C 1192, 1174 (s); 1H NMR (400 MHz, ppm, CDCl3) δ  1.44 (9 H, s, C(CH3)3), 3.63 (3 
H, s, COOCH3), 3.87 (2 H, t, J 5.5, ArOCH2CH2), 4.18 (2 H, t, J 5.5, ArOCH2), 5.70 (1 
H, s, =CHH), 6.03 (1 H, s, =CHH), 6.89 (2 H, d, J 8, CArH3,5), 6.97 (1 H, t, J 7.5, 
CArH4), 7.29 (2 H, t, J 8, CArH2,6); 
13C NMR (100 MHz, ppm) δ 28.4 (C(CH3)3), 49.9 
(ArOCH2CH2), 52.2 (COOCH3), 65.8 (ArOCH2), 81.3 (C(CH3)3), 114.4 (ArC3,5), 119.2 
(=CH2), 120.9 (ArC4), 129.5 (ArC2,6), 140.7 (C=CH2), 153.8 (C=O, Boc), 158.5 (ArC1), 
165.4 (COOCH3); MS (EI) m/z (%) 321 (M
+, 78), 264 (M+ – C(CH3)3, 100), 220 (M
+ – 
O
N
COOMe
Boc
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COOC(CH3)3, 38); Elemental analysis calcd. (%) for C12H17NO4: C 63.54, H 7.21, N 
4.36 found C 60.6, H 7.1, N 4.2. 
 
Attempted AuCl3/AgOTf catalysed cyclization of 223 (see Table 13): 
[Entry 1] tert-Butyl 1-(methoxycarbonyl)vinyl-2-phenoxyethylcarbamate 223 (0.20 g, 
0.6 mmol) was dissolved in DCE (3 mL) in a test tube. AuCl3 (10 mg, 0.03 mmol) and 
AgOTf (24 mg, 0.09 mmol) were added to the test tube and stirred for 24 h. The 
reaction mixture was then filtered through a pad of silica (Et2O) and the solvent was 
evaporated under reduced pressure to give back the starting material 223 (0.18 g, 91%). 
[Entry 2] Procedure followed as per Entry 1. 223 (0.10 g, 0.3 mmol), AgOTf (12 mg, 
0.04 mmol) and AuCl3 (5 mg, 0.02 mmol) were used. Reaction time was increased to   
5 days. 223 was recovered (88 mg, 88%). 
[Entry 3] Procedure followed as per Entry 1. 223 (0.11 g, 0.3 mmol), AgOTf (14 mg, 
0.05 mmol) and AuCl3 (5.3 mg, 0.02 mmol) and MeCN (3 mL) were used. Reaction 
time was 24 h. 223 was recovered (89 mg, 79%). 
[Entry 4] Procedure followed as per Entry 3. 223 (0.17 g, 0.5 mmol), AgOTf (21 mg, 
0.08 mmol) and AuCl3 (8 mg, 0.03 mmol) and MeCN (5 mL) were used. Reaction time 
was 5 days. 223 was recovered (89 mg, 79%). 
[Entry 5] Procedure followed as per Entry 1. 223 (0.29 g, 0.9 mmol), AgOTf (35 mg, 
0.13 mmol) and AuCl3 (14 mg, 0.04 mmol) were used. The reaction was refluxed for  
24 h. 223 was recovered (0.23 g, 78%). 
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[Entry 6] Procedure followed as per Entry 5. 223 (0.21 g, 0.6 mmol), AgOTf (25 mg, 
0.10 mmol) and AuCl3 (10 mg, 0.03 mmol) were used. The reaction was refluxed for  
24 h. 223 was recovered (0.17 g, 80%). 
 
Methyl 2-(benzylamino)-3-hydroxypropanoate (236)
[131]
: 
 
(±)-Serine methyl ester hydrochloride (9.30 g, 59.4 mmol), potassium acetate (5.83 g, 
59.4 mmol) and activated 4 Å molecular sieves (20 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol  (200 
mL) was added via a canula and the reaction mixture was stirred for 15 min. A solution 
of benzaldehyde 230 (5.00 g, 30.1 mmol) was prepared in MeOH (20 mL) and 
transferred to the reaction vessel via a syringe. The mixture was stirred for 2 h, and then 
a solution of sodium cyanoborohydride (3.73 g 59.4 mmol) in MeOH (20 mL) was 
slowly added over 30 min (evolution of gas was observed with mild exotherm). The 
reaction mixture was then stirred at room temperature for 15 h. Excess sodium 
cyanoborohydride was hydrolysed by adding 6M HCl (25 mL). The gas evolved was 
passed through 5M NaOH. When no more gas was seen to evolve, the mixture was 
rendered alkaline by careful addition of saturated solution of Na2CO3 (25 mL). The 
mixture was filtered through a sintered funnel and the slurry was washed thoroughly 
with MeOH (100 mL). The solvent was removed under reduced pressure leaving an 
aqueous slurry which was diluted with H2O (100 mL) and then extracted with Et2O (3 × 
100 mL). The combined organic layers were dried over MgSO4 and evaporated in 
N
H
COOMe
HO
1
2
3
4
5
6
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vacuo to give 236 as a colourless oil (5.10 g, 82%). IR υmax(neat)/cm
-1 3314 NH,OH 
(br), C=O 1733 (s), C=C 1660 (m,w), C-O-C 1197, 1175 (s); 1H NMR (400 MHz, ppm, 
CDCl3) δ  2.78 (2 H, s, br, NH, OH), 3.44 (1 H, dd, J 6, 4.5, CHCH2OH), 3.65 (1 H, dd, 
J 11, 6, CHHOH), 3.74 (1 H, d, J 13, ArCHH), 3.76 (3 H, s, COOCH3), 3.79 (1 H, dd, J 
11, 4.5, CHHOH), 3.88 (1 H, d, J 13, ArCHH), 7.24 – 7.39 (1 H, m, CArH4), 7.32 – 7.39 
(4 H, m, CArH2,3,5,6); 
13C NMR (100 MHz, ppm) δ 52.1 (ArCH2), 52.2 (COOCH3), 61.8 
(CHCH2OH), 62.5 (CH2OH), 127.4 (ArC4), 128.3 × 2, 128.6 × 2 (ArC2,3,5,6), 139.2 
(ArC1), 173.5 (COOCH3); MS (EI) m/z (%) 209 (M
+, 1), 178 (M+ – OCH3, 30), 150 
(M+ – COOCH3, 37), 107 (M
+ – CH2OH, – COOMe, 28), 91 (M
+ – 
NHC(COOMe)CH2OH);   Elemental analysis calcd. (%) for C11H15NO3: C 63.14, H 
7.23, N 6.69 found C 63.5, H 6.7, N 6.4. The experimental data was consistent with the 
values reported in literature.[131] 
 
Methyl 2-(3-methoxybenzylamino)-3-hydroxypropanoate (237): 
 
(±)-Serine methyl ester hydrochloride (9.20 g, 58.8 mmol), potassium acetate (5.80 g, 
58.8 mmol) and activated 4 Å molecular sieves (20 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(200 mL) was added via a canulla and the reaction mixture was stirred for 15 min. A 
solution of 3-methoxybenzaldehyde 231 (4.00 g, 29.4 mmol) was prepared in MeOH 
(20 mL) and transferred to the reaction vessel via a syringe. The mixture was stirred for 
2 h, and then a solution of sodium cyanoborohydride (3.70 g 58.8 mmol) in MeOH    
N
H
COOMe
HO
1
2
3
4
5
6MeO
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(20 mL) was slowly added over 30 min (evolution of gas was observed with mild 
exotherm). The reaction mixture was then stirred at room temperature for 15 h. Excess 
sodium cyanoborohydride was hydrolysed by adding 6M HCl (25 mL). The gas 
evolved was passed through 5M NaOH. When no more gas was seen to evolve, the 
mixture was rendered alkaline by careful addition of saturated solution of Na2CO3     
(25 mL). The mixture was filtered through a sintered funnel and the slurry was washed 
thoroughly with MeOH (100 mL). The solvent was removed under reduced pressure 
leaving an aqueous slurry which was diluted with H2O (100 mL) and then extracted 
with Et2O (3 × 100 mL). The combined organic layers were dried over MgSO4 and 
evaporated in vacuo to give 237 as a colourless oil (5.91 g, 84%). IR υmax(neat)/cm
-1 
OH, NH 3458 (br), C=O 1733 (s), C-O-C 1162, 1039 (s);  1H NMR (400 MHz, ppm, 
CDCl3) δ 2.65 ( 2 H, s, br, NH, OH), 3.45 (1 H, dd, J 6, 4.5 CHCH2OH), 3.65 (1 H, dd, 
J 11, 6, CHHOH), 3.74 (1 H, d, J 13, ArCHH), 3.76 (3 H, s, COOCH3), 3.79 (1 H, dd, J 
11, 4.5, CHHOH), 3.82 (3 H, s, ArOCH3), 3.88 (1 H, d, J 13, ArCHH), 6.83 (1 H, d, J 
8, CArH6), 6.88 – 6.93 (2 H, m, CArH2,4), 7.26 (1 H, t, J 8, CArH3); 
13C NMR (100 MHz, 
ppm) δ 52.0 (ArCH2), 52.2 (COOCH3), 55.2 (OCH3), 61.8 (CHCH2OH), 62.5 
(CH2OH), 112.8, 113.7 (ArC4,6), 120.5 (ArC2), 129.6 (ArC3), 140.9 (ArC1), 159.8 
(ArC5), 173.5 (COOCH3); MS (EI) m/z (%) 239 (M
+, 3), 208 (M+ – CH2OH, 29), 180 
(M+ – COOCH3, 36), 136 (M
+ – CH(COOCH3)CH2OH, 23), 121 (M
+ – 
NHCH(COOCH3)CH2OH, 100); Elemental analysis calcd. (%) for C12H17NO4: C 
62.50, H 5.62, N 5.85 found C 62.6, H 5.6, N 5.9. 
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tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethylbenzylcarbamate (238)
[130]
: 
 
Methyl 2-(benzylamino)-3-hydroxypropanoate 236 (4.73 g, 22.6 mmol) and NaHCO3 
(5.70 g, 67.8 mmol) were taken in a Schlenk tube and dissolved in MeOH (10 mL). The 
tube was subjected to sonication for 10 mins and a solution of (Boc)2O (5.42 g,        
24.9 mmol) in MeOH (10 mL) was added. The tube was then sonicated and the reaction 
was monitored by TLC. After 12 h, the solvent was evaporated in vacuo and the slurry 
was extracted with Et2O (25 mL × 3). The organic extracts were washed with H2O     
(50 mL) and brine (50 mL) and dried over MgSO4. The solvent was evaporated in 
vacuo to give the compound 238 as a colorless oil (6.66 g, 95%). (SiO2; hexane/Et2O, 
1:1; Rf = 0.35); IR υmax(neat)/cm
-1 OH 3449 (br), C=O 1740,1691 (s), C-O-C 1248, 
1161 (s);  1H NMR (400 MHz, ppm, CDCl3) δ  1.47 [9 H, s, C(CH3)3], 2.42 (1 H, s, br, 
OH), 3.41 – 3.58 (1 H, m, br, CHCH2OH), 3.72 (3 H, s, COOCH3), 3.76 – 3.90 (1 H, m, 
CHHOH), 3.99 – 4.21 (1 H, m, CHHOH), 4.44 – 4.57 (2 H, m, br, ArCH2), 7.27 – 7.39 
(5 H, CArH2,3,4,5,6);  
13C NMR (100 MHz, ppm) δ 28.3 (C(CH3)3), 52.1 (COOCH3), 52.4 
(ArCH2), 61.0 (CHCH2OH), 61.7 (CH2OH), 81.3 [C(CH3)3], 127.5, 128.4, 128.6 × 2 
(ArC2,3,4,5,6), 139.9 (ArC1), 154.8 (COOC(CH3)3), 172.0 (COOCH3); MS (EI) m/z (%) 
309 (M+, 23), 252 (M+ – C(CH3)3, 29), 208 (M
+ – COOC(CH3)3, 19), 178 (M
+ – 
COOC(CH3)3, – OCH3, 38), 150 (M
+ – COOC(CH3)3, – COOCH3, 48), 106 (M
+ – 
COOC(CH3)3, – COOCH3, – CHCH2OH, 44), 91 (M
+ – 
N(COOC(CH3)3)CH(COOCH3)CH2OH, 100); Elemental analysis calcd. (%) for 
N COOMe
HO
Boc
Chapter 6 
~ 202 ~ 
 
C11H15NO3: C 62.12, H 7.49, N 4.53 found C 62.2, H 7.4, N 4.4. The experimental data 
was consistant with the values reported in literature.[130] 
 
tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-3-methoxybenzylcarbamate (239): 
 
Methyl 2-(3-methoxybenzylamino)-3-hydroxypropanoate 237 (5.91 g, 24.7 mmol) and 
NaHCO3 (6.31 g, 75.1 mmol) were taken in a Schlenk tube and dissolved in MeOH    
(20 mL). The tube was subjected to sonication for 10 mins and a solution of (Boc)2O 
(5.93 g, 27.2 mmol) in MeOH (10 mL) was added. The tube was then sonicated and the 
reaction was monitored by TLC. After 12 h, the solvent was evaporated in vacuo and 
the slurry was extracted with Et2O (25 mL x 3). The organic extracts were washed with 
H2O (50 mL) and brine (50 mL) and dried over MgSO4. The solvent was evaporated in 
vacuo to give the compound 239 as a colorless oil (8.83 g, 97%). (SiO2; hexane/Et2O, 
1:1; Rf = 0.26 ); IR υmax(neat)/cm
-1 OH 3458 (br), C=O 1741,1693 (s), C-O-C 1249, 
1162 (s);  1H NMR (400 MHz, ppm, CDCl3) δ 1.46 [9 H, s, (CH3)3], 2.53 (1H, s, br, 
OH), 3.44 – 3.65 (1 H, m CHCH2OH), 3.72 (3 H, s, COOCH3), 3.77 – 3.91 (1H, m, 
CHHOH ), 3.81 (3 H, s, OCH3), 4.02 – 4.18 (1H, m, br, CHHOH), 4.38 – 4.69 (2 H, m, 
br, ArCH2 ), 6.79 – 6.98 (3 H, m, br, CArH2,4,6), 7.26 (1 H, m, CArH3); 
13C NMR (100 
MHz, ppm) δ 28.3 (C(CH3)3), 52.0 (ArCH2), 52.2 (COOCH3), 55.2 (OCH3), 61.1 
(CHCH2OH), 61.7 (CH2OH), 81.3 [C(CH3)3], 112.9, 113.5, 120.1 (ArC2,4,6), 129.6 
(ArC3), 139.4 (ArC1), 155.5 (COOC(CH3)3), 159.8 (ArC5), 173.5 (COOCH3); MS (EI) 
m/z (%) 339 (M+, 5), 283 (M+ – C(CH3)3, 35), 238 (M
+  – COOC(CH3)3), 34), 180 (M
+ 
N COOMe
HO
Boc
MeO
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– COOC(CH3)3, – COOCH3, 38), 136 (M
+ – COOC(CH3)3, – COOCH3, – CHCH2OH, 
44), 121 (M+ – N(COOC(CH3)3CH(COOCH3)CH2OH), 100); Elemental analysis calcd. 
(%) for C12H17NO4: C 60.16, H 7.42, N 4.13 found C 60.3, H 7.4, N 3.9.  
 
tert-Butyl 1-(methoxycarbonyl)vinylbenzylcarbamate (232)
[129]
: 
 
238 (6.00 g, 19.4 mmol) was weighed in a Schlenk tube and dissolved in DCM (20 
mL). TsCl (4.50 g, 23.3 mmol) was added to the tube followed by Et3N (8.20 mL,    
58.3 mmol) and the reaction mixture was stirred for 12 h. The reaction mixture was 
then diluted with DCM (25 mL) and washed with H2O (50 mL), dil. HCl (25 mL), sat. 
soln. of Na2CO3 (25 mL). The organic extract was dried over MgSO4 and the solvent 
evaporated to give the crude product as a red oil. Column chromatography (SiO2; 
hexane/ Et2O, 1:1; Rf = 0.46) gave 232 as a colorless oil (4.29 g, 76%).                        
IR υmax(neat)/cm
-1 C=O 1733, 1706 (s), C=C 1630 (w), C–O 1154 (s); 1H NMR (400 
MHz, ppm, CDCl3) δ  1.45 [9 H, s, (CH3)3], 4.70 (2 H, s, ArCH2), 3.78 (3 H, s, CH3), 
5.24 (1 H, s, =CHH), 5.81 (1 H, s, =CHH), 7.44 – 7.17 (5 H, m, CArH2,3,4,5,6 ); 
13C NMR 
(100 MHz, ppm) δ 28.1 [C(CH3)3], 52.3 (COOCH3), 52.8 (ArCH2), 81.7 (C(CH3)3), 
117.5 (=CH2),  123.4, 127.0, 127.3, 128.5 × 2 (ArC2,3,4,5,6), 139.67 (ArC1), 154.3 
(C=CH2), 155.6 (COOC(CH3)3),  165.5 (COOCH3); MS (ESI) m/z (%) 314 (MNa
+, 42), 
190 (M+ –  COOC(CH3)3, 100), 132 (MH
+ – COOC(CH3)3, –  COOCH3, 34); Elemental 
analysis calcd. (%) for C16H21NO4: C 65.96, H 7.27, N 4.81 found C 66.1, H 7.2, N 4.7. 
The experimental data was consistent with the values reported in literature.[129] 
N COOMe
Boc
Chapter 6 
~ 204 ~ 
 
tert-Butyl 1-(methoxycarbonyl)vinyl-3-methoxybenzylcarbamate (233): 
 
tert-Butyl 1-(methoxycarbonyl)-2-hydroxyethyl-3-methoxybenzylcarbamate 239 (8.31 
g, 19.4 mmol) was weighed in a Schlenk tube and dissolved in DCM (25 mL). TsCl 
(5.60 g, 29.4 mmol) was added to the tube followed by Et3N (10.30 mL, 73.5 mmol) 
and the reaction mixture was stirred for 12 h. The reaction mixture was then diluted 
with DCM (25 mL) and washed with H2O (50 mL), dil. HCl (25 mL), saturated soln. of 
Na2CO3 (25 mL). The organic extract was dried over MgSO4 and the solvent 
evaporated to give the crude product as a red oil. Column chromatography (SiO2; 
hexane/ Et2O, 1:1; Rf = 0.42) gave 233 as a colorless oil (6.17 g, 78%).                        
IR υmax(neat)/cm
-1 C=O 1733, 1705 (s), C=C 1630 (m), C-O-C 1251, 1153 (w);    1H 
NMR (400 MHz, ppm, CDCl3) δ 1.46 [9 H, s, C(CH3)3], 3.79 (3 H, s, COOCH3), 3.81 
(3 H, s, OCH3), 4.70 (2 H, s, ArCH2), 5.24 (1 H, s, =CHH), 5.78 (1 H, s, =CHH), 6.81 
(1 H, dd, J 8, 2,  ArC6), 6.88 (2 H, d, J 8, ArC2,4), 7.24 (1 H, t, J 8, ArC3); 
13C NMR 
(100 MHz, ppm) δ 28.1 [C(CH3)3], 52.2 (COOCH3), 52.7 (ArCH2), 55.2 (OCH3), 81.4 
(C(CH3)3), 112.8, 112.9 (ArC4,6), 116.7 (=CH2), 119.8 (ArC2), 129.4 (ArC3), 139.8 
(ArC1), 154.1 (C=CH2), 159.8 (ArC5), 155.2 (COOC(CH3)3), 165.3 (COOCH3); MS 
(ESI) m/z (%) 344 (MNa+, 57), 220 (M+ – COOC(CH3)3), 205 (M
+ – COOC(CH3)3, – 
CH3, 100), 162 (M
+ – COOC(CH3)3, – COOCH3, 17);   Elemental analysis calcd. (%) 
for C17H23NO5 (321.16): C 63.54, H 7.21, N 4.36 found C 63.5, H 7.1, N 4.2. 
 
 
N COOMe
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Attempted AuCl3/AgOTf catalysed cyclization of 232 and 233 (Scheme 114, Table 
14): 
[Entry 1] tert-Butyl 1-(methoxycarbonyl)vinylbenzylcarbamate 232 (0.10 g, 0.3 mmol) 
was dissolved in DCE (3 mL) in a test tube. AuCl3 (5 mg, 0.02 mmol) and AgOTf      
(13 mg, 0.05 mmol) were added to the test tube and stirred for 24 h. The reaction 
mixture was then filtered through a pad of silica (Et2O) and the solvent was evaporated 
under reduced pressure to give back the starting material 232 (0.87 g, 87%). 
[Entry 2] Procedure followed as per Entry 1. 232 (0.14 g, 0.5 mmol),  AgOTf (19 mg, 
0.07 mmol) and AuCl3 (7.3 mg, 0.02 mmol) were used. Reaction time was increased to 
48 h. 232 was recovered (0.13 g, 91%). 
[Entry 3] Procedure followed as per Entry 1. 233 (0.10 g, 0.3 mmol),  AgOTf (12 mg, 
0.05 mmol) and AuCl3 (5 mg, 0.02 mmol) were used. Reaction time was 48 h. 233 was 
recovered (90 mg, 90%). 
[Entry 4] Procedure followed as per Entry 1. 233 (0.11 g, 0.3 mmol),  AgOTf (13 mg, 
0.05 mmol) and AuCl3 (5 mg, 0.02 mmol) were used. The reaction was refluxed for    
24 h. 223 was recovered (0.10 g, 91%). 
[Entry 5] Procedure followed as per Entry 1. 233 (0.13 g, 0.4 mmol),   AgOTf (16 mg, 
0.06 mmol) and AuCl3 (6 mg, 0.02 mmol) were used. The reaction was refluxed for 48 
h. 233 was recovered (0.11 g, 86%). 
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Methyl 2-(3,5-dimethoxybenzylamino)-3-hydroxypropanoate (241): 
 
(±)-Serine methyl ester hydrochloride (9.42 g, 60.2 mmol), potassium acetate (5.90 g, 
60.1 mmol) and activated 4 Å molecular sieves (20 g) were successively introduced into 
a reaction vessel which was then evacuated and filled with nitrogen. Methanol         
(200 mL) was added via a canula and the reaction mixture was stirred for 15 min. A 
solution of 3,5-dimethoxybenzaldehyde 240 (5.00 g, 30.1 mmol) was prepared in DCM 
(20 mL) and transferred to the reaction vessel via a syringe. The mixture was stirred for 
2 h, and then a solution of sodium cyanoborohydride (3.80 g 60.2 mmol) in MeOH (20 
mL) was slowly added over 30 min (evolution of gas was observed with mild 
exotherm). The reaction mixture was then stirred at room temperature for 15 h. Excess 
sodium cyanoborohydride was hydrolysed by adding 6M HCl (25 mL). The gas 
evolved was passed through 5M NaOH. When no more gas was seen to evolve, the 
mixture was rendered alkaline by careful addition of saturated solution of Na2CO3 (25 
mL). The mixture was filtered through a sintered funnel and the slurry was washed 
thoroughly with MeOH (100 mL). The solvent was removed under reduced pressure 
leaving an aqueous slurry which was diluted with H2O (100 mL) and then extracted 
with Et2O (3 × 100 mL). The combined organic layers were dried over MgSO4 and 
evaporated in vacuo to give e as a colourless oil (6.41 g, 79%). IR υmax(neat)/cm
-1 NH, 
OH 3336 (br), C=O 1731 (s), C–O 1204 (s); 1H NMR (400 MHz, ppm, CDCl3) δ 2.64 
(2 H, s, NH, OH), 3.45 (1 H, dd, J 6, 4.5 CHCH2OH), 3.64 (1 H, dd, J 11, 6, CHHOH), 
3.69 (1H, d, J 13, ArCHH), 3.77 (3 H, s, COOCH3), 3.80 (6 H, s, OCH3 × 2), 3.78 – 
3.82 (1 H, dd, J 11, 4.5, CHHOH) 3.85 (1 H, d, J 13, ArCHH) 6.38 (1 H, t, J 2, CArH4), 
MeO
OMe
N
H
COOMe
HO
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6.50 (2 H, d, J 2, CArH2,6 ); 
13C NMR (100 MHz, ppm) δ 52.1 (ArCH2), 52.2 
(COOCH3), 55.3 (OCH3 × 2), 99.3 (ArC4), 106.1 (ArC2,6), 140.4 (ArC1), 160.9 (ArC3,5), 
173.4 (COOCH3); MS (CI, NH3) m/z (%) 270 (MH
+, 100), 252 (M+ – OH, 3), 238 (M+ 
– CH2OH, 4), 210 (M
+ – COOCH3, 4); Elemental analysis calcd. (%) for C13H19NO5 
(269.29): C 57.98, H 7.11, N 5.20, found: C 58.1, H 7.1, N 5.0. 
 
tert-Butyl 1-(methoxycarbonyl)vinyl-3,5-dimethoxybenzylcarbamate (242): 
 
Di-tert-butyl dicarbonate (5.52 g, 25.3 mmol) was added to a solution of methyl 2-(3,5-
dimethoxybenzylamino)-3-hydroxypropanoate 241 (5.67 g, 21.1 mmol) in dry DCM 
(25 mL). The mixture was stirred for 20 h at room temperature. Tosyl chloride (6.02 g, 
31.6 mmol) was added to the reaction mixture followed by triethylamine (8.90 mL,  
63.2 mmol). The mixture was stirred for 12 h and diluted with DCM (25 mL), washed 
with H2O (50 mL), HCl (50 mL), saturated solution of Na2CO3 (50 mL), brine (50 mL), 
dried over MgSO4 and the solvent evaporated in vacuo. Column chromatography (SiO2; 
Hexane/ Et2O 1:1; Rf = 0.38) yielded compound 242 as a colourless oil (6.07 g 82%). 
IR υmax(neat)/cm
-1 C=O 1736 (s), C=C 1596 (s), C-O-C 1153 (s); 1H NMR (400 MHz, 
ppm, CDCl3) δ 1.46 [9 H, s, C(CH3)3], 3.79 (6 H, s, OCH3 × 2), 3.80 (3 H, s, COOCH3), 
4.67 (2 H, s, ArCH2 ), 5.26 (1 H, s, =CHH), 5.77 (1 H, s, =CHH), 6.37 (1 H, t, J 2, 
CArH4), 6.48 (2 H, d, J 2, CArH2,6); 
13C NMR (100 MHz, ppm) δ 28.1 [C(CH3)3], 52.2 
(COOCH3), 52.8 (ArCH2), 55.3 × 2 (ArOCH3 × 2), 81.5 (C(CH3)3), 99.3 (ArC4), 105.2 
× 2 (ArC2,6), 116.5 (=CH2), 140.4 (ArC1), 154.0 (C=CH2), 155.3 (COOC(CH3)3), 160.9 
MeO
OMe
N COOMe
Boc
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× 2 (ArC3,5), 173.4 (COOCH3); MS (CI, NH3) m/z (%) 369 (MNH4
+, 83), 352 (MH+, 
56), 313 (MNH4
+ – C(CH3)3, 100),  296 (MNH4
+ – OC(CH3)3, 75); Elemental analysis 
calcd. for (%) C18H25NO6: C 61.52, H 7.17, N 3.99, found C 61.52, H 7.08, N 3.85. 
 
Attempted AuCl3/AgOTf catalysed cyclization of 242 (see Scheme 117, Table 15): 
[Entry 1] 242 (0.12 g, 0.3 mmol) was dissolved in DCE (3 mL) in a test tube. AuCl3 
(5.2 mg, 0.02 mmol) and AgOTf (13 mg, 0.05 mmol) were added to the test tube and 
stirred for 24 h. The reaction mixture was then filtered through a pad of silica (Et2O) 
and the solvent was evaporated under reduced pressure to give back the starting 
material 242 (0.11 g, 91%). 
[Entry 2] Procedure followed as per Entry 1. 242 (0.10 g, 0.3 mmol),  AgOTf (12 mg, 
0.04 mmol) and AuCl3 (5 mg, 0.02 mmol) were used. The reaction was refluxed for    
24 h. 242 was recovered (0.093 g, 89%). 
 
3-(1-(4-Methoxyphenyl)ethyl)-1-methyl-1H-indole (250)
[127]
: 
 
N-Methyl indole 244 (0.047 mL, 0.4 mmol) and 4-vinyl anisole 249 (0.056 mL, 0.42 
mmol) were taken in a vial and dissolved in toluene (1 mL). The vial was sealed and 
stirred at 85 °C for 2 h. The vial was then cooled to room temperature and filtered over 
a pad of silica (Et2O). The solvent was evaporated in vacuo and 250 was obtained as a 
N
O
1
2
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5
6
7
8
9
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red oil (85 mg, 78%). IR υmax(neat)/cm
-1 C-O-C 1150 (s), C=C 1626; 1H NMR (400 
MHz, ppm, CDCl3) δ 1.72 (3 H, d, J 7, CHCH3), 3.46 and 3.81 (6 H, s × 2, NCH3 and 
OCH3), 4.24 (1 H, q, J 7, CHCH3), 6.53 [1 H, s, NCH2 (C-2)], 6.78 – 6.89 [2 H, m, 
CArH (C-14,15)], 7.07 – 7.11 [2 H, m, CArH (C-16,17)], 7.10 – 7.32 [3 H, m, CArH, (C-
6,7,8)], 7.65 [1 H, d, J 8, CArH (C-5)]; 
13C NMR (100 MHz, ppm) δ 22.8 (CHCH3), 
29.7 (NCH3), 37.4 (CHCH3), 55.3 (OCH3), 99.0 (NCH=), 114.0 [ArC (C-13,14)],  
115.0 [ArC (C-3)], 108.8, 119.2, 120.1, 120.9 [ArC (C-5,6,7,8)], 127.6 [ArC (C-4)], 
128.3 [ArC (C-16,17)], 137.0 [ArC (C-9)], 142.1 [ArC (C-12)], 159.4 [ArC (C-15)]; 
HRMS (ESI) calcd. for C18H20NO
+ (266.1542), found 266.1545. The experimental data 
was consistent with the values reported in literature.[127] 
 
Attempted (PPh3)AuCl/AgOTf catalysed cyclization of 223, 233 and 242 (see 
Scheme 121, Table 16): 
[Entry 1] 223 (0.12 g, 0.4 mmol) was dissolved in toluene (1 mL) and (PPh3)AuCl       
(4 mg, 0.007 mmol) and AgOTf (4 mg, 0.014 mmol) were added and stirred at 85 °C 
for 12 h. The reaction was cooled to room temperature and the contents were filtered 
over a pad of silica. The solvent was evaporated in vacuo and a crude oil was obtained 
(0.11 g, 94%) which was characterised as 223. 
[Entry 2] Procedure followed as per Entry 1. 233 (0.13 g, 0.4 mmol), (PPh3)AuCl        
(4 mg, 0.008 mmol) and AgOTf (4 mg, 0.02 mmol) were used. 233 was recovered  
(0.12 g, 92%). 
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[Entry 3] Procedure followed as per Entry 1. 233 (0.11 g, 0.3 mmol), (PPh3)AuCl        
(2 mg, 0.006 mmol) and AgOTf (3.5 mg, 0.013 mmol) were used. The reaction was 
refluxed for 12 h. 233 was recovered (0.078 g, 71%). 
[Entry 4] Procedure followed as per Entry 1. 242 (0.15 g, 0.4 mmol), (PPh3)AuCl        
(4 mg, 0.008 mmol) and AgOTf (4 mg, 0.02 mmol) were used. 242 was recovered   
(0.12 g, 80%). 
[Entry 5] Procedure followed as per Entry 1. 242 (0.13 g, 0.3 mmol), (PPh3)AuCl        
(3 mg, 0.007 mmol) and AgOTf (4 mg, 0.015 mmol) were used. The reaction was 
refluxed for 12 h. 242 was recovered (0.098 g, 76%). 
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